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Abstract
The adenovirus codes for a protease which is essential for virion infectivity. This 
protease requires the presence of a peptide cofactor in order to develop optimal activity. 
This peptide, GVQSLKRRRCF, originates from the C-terminal of a viral protein, pVI, 
and some evidence regarding its specificity came from observations showing that neither 
of the peptides GVQSLKRRRAF or KRRRCF was able to activate the protease, 
indicating that both the cysteine and the N-terminal were important in the activation 
process. However, the mechanism by which the peptide activates the protease has never 
been elucidated.
In this project, several factors contributing to the activation mechanism of the human 
adenovirus type 2 protease were studied, such as the peptide N-terminal length and 
composition, the environment close to the cysteine and the distance between the 
N-terminal and the cysteine, in view of assessing the relevance of each of these 
parameters in the activation process and proposing a mechanism of activation.
Based on the above studies, attempts of protease inhibition were also performed 
based on the activation process rather than on the blocking of the active site, and the 
relevance of these results was related with the proposed activation mechanism.
An attempt to clone an avian adenovirus protease was also performed, in order to 
try and compare the activation processes between the two proteases.
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Introduction
1. introduction
Lying in the frontier between live beings and inanimate substances, viruses represent 
one of the most fascinating examples of evolution towards a very compact, yet extremely 
effective form of parasitism.
Structurally, viruses consist of a protein shell which protects their genetic material, 
and in some cases an outer membrane made of lipids and glycoproteins envelops the 
protein capsid. Whilst outside a host, they present no biological activity whatsoever, 
rather behaving like ‘inorganic’ substances, waiting for the appropriate moment to 
unleash their infective power,
By themselves, viruses are not able to reproduce, requiring the invasion of a host 
cell in order to use their cellular machinery for the replication o f DNA and protein 
synthesis, so that new virions can be produced. Throughout this operation, they subvert 
the cell cycle equilibrium, virtually shutting down many unessential cellular processes and 
using others for their own benefit, so that at the end of their infectious cycle the host cell 
has basically turned into a virion factory, usually at the expense of its own viability or, in 
some instances, resulting is such a disorganised cell that it loses control of its own 
replication and becomes malignant -  a tumour is born. In some instances, however, 
viruses incorporate their genetic information into the genome of their host without 
destroying it, thus becoming permanent ‘guests’ waiting for any opportunity to produce 
outbursts of new infectious particles.
How can a virus be stopped? Ideally, in organisms with an immunological defence 
system, this deals with the invading virion before it penetrates any cell, or in the situation 
where cells have already been infected, the immune system chooses to destroy these cells 
before new virions are released. However, this system is unfortunately not always 
completely efficient, and other means have to be sought for. In this search for antiviral 
agents, an understanding of the viral infection mechanisms is necessary for potential 
weaknesses to be identified and exploited.
One of the ‘weaknesses’ o f the adenovirus is that it needs to use a viral-coded 
enzyme to process some of its capsid proteins in order to become infectious. Therefore, a 
study of the operating mechanism of this molecule should enable the devising of a mode 
of inhibiting its action, thus allowing for a way of stopping the production of more 
virions. The broad aim of this project was then to unveil some of the characteristics of
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the mechanism by which this enzyme becomes active, so that possible inhibitory  ^
substances can be conceived.
1.1. The Adenovirus
Adenovirus vinons were observed (Horne et al., 1959) to present an icosahedral 
shape (cf. Figure 11), with a diameter of 60 to 90 nm. They contain double-stranded 
DNA. a genome of 34 to 36 kbp with the potential to code for at least 50 proteins 
(Hierholzer et a i ,  1991) They are responsible for several pathologies, including ocular, 
respiratory, and gastrointestinal infections (Wadell, 1994).
Figure 1.1 - Electron micrograph of human adenoMrus t\pe 2 vinon (Norrbv'. 1969b).
Several aspects of adenovirus history, classification, pathogenicity, morphology and 
molecular biology are discussed below, in view of a better understanding on the 
importance of studying this virus.
1.1.1. History
In 1953, Rowe and co-workers (Rowe et a i, 1953) explanted surgically removed 
adenoids from children in order to evaluate different tissues for growth of polio viruses. 
After 4 weeks, the epithelial-like cells of some of the cultures exhibited a slowly 
progressive cytopathic effect. This change proved to be the result of the replication of 
previously unidentified viruses present in the adenoid tissues. One year later, Hilleman 
and Werner (Hilleman and Werner, 1954) isolated by tissue culture technique agents 
from respiratory secretions that induced cytopathic changes in human cells. An increase 
in neutralising and complement-fixing antibodies to the virus was shown to occur in the 
patients. The viruses discovered by the two groups were soon shown to be related 
(Huebner et al., 1954) and were initially called adenoid degeneration (AD), respiratory 
illness (RI), adenoidal-pharyngeal-conjunctival ( APC), or acute respiratory disease 
(,\RD) agents.
Due to this variability in the nomenclature employed by the various laboratories 
involved in the study of these viruses, a group of researchers met and agreed on the
{ntroduction
name adenoviruses (Enders et al., 1956) as being generally acceptable and in accordance 
with the recommendations of the Subcommittee on Viruses of the International 
Nomenclature Committee, based on the original source of tissue (adenoid) in which the 
prototype viral strain was discovered.
It was in 1962 that a seminal discovery was made (Trentin et al., 1962), that human 
adenovirus type 12 induced malignant tumours following inoculation into new-born 
hamsters. It was the first time that a human virus was shown to be oncogenic. Almost 
simultaneously, a report (Huebner et al., 1962) described a similar property with human 
adenovirus type 18. Subsequently, further reports confirmed the oncogenicity of various 
other human and non-human adenoviruses in several species of rodents (Darbyshire, 
1966; Girardi et al., 1964; Huebner et al., 1965; Huebner et al., 1964; Huebner et al., 
1963; Hull et a l,  1965; Pereira et a l ,  1965; Rabson et a l,  1964; Sarma et a l,  1965; 
Yabe et a l,  1964). The tumours formed have usually the characteristics of 
undifferentiated sarcomas, although malignant lymphomas were also observed 
sporadically (Larsson et a l,  1965). However, no evidence of linking of adenoviruses 
with malignant disease in humans has been reported so far; although there is one report 
of adenovirus-related RNA in neurogenic tumours (Ibelgaufts et a l ,  1982), thorough 
research has failed to find adenovirus nucleic acids in human tumours (Green et a l,  
1980; Mackey et a l, 1976). Yet, the ability of inducing tumours in animals, as well as to 
transform cells, has established adenoviruses as a precious model system for probing the 
mysteries of oncogenesis (Shenk, 1996).
The above in vitro transformation of cultured cells by adenoviruses was first 
demonstrated by McBride and Wiener (McBride and Wiener, 1964), who infected 
cultures of new-born hamster kidney cells with human adenovirus type 12 and detected 
transformed cells about 8 to 10 weeks later. Subsequently, a report (Freeman et a l, 
1967) showed the transformation of rat embryo fibroblasts by the same adenovirus. The 
studies of adenovirus-infected cells have progressed much since then, and these have 
made innumerable contributions to the understanding of viral and cellular gene 
expression and regulation, DNA replication, cell cycle control, and cellular growth 
regulation (Shenk, 1996).
One of the major contributions to modern biology of the adenovirus system was 
however to host the discovery of mRNA splicing. Studies on the biogenesis of viral 
mRNA first showed that many mRNAs were produced from a large nuclear transcript
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(Bachenheimer and Darnell, 1975; Weber et al., 1977), and subsequent analysis of the 
adenovirus mRNA structure revealed the existence of introns (Berget et al., 1977; Chow 
et al., 1977). Nowadays, the usefulness of adenoviruses as vectors for gene therapy is 
the subject of intense exploration (Shenk, 1996).
1.1.2. Classification
Over 100 serotypes of adenovirus are classified within the family Adenoviridae. 
possibly the most diverse family of DNA viruses (Kitchingman, 1994). However, as not 
all of the family members contain the same common antigen, two genera have been 
established, based on a common antigen characterisation, which resides in the hexon of 
the outer capsid (Pereira et al., 1963): Aviadenovirus (lack a common antigen) and 
Mastadenovirus (share genus-specific antigen -  bovine adenovirus serotypes 4-8 are an 
exception (Wadell, 1994)).
L I.2.1. Aviadenoviruses
This genus is limited to viruses of birds. The known hosts are fowl, turkey, goose, 
pheasant and duck. Aviadenoviruses can only replicate in avian cells, preferably from the 
homologous species (Russell, 1994).
The prototype avian adenovirus is also known as CELO (Chicken Embryo Lethal 
Orphan), and it has been the major subject of avian adenovirology for a number of years. 
The interest was partially based on the fact that CELO causes tumours in baby hamsters 
(Sarma et al., 1965). Yet, interest in CELO virus has waned in recent years, as there are 
few serious health or economic consequences of its infection (Chiocca et al., 1996).
Another avian adenovirus was discovered to cause an epidemic of reduced laying 
and soft-shell or shell-less eggs in some flocks of chickens in 1976, and was thus 
denominated EDS’76 (Egg Drop Syndrome 1976 virus) and shown to be a duck 
adenovirus (Russell, 1994), strain 127.
1.1.2.2. Mastadenoviruses
This genus comprises virus that infect mammals, including human, simian, bovine, 
equine, porcine, ovine, canine, murine and opossum viruses.
The serotype is defined through quantitation of neutralisation with hyperimmune 
sera, and the ratio of homologous to heterologous neutralisation titer must be greater
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than 16. The designation of recombinant should be used only when the two parent 
genomes have been identified (Wadell, 1994),
There are 47 human adenovirus serotypes (cf. Table 1.1) known to date (Shenk, 
1996), and these are distinguished on the basis of their resistance to neutralisation by 
antisera to other known serotypes. The type-specific neutralisation is predominantly the 
result of antibody binding to epitopes on the virion hexon protein and the terminal knob 
portion of the fiber protein (Norrby, 1969b; Toogood et a i, 1992). Various other 
schemes of classification have produced similar groupings, suggesting that the 
classification based on hemagglutination is a reasonable standard (Shenk, 1996).
Table 1.1- Classification and properties of human adenoviruses (adapted from (Shenk, 1996; Wadell.
1994)).
Subgroup Hemag­
glutination
Group
Serotypes Oncogenic 
Potential 
(Tumours in 
Animals)
% ofG C  
in DNA
Tropism
Symptoms
A
B
IV 
(little or no 
agglutination)
I
(complete 
agglutination of 
monkey 
erythrocytes)
12, 18,31
3,7 ,11,  
14, 16, 
21,34,35
High
Moderate
48-49
50-52
Cryptic enteric 
infection
Respiratory 
disease; 
persistent 
infections of 
the kidney
C III 
(partial 
agglutination of 
rat erythrocytes)
1,2, 5,6 Low or 
none
57-59 Respiratory 
disease persists 
in lymphoid 
tissue
D II
(complete 
agglutination of 
rat erythrocytes)
8, 9, 10, 
13, 15,
17, 19,
20, 22-30, 
32, 33, 
36-39, 
42-47
Low or 
none 
(mammary 
tumours)
57-61 Keratocon­
junctivitis
E III 4 Low or 
none
57-59 Conjunctivitis;
respiratory
disease
F III 40,41 Unknown 52 Infantile
diarrhoea
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Although there is a noticeable variability within all the adenoviruses, they all present 
a similar structure and genome organisation, and many functional proteins exhibit a high 
conservation among the viruses of different subgroups. Therefore, the descriptions of 
morphology and molecular biology in the following sections will be based on the human 
adenovirus serotype 2 (Ad2), whose complete genome is known since 1984 (Roberts et 
a i,  1984), and also this is the serotype to which the protease studied in this work 
belongs.
1.1.3. Pathogenicity
There is a wide range of pathogenicity among the 47 human adenovirus serotypes 
(Wadell, 1994): Ad7 is the most severe cause of respiratory infections, whereas within all 
of the 28 serotypes of subgenus D which have a preference for the eye, only Ad8 is 
responsible for the most severe outbreaks of keratoconjunctivitis. Even within a serotype 
there are differences: Ad 19 prototype has seldom been isolated for the past three decades 
whereas its variant Ad 19a has been the cause of numerous outbreaks of 
keratoconjunctivitis since 1973.
Serotypes 1, 2, 5 and 6 are particularly involved in sporadic infections in adults, and 
these are the types commonly found latent in human adenoids and tonsils (Rowe, cited in 
(Andrewes et a i,  1978)). Serotypes 3, 4, 7, 14 and 21 in particular cause outbreaks of 
fever and pharyngitis, especially in service recruits and boarding schools, and the 
occurrence of conjunctivitis in some of those outbreaks has led to the use of the term 
‘pharyngoconjunctival fever’ (Andrewes etal., 1978).
Ad 18 and Ad31 were obtained from infants with gastrointestinal disease, but it is 
still difficult to evaluate their role as a cause of diarrhoea. Ad 14 causes outbreaks among 
military recruits, Adi 1, Ad34 and Ad35 cause persistent infections of kidneys. Ad4 
(subgenus E) is responsible for epidemic outbreaks of respiratory disease among military 
recruits, and a distinct genome Ad4a is second only to Ad8 as a cause of adenovirus- 
associated eye disease in Japan. Ad40 and Ad41 are second only to rotaviruses as a 
cause of infantile diarrhoea, but in contrast to rotaviruses they cause this illness 
throughout the year (Wadell, 1994).
1.1.4. Morphology
The adenoviruses are non-enveloped viruses, icosahedral in shape, and with a 
diameter ranging from 70 to 100 nm (cf. Figure 1.2). The virions are composed of DNA
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(13% of total mass), protein (87% of total mass) and trace amounts of carbohydrates, as 
the fiber protein of the vinon is modified by addition of glucosamine (Green and Pina, 
1963, Ishibashi and Maizei. 1974a; Ishibashi and Maizel, 1974b). The virus consists of a 
protein shell enclosing a DNA-containing core, and the shell (capsid) is made of 252 
subunits (capsomeres), of which 240 are hexons (surrounded by six neighbours) and 12 
are pentons (surrounded by five neighbours) (Ginsberg et a i ,  1966). Each penton is 
located at a vertex of the particle and it consists of a base anchored in the capsid and a 
projecting fiber, whose length varies among different serotypes (Norrby, 1966; Norrby, 
1969a).
CA PSID
Figure 1.2- Scheme of an adenovirus virion. Figure 1.3- Schematic section of an
adenovirus particle. Vinon constituents are 
designated b\ their polypeptide numbers with 
the exception of the terminal protein (TP).
From (Stewart et al.. 1991).
The virion capsid is constituted of seven polypeptides (cf. Figure 1.3). Polypeptide 
II is the most abundant constituent, as hexon capsomeres are made of trimers of this 
protein. Polypeptides VI, VIII and IX were shown to be associated with the hexon 
(Everitt et a i,  1973), and these probably stabilise the hexon capsomere lattice, with 
polypeptides VI and VIII possibly bridging between the capsid and core components of 
the virion. Polypeptide III associates in pentameres to form the penton base protein (van 
Oostrum and Burnett, 1985), whereas polypeptide Ilia associates with hexon units that 
surround the penton, probably linking adjacent facets of the capsid and bridging between 
hexons and polypeptide VII of the core (Everitt et al., 1975; Everitt et a i,  1973) 
Polypeptide IV trimerises to form the fiber protein (van Oostrum and Burnett, 1985) that 
projects from the penton base, and to the combination of penton base and fiber the 
designation penton capsomere is given.
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The virion core contains four known proteins, as well as the viral genome. 
Polypeptides V, VII and mu are basic, arginine-rich components of the core (Hosakawa 
and Sung, 1976; Russell et a i, 1968), and all these proteins contact the viral DNA 
(Anderson et a i ,  1989; Chatterjee et a i, 1986). Although the function of mu protein is 
unknown (Hosakawa and Sung, 1976), polypeptide VII (the major core protein) is 
supposed to serve as a hi stonelike centre around which viral DNA is wrapped 
(Chatterjee et a i, 1986; Mirza and Weber, 1982), and polypeptide V can bind to a 
penton base (Everitt et a i, 1975) and it might bridge between the core and the capsid, 
positioning one relative to the other. The remaining protein present in the core, the 
terminal protein, is covalently attached to the 5’ ends of the viral DNA, and only two 
copies of it exist per virion. It serves as a primer for DNA replication (Challberg et a i,  
1980; Challberg and Kelly, 1981; Enomoto et a i ,  1981; Lichy et a i ,  1981; Tamanoi and 
Stillman, 1982), and it mediates attachment of the viral genome to the nuclear matrix 
(Bodnar a/., 1989; Fredman and Engler, 1993; Schaacke/nr/,, 1990).
1.1.5. Molecular Biology
Adenoviruses have provided an invaluable tool for pioneering studies on elementary 
cellular mechanisms in molecular biology. The organisation of genetic functions on the 
viral genome, mapping and temporal regulation of viral gene expression, replication of 
the viral genome, splicing of RNA, the importance of /m/?j-activating or enhancing 
genetic functions, promoter nucleotide sequence motifs interacting with specific host 
proteins, the role of sequence-specific promoter méthylations in the long-term silencing 
of genes, translational control by low-molecular-weight ‘virus-associated’ (VA) RNA, 
integration of viral (foreign) DNA into the host genome, specific shut-off of cellular 
genes in adenovirus-transformed cells, and other principles, have been recognised by 
using the adenovirus system (Doerfler, 1994).
1.1.5.1. Genome Organisation
The adenovirus genome consists of a single linear, double-stranded DNA molecule, 
with a molecular weight in the range of 20-25x10^ daltons (Green et a i,  1967; Van der 
Eb et a i ,  1969), ranging from 36 to about 45 kb (Kitchingman, 1994).
Encoded in the viral chromosome are five early transcription units (El A, E lB , E2, 
E3 and E4), two delayed early units (IX and IVa2), and one late unit (major late) that is 
processed to generate five families of late mRNAs (LI to L5), all of which are
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transcribed by RNA polymerase II, cf. Figure 1.4 (reviewed in (Pettersson and Roberts, 
1986)). The chromosome contains also one or two (depending on the serotype) viral 
associated (VA) genes transcribed by RNA polymerase III. The genome map is 
represented by convention with the E l A gene at the left end, and both strands of the viral 
DNA are transcribed with the rightward reading strand on the conventional map coding 
for the E l A, ElB, IX, major late, VA RNA and E3 units, and the leftward reading strand 
coding the E4, E2 and IVa2 units.
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Figure 1.4 - Map of transcription and translation of adenovirus type 2. Early mRNAs are designated E 
and late mRNAs are designated L, Polypeptides are identified by the conventional numbering system 
(Roman numerals) for the virion structural components and by size (kDa) for non-structural peptides
(Shenk. 1996).
Each of the adenovirus genes transcribed by RNA polymerase II originates multiple 
mRNAs that are differentiated by alternative splicing, and in some cases by the use of 
different poly(A) sites. As mentioned before, it was the analysis of adenovirus mRNA 
structure that led to the discovery of splicing (Berget et al., 1977; Chow et al., 1977).
Several individual adenovirus transcription units code for a series of polypeptides 
with related ftmctions. As discussed further below, the E l A unit encodes two proteins 
that activate transcription and induce the host cell to enter the S phase of the cell cycle; 
ElB  codes for two proteins which cooperate with E l A products to induce cell growth; 
E2 encodes three different proteins, all directly related to DNA replication; E3 encodes
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products that modulate the response of the host to the adenovirus infection; and the late 
family of mRNAs is related with the production and assembly of capsid elements. The E4 
unit is the only that seems to code for a diverse set of functions, mediating transcriptional 
regulation, mRNA transport and DNA replication (Shenk, 1996). The VA RNAs do not 
code for any polypeptide, but rather for polymerase III products that help in the 
regulation of the translation of viral mRNAs, perhaps also in the shut-off of cellular 
protein synthesis in adenovirus-infected cells (Doerfler, 1994).
1.1.5.2. Infectious Cycle
The replication cycle of the adenovirus is conventionally divided into two phases, 
separated by the onset of viral DNA replication (cf. Figure 1.5). The designation of early 
events applies to those which start as soon as the infecting virus interacts with the host 
cell, and includes adsorption, penetration, transcription, and translation of an early set of 
genes. The early viral gene products mediate viral gene expression and DNA replication, 
induce cell cycle progression, block apoptosis, and antagonise a variety of host antiviral 
measures. In HeLa cells infected at a multiplicity of 10 plaque-forming units (p.f.u.) per 
cell, the early phase lasts for about 5 to 6 hours, after which viral DNA replication is first 
detected. Concomitant with the onset of viral DNA replication, the late phase of the 
cycle begins with expression of a new set of late viral genes and assembly of progeny 
virions. The infectious cycle is completed after 20 to 24 hours in HeLa cells, and at the 
end of that, circa 10"^  progeny virus particles per cell have been produced, along with the 
synthesis of a substantial excess o f virion proteins and DNA that are not assembled into 
virions (Green and Daesch, 1961). Cells infected at high multiplicity seldom divide 
(Horwitz, 1971), and therefore at the end of the infectious cycle the DNA and protein 
content of the infected cell has increased about twofold (Shenk, 1996).
Early and late, although convenient terms for the description of events occurring 
during the replication cycle, do not correspond to a sharp functional distinction between 
early and late events, as this separation is often unclear. For example, early genes are still 
expressed at late times after infection, and the promoter which controls expression of the 
major late transcription unit also directs a low transcription level early after infection. 
The viral genes that code for proteins IVa2 and IX begin to be expressed at an 
intermediate time (Pettersson and Roberts, 1986) and therefore form a “delayed early” 
category.
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Figure 1.5 - Schematic diagram depicting the relative timing of the main events occurring during the 
adenovirus infection cycle. Viral gene products known to mediate each event are listed in parentheses. 
Times for stages of viral replication and interactions with host cell are as per growth of HeLa cells 
infected at a multiplicity of 10 p.f.u./cell. HeLa cells die at 20 to 24 hours after infection. Times for 
interaction with host organism are artificial and meant to place interactive events in a time frame 
relative to that of the viral replication cycle (from (Shenk, 1996)).
/. 1.5.2.1. Adsorption and Entry
The attachment of adenovirus type 2 to cells is mediated by the fiber protein 
(Londberg-Holm and Phiiipson, 1969), whose distal knob domain at the C-terminal of 
the protein is thought to bind to a cellular receptor (Devaux et al., 1987), The identity of 
this receptor is still a mystery, although three cellular membrane polypeptides have been 
captured on a penton-fiber affinity matrix and shown to inhibit Ad2 attachment to cells 
(Hennache and Boulanger, 1977). The finding that Ad2 binds to some cells but does not 
enter them effectively (Silver and Anderson, 1988) suggested the possibility that a 
second protein-protein recognition event should occur for internalisation, and this has 
now been identified. The penton base protein binds to specific members of a family of 
heterodimeric cell surface receptors designated integrins (Wickham et ai., 1993). Yet, 
the penton-integrin interaction on its own is not sufficient for viral binding to cells, as 
soluble fiber or fiber antibodies can block adsorption completely. Therefore, adsorption 
and internalisation is a two-component process which requires the interaction of both 
fiber and penton proteins with their related cellular targets.
Once adsorbed, the Ad2-receptor complexes diffuse into coated pits and are 
internalised by receptor-mediated endocytosis (Chardonnet and Dales, 1970a;
Introduction______________________________________________________________ 12
Chardonnet and Dales, 1970b; FitzGerald et a i,  1983; Varga et al., 1991). The process 
is triggered by the penton-integrin interaction, since purified penton but not fiber protein 
is rapidly internalised by cultured cells (Wickham et al., 1993). This process is quite 
efficient (Greber et al., 1993), as 80-85% of the viruses that bind to the surface of a 
susceptible cell are internalised, and penetration occurs quickly, with half of the adsorbed 
viruses moving to the endosomes within 10 minutes, with a subsequent 90% of the latter 
moving successfully to the cytosol within a half time of circa 5 minutes. This movement 
to the cytosol is somehow triggered by the acidic pH of the endosome (Pastan et al., 
1986; Seth et al., 1984; Svensson, 1985), and the penton base is thought to play an 
essential role in the process.
The virus particles are then transported through the cytosol to the nucleus by a 
process that probably involves microtubules (Dales and Chardonnet, 1973; Luftig and 
Weihing, 1975). About 40 minutes after penetration, virus particles can be seen at 
nuclear pore complexes, suggesting that release of DNA is occurring at the nuclear 
membrane. After 2 hours, about 40% of the internalised particles have released their 
DNA free from hexon proteins, although it is unknown which portion of the released 
DNA localises to the nucleus.
There is a sequential disassembly of the virion during the internalisation process 
(Greber et al., 1993). This happens by selective dissociation and proteolytic degradation 
of the virion constituents. The process starts with the loss of the proteins at the vertices 
of the particle: the fiber, the polypeptide Ilia, located near the peripentonal hexons (cf. 
1.1.4), and the penton are considerably lost by 15 minutes after penetration in the cell. 
Polypeptide VIII detaches form the particle as the penton capsomeres are lost, and 
degradation of polypeptide VI occurs shortly after the particle entry into the cytosol. The 
internal localisation of this polypeptide suggests that it might be degraded by the virus- 
coded protease (Mangel et al., 1993; Tihanyi et al., 1993; Webster et a i,  1993). As both 
polypeptides VI and VIII bridge from the DNA core to the capsid, their loss should 
prepare the particle for the release of its DNA. Somewhat later, polypeptide IX is 
released from the infecting particle, and finally the DNA-containing core is freed from 
hexons.
When the viral DNA reaches the nucleus, it associates with the nuclear matrix 
through its terminal protein (Bodnar et al., 1989; Fredman and Engler, 1993; Schaack et 
al., 1990). Apparently, this protein which arrives with the infecting genome is the first
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viral gene product that functions within the nucleus to initiate the program of viral gene 
expression.
1.1.5.2.2. Activation o f Early Viral Genes
Early adenovirus gene expression has three main objectives: (a) to induce the host 
cell in entering the S phase of the cell cycle, thus providing with an optimal environment 
for viral replication, in which El A and ElB  gene products are involved; (b) to set up 
viral systems protecting the infected cell from various antiviral defences of the host 
organism, where E3 and VA RNA genes contribute to these defences; and (c) to 
synthesise viral gene products needed for viral DNA replication. All these objectives rely 
on the transcriptional activation of the viral genome, and the main activating proteins are 
coded within the E l A gene (reviewed in (Nevins, 1992; Shenk and Flint, 1991)).
E l A is the first viral transcription unit to be expressed after the viral chromosome 
reaches the nucleus. This unit codes for two mRNAs during the early phase of infection 
which translate into two polypeptides usually referred to as 12S and 13 S E l A proteins, 
and three additional E l A mRNA species accumulate later in the infectious cycle 
(Stephens and Harlow, 1987; Ulfendahl et al., 1987), but no definite function has been 
described for their products. The primary E l A translation products undergo extensive 
phosphorylation (Harlow et a i,  1985), but the purpose of these modifications is not clear 
at present. The two above proteins encoded in the E l A region present three conserved 
regions, CRl, CR2 and CR3, separated by less highly conserved domains (Dyson et al., 
1992; Moran and Mathews, 1987; Nevins, 1992; Shenk and Flint, 1991; van Ormondt et 
al., 1980), and they do not exhibit sequence-specific DNA binding (Chatterjee et al., 
1988; Ferguson et al., 1985); instead, they bind to cellular proteins and modulate their 
fimction. The three conserved regions in the E l A proteins define domains that play 
major roles in protein-protein interactions. El A proteins activate the expression o f other 
adenovirus transcription units by increasing the rate of transcription (Nevins, 1981), and 
since they activate those genes in trans, they are usually referred to as ^a«5-activators. 
The mechanism of /ra/w-activation occurs through direct interaction of E l A proteins 
with auxiliary factors that mediate basal transcription, with activating proteins that bind 
to upstream promoter and enhancer elements, and with regulatory subunits that influence 
the activity of DNA-binding factors, and the three domains mentioned above mediate 
these protein-protein interactions which activate transcription (Shenk, 1996).
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The expression of the adenovirus VA RNA genes is also induced by El A proteins 
(Hoeffler et a i ,  1988; Hoeffler and Roeder, 1985; Yoshinaga et a i,  1986), and they are 
transcribed by RNA polymerase III, and their role in infection is explained below (cf. 
1.1.5.2.6).
Other than El A proteins, two more gene products have been observed to activate 
adenovirus promoters: E4-17 kd polypeptide (Hardy et al., 1989; Huang and Hearing, 
1989; Neill et a i,  1990; Raychaudhuri et al., 1990), and the E2 DNA-binding protein 
(Chang and Shenk, 1990; Morin et a i ,  1989), but the mechanism of transcription 
stimulation of the latter is unclear at present.
Generally, the early genes remain active during all of the viral replication cycle, 
although their rate of transcription decreases gradually, in part due to cell death. 
However, there are three known down-regulatory events, and in each of them it seems 
that a viral protein, accumulating as a response to an activation event, acts subsequently 
to inhibit continued transcriptional stimulation effected by one or more early promoter 
elements. First, E l A proteins can repress the activity of several known enhancers, 
including the enhancer lodged upstream of the E lA  gene itself (Borelli et a i,  1984; 
Velcich and Ziff, 1985). Second, whereas E2 DNA-binding protein activates some 
promoters, it apparently inhibits transcription from the E4 promoter by an unknown 
mechanism (Handa et a i,  1983; Nevins and Winkler, 1980). Third, the induction of API 
(a cellular transcription factor) activity by E lA  and cyclic AMP is transient (Muller et 
a i,  1989), and is antagonised by E4-14 kd which accumulates in response to the ElA- 
mediated activation of the E4 gene (Muller et a i ,  1992).
As soon as the early mRNAs are synthesised, they are translated on polysomes 
together with cellular mRNAs. If at first they do not seem to present any competitive 
advantage, as the infection passes on to the late phase, cellular mRNAs are removed 
from polysomes (Shenk, 1996).
1.1.5.2.3. Activation o f  the Host Cell
It has been known for long that adenovirus infections induce quiescent cells into 
starting the S phase of the cell cycle, thus creating an environment suitable for viral 
replication (reviewed in (Tooze, 1981)). As mentioned above, the function of E lA  
proteins is essentially to modulate the cell cycle, and this is accomplished by interaction 
with a retinoblastoma tumour suppressor protein, pRB, as this protein has been shown to 
inhibit cell cycle progression, causing cells to stop at mid-to-Iate Gi (Goodrich et a i.
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1991; Hinds et al., 1992). E lA  proteins disrupt a series of complexes which contain 
different pRB family members, multiple transcription factor subunits (E2F), and cyclins 
with associated kinases, These complexes regulate the cell cycle progression in a normal 
healthy cell, and their dissociation by E l A deregulates normal cell cycle control, allowing 
quiescent cells to start DNA synthesis as a consequence of infection.
However, there are two distinct regions in the E lA  proteins which can induce cells 
to progress from Gi to S through two independent mechanisms: the already mentioned 
binding to pRB family members, and also the binding to another cellular protein, p300. 
Presumably, the viral proteins utilise simultaneously the two mechanisms because they 
work more effectively than either alone, or because there may exist cells in which one 
pathway functions better than the other (Shenk, 1996).
Another viral early protein, ElB-55 kd, also modulates cell cycle progression. This 
protein aims at the cellular p53 tumour suppressor protein, akin to members of the family 
of pRB in that it also regulates progression from G% to S. It seems that p53 normally 
works as a component of a Gi checkpoint that is induced by DNA damage (Diller et al., 
1990; Hartwell, 1992; Lin et al., 1992), as it can block cell cycle progression and 
contribute to the activation of genes known to be induced by DNA damage. Currently, 
p53 is thought to transcriptionally activate genes that prevent entry into S phase, 
although it is not clear whether transcriptional repression by p53 also contributes to this 
process. The ElB-55 kd protein of Ad5 binds to p53 within infected cells (Sarnow et al., 
1982) and it can block transcriptional activation by p53. Therefore, like E lA  proteins, 
ElB-55 kd protein binds to a tumour suppressor protein, antagonises its normal activity 
and helps deregulating the cell cycle progression. However, in contrast to E l A proteins, 
ElB-55 kd alone is not enough to stimulate quiescent cells to start the S phase of the cell 
cycle. Supposedly, therefore, the ElB-55 kd protein works together with the E lA  
proteins in activating more efficiently quiescent cells. Also, as E lA  proteins somehow 
stabilise p53 by increasing its steady state level (Lowe and Ruley, 1993), E lB  proteins 
must contribute to the activation of quiescent cells by preventing the implementation of a 
cell cycle blockage by too high levels o f p53.
1.1.5.2.4. Inhibition o f Apoptosis
As mentioned above, E lA  proteins in quiescent cells can induce effectively cellular 
DNA synthesis, as well as transient cell proliferation. Yet, E lA  expression is not 
sufficient to induce long-term growth of primary cells, as besides inducing proliferation,
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E lA  proteins also cause apoptosis. Apoptosis, also designated programmed cell death, 
is associated with well-defined nucleus morphological changes as well as DNA 
fragmentation; this distinguishes it from necrosis, cell death characterised by extensive 
cytoplasmic destruction induced by an adverse environment or by damage (reviewed in 
(White, 1993; Williams and Smith, 1993).
Apoptosis induced by E lA  involves the induction of p53 (Debbas and White, 1993; 
Lowe and Ruley, 1993). High-level expression of p53 can either cause the blocking of 
the cell cycle progression (reviewed in (Perry and Levine, 1993)) or the induction of 
apoptosis (Clarke et al., 1993; Lowe et al., 1993; Shaw et al., 1992; Yonish-Rouach et 
al., 1991). E lA  proteins stabilise p53, causing it to accumulate in the nucleus (Lowe and 
Ruley, 1993), as mentioned previously, but both Ad5 E lB  proteins can prevent ElA- 
induced apoptosis (Rao et al., 1992). Whilst the Ad5 ElB-55 kd protein probably blocks 
apoptosis by binding to p53 and altering its function, either the ElB-19 kd protein or the 
cellular Bcl-2 proto-oncoprotein can block ElA-induced apoptosis in a more efficient 
way than ElB-55 kd (Rao et al., 1992). However, the mechanism of p53-induced 
apoptosis, as well as the mechanism of ElB-19 kd apoptosis blocking, remain 
unexplained. But, as either ElB-19 kd or Bcl-2 can block p53-mediated transcriptional 
repression (Shen and Shenk, 1994), it is possible that p53 might mediate apoptosis, at 
least partially, by repressing transcription.
Therefore, apoptosis is an example of a cellular response to infection, with the 
potential of inhibiting viral growth and preventing its spread within the infected 
organism. Yet, adenoviruses evolved in such a way that allowed the coding of a gene 
product that effectively blocks the cellular defence (Shenk, 1996).
1.1.5.2.5. Viral DNA Replication
As a consequence of the expression and subsequent action of E lA  proteins, the 
infected cell enters the S phase of the cell cycle, thus becoming the optimal environment 
for viral DNA replication (reviewed in (Challberg and Kelly, 1989; Hay and Russell, 
1989; Stillman, 1989)). In Ad2 replication starts at about 5 hours after infection of HeLa 
cells, at a multiplicity of 10 p.f.u. per cell, continuing until the host cell dies (cf. Figure 
1.5).
The viral chromosome presents inverted terminal repeats which function as 
replication origins. In vivo studies agree with a model in which adenovirus DNA 
replication takes place in two stages (Lechner and Kelly, 1977). In the initial stage,
Introduction____________________________________________________________17_
synthesis is initiated at any of the terminus of the linear double stranded DNA, 
proceeding continuously until the other end of the genome is reached. Of the two DNA 
strands, only one is used as a synthesis template, so that the replication products are a 
double stranded DNA composed of a parental and a daughter strand, together with a 
single strand of DNA. The second stage of the replication process comprises the 
complementation of the displaced single parental strand of DNA template. This strand 
forms a structure known as the “panhandle” by annealing its two inverted terminal 
repeats and thus forming a circle with a double stranded “handle” which is identical in 
structure to either termini of the initial linear duplex DNA. This similarity permits the 
same initiation of replication complex that operates in the first stage to recognise and 
generate a second complementary strand, thus creating another double stranded DNA 
composed of a parental and a daughter strand (Shenk, 1996).
The inverted terminal repeats include the origin of replication, and three functional 
domains have been established. The first domain, encompassing the first 18 base pairs of 
the DNA, is known as domain A. A cellular protein, ORP-A, is known to bind to the first 
12 bp (Rosenfeld et al., 1987), although its binding does not seem to be essential for 
replication, A complex formed by two viral proteins binds to the following 9 to 18 bp 
(Chen etal., 1990; Mul and van der Vliet, 1992; Temperley and Hay, 1992), the terminal 
protein (TP) and the DNA polymerase. Both these proteins are coded in the E2 region of 
the viral genome, and TP is synthesised as a precursor (pTP) which is active in the 
initiation of DNA replication (Challberg et a i, 1980; Stillman et a l ,  1981) and found 
covalently bound to the 5’ ends of the viral chromosome, as mentioned earlier. This 
precursor is cleaved later on during virus assembly by the viral protease to generate TP, 
which remains bound to the genome (Challberg and Kelly, 1981), although it seems that 
both the cleaved portions of the protein remain associated with the genomic termini 
(Schaack et al., 1990). The preterminal protein functions as a primer for the replication 
of DNA (Rekosh et al., 1977), by preserving its terminal sequence integrity during 
several rounds of DNA replication, With regard to the DNA polymerase, it possesses 5’ 
to 3’ polymerase activity as well as 3’ to 5’ exonuclease activity, which is possibly used 
as a proof-reading function during the polymerisation process (Field et al., 1984).
Domain B goes from base pairs 19 to 39, and domain C from 40 to 51, and although 
these are not essential for replication, they do enhance the efficiency of initiation, by 
binding cellular factors. Thus, domain B binds nuclear factor I (NF-I) and domain C
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binds nuclear factor III (NF-III), but whereas NF-I is known to interact with the pTP- 
polymerase complex and stabilise it at the origin (Bosher et a l ,  1990; Chen et a l,  1990; 
Mul and van der Vliet, 1992; Mul et a l, 1990), stimulated by a third viral protein (E2 
single-stranded DNA-binding protein, DBP (Cleat and Hay, 1989; Stuiver and van der 
Vliet, 1990)), the mechanism by which NF-III stimulates initiation remains unclear, and 
perhaps the finding that this nuclear factor induces DNA bending when NF-III binds to it 
(Verrijzer et a l ,  1991) will be related to its function. It is possibly interesting to note that 
both these nuclear factors are also transcription factors.
The elongation of the DNA chain requires two virus E2-coded proteins, the 
polymerase and DBP, and a cellular protein, nuclear factor II (NF-II). The function of 
DBP, which coats the single-stranded replication intermediates, seems to be the 
enhancement of the efficiency of processing of the polymerase (Field et a l ,  1984; 
Lindenbaum et a l ,  1986), which will probably enable it to travel along the entire length 
of the genome after initiation at the terminus.
1.1.5.2.6. Activation o f Late Gene Expression and Host CeU Shutoff
As already mentioned earlier, the late genes start to be efficiently expressed after the 
start of viral replication. In adenoviruses, these genes are under the control of the major 
late promoter, which shows low levels of activity at early stages of infection, but 
becomes extensively more active at a later time after infection (Shaw and Ziff, 1980). 
Apparently, at least two factors contribute to the activation of this promoter: a c/j-acting 
modification in the viral genome, and the induction of at least one more virus-coded 
trans~?LQii\n% factor.
Several explanations have been put forward to describe the m-acting genome 
modification. It is possible that the viral chromatin has to undergo some composition 
modification during DNA replication in order to activate the major late promoter, or 
perhaps the replication enables the access of transcription factors to the promoter, as 
histones or histone-like proteins are removed and later rebound to DNA during 
replication, allowing a binding competition to DNA between transcription factors and 
histones. Another possibility is that the viral genome might establish a compartmentalised 
environment in the nucleus, thereby taking some time for some cellular factors to reach 
the appropriate environment for late gene expression. Discrete centres at which 
replication and transcription occur have been observed in infected nuclei by electron 
microscopy (Martinez-Palomo and Granboulan, 1967; Moyne et a l ,  1978), Whatever
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the mechanism, a transcription factor termed USF or MLTF has been observed to bind to 
the upstream site in the major late promoter (Carthew et a i, 1985; Miyamoto et al., 
1985; Sawadago and Roeder, 1985) only after the start o f DNA replication (Toth et al.,
1992), and when bound this factor is known to activate transcription. In addition to 
USF/MLTF, a viral transcription factor also contributes to the activation of the major 
late promoter, coded by the IVa2 gene (Tribouley etal., 1994).
After the onset of viral DNA replication and synthesis of the late mRNAs, the 
cytoplasmic accumulation of cellular mRNAs is blocked (Beltz and Flint, 1979), although 
their synthesis continues, which suggests that some sort of blocking of their transport 
occurs. This is mediated by a complex of two viral proteins (Sarnow et al., 1984), 
ElB-55 kd (Babiss and Ginsberg, 1984; Pilder et al., 1986) and E4-34 kd (Halbert et al., 
1985; Weinberg and Ketner, 1986), and these same proteins are necessary for efficient 
cytoplasmic accumulation of viral mRNAs late after infection (Babiss et al., 1985; Bridge 
and Ketner, 1990; Halbert et al., 1985; Pilder et a i,  1986; Weinberg and Ketner, 1986). 
The distinction between viral and cellular mRNAs is not based on the identity of 
individual mRNAs, A model has been proposed (Ornelles and Shenk, 1991) in which the 
E1B-E4 complex relocalises a cellular factor necessary for mRNA transport from its 
synthesis site to the nuclear pore, which would account for the simultaneous inhibition of 
host and activation of viral mRNA transport, as this transport factor would be moved 
from the sites of host transcription and processing to the viral centres. However, this 
putative transport factor has not yet been found.
Besides the facilitated transport of viral mRNAs from the nucleus, they are also 
preferentially translated in the cytoplasm late after infection (reviewed in (Zhang and 
Schneider, 1993)), and there are various regulatory components that work together in 
this selective translation. One of these components involves the cellular protein kinase R 
(PKR), which when activated by double-stranded RNA accumulated within adenovirus- 
infected cells (Maran and Mathews, 1988; OMalley et al., 1986) subsequently 
phosphorylates eIF-2a, thus inactivating this initiation factor and blocking translation of 
host cell mRNA, The adenovirus coded VA RNAs inhibit activation of PKR, and as they 
are found together with viral mRNAs (Mathews, 1980) they might protect viral protein 
synthesis.
The inactivation of eIF-4F (a cellular initiation factor with helicase properties) by 
dephosphorylation late in infection also helps in the selective translation of viral mRNA,
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as the five families of mRNAs encoded by the adenovims major late transcription unit all 
possess a non-coding region known as the tripartite leader sequence, a nucleotide 
sequence that virtually lacks secondary structure (Dolph et a i ,  1990), which therefore is 
postulated (Huang and Schneider, 1991) not to need helicase activity in order to be 
translated, unlike cellular mRNAs.
Finally, a viral protein, L4-100 kd, seems to activate selectively late protein synthesis 
(Hayes et al., 1990). This protein can bind to mRNA (Adam and Dreyfuss, 1987), 
suggesting a function at the polysome in facilitating viral translation.
1.1.5.2.7. Virus Assembly and Release from the Cell
The final stage of the virus infection is enabled with the production of large 
quantities of structural proteins. Trimeric hexon capsomeres are rapidly formed from 
monomers immediately after their synthesis in the cytoplasm (Horwitz et a l,  1969), 
helped by L4-100 kd (the same protein which stimulates late viral translation), which acts 
as a scaffold in the trimérisation by an unknown mechanism. Penton capsomeres 
assemble somewhat more slowly in the cytoplasm (Horwitz et al., 1969), the fiber and 
the penton base being assembled independently and joining in the end to form the 
complete penton capsomere (Horwitz et al., 1969; Velicer and Ginsberg, 1970). 
Following their production, hexon and penton capsomeres accumulate in the nucleus, 
where virion assembly takes place.
The process of assembly seems to start with the formation of an empty capsid 
(Phiiipson, 1984; Sundquist et a l ,  1973), with the subsequent entry of a viral DNA 
molecule. This DNA-capsid recognition event is mediated by the packaging sequence, a 
c/5-acting DNA element located about 260 bp from the left end of the viral genome 
(Grable and Hearing, 1992; Hammarskjold and Winberg, 1980; Hearing et a l ,  1987; 
Tibbetts, 1977). Presumably, one or more unknown proteins bind at that sequence and 
mediate the interaction between DNA and the capsid. The sequence is only effective 
when near to the end of the genome, suggesting that proteins which interact at the 
terminal origin of replication might have a role in this process. Capsid assembly does not 
seem to occur in the absence of interacting DNA, rather being probably initiated in 
association with viral DNA, mediated by the packaging sequence. The mechanism of 
DNA entry is controversial (D'Halluin et a l ,  1980; Hasson et a l, 1992; Weber et a l,  
1985); some suggest that the DNA enters the capsid as it is replicated, others suggest 
these events occur in separate nuclear compartments. L I-52/55 kd seems to facilitate the
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process (Hasson et a i,  1992; Hasson et al., 1989), probably also acting as a scaffold.
The L3-coded protease (Mangel et al., 1993; Tihanyi et al., 1993; Webster et al., 1993) 
functions late in the assembly process by cleaving virion capsid components, thus 
stabilising the virion particle and rendering it infectious.
Once the particle is assembled, it needs to exit the cell. Apparently, there are at least 
two viral mechanisms that facilitate the release and proliferation of progeny virus, both 
involving the disruption of intermediate filaments which are components of the 
cytoskeleton. After infection vimentin is cleaved very rapidly, apparently both by a viral 
gene expression independent process related with the adsorption process (Belin and 
Boulanger, 1987), and in response to protein ElB-19 kd (White and Cipriani, 1989;
White and Cipriani, 1990), thus collapsing the extended vimentin system into the 
perinuclear region (Defer et al., 1990; Zhai et al., 1988). Also late in the infectious cycle, 
the viral protease cleaves the cellular cytokeratin K18 (Chen et al., 1993), which 
prevents its polymerisation into filaments and causes it to accumulate in clumps, thus 
disturbing the mechanical integrity of the cell and rendering it more prone to lysis and 
subsequent release of the progeny virus.
1.2. The Adenovirus Protease
The role of proteases as biological regulators was neglected for many years.
Although for many early researchers proteases seemed to be boring catalysts present only 
to annoy biochemists, in recent years it became obvious that proteolysis plays a vital role 
in many biological processes (reviewed in (Wolf, 1992)). In particular, it became evident 
that viral proteases play a vital role in the morphogenesis of virus particles (reviewed in 
(Hellen and Wimmer, 1992)), namely in two processes: virus assembly, and subsequent 
maturation, related to infectivity.
Several characteristics of the adenovirus protease make it an attractive target for 
antiviral therapy: its role in virion infectivity, its unusual specificity, and its mechanism of
activation. |
!
1.2.1. History j
!
The first evidence of proteolytic processing of adenovirus proteins late in infection 4
was reported in 1973 (Anderson et al., 1973; Eron et a i ,  1974; Ishibashi and Maizel, j
•1974a), but the suggestion that it might be virus-encoded came from temperature- j
sensitive (tsl) mutant studies (Bhatti and Weber, 1978; Weber, 1976), where at the non- j
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permissive temperature (39°C) some virai protein precursors were observed not to be 
cleaved.
Whilst initial attempts to characterise the protease using inhibition studies (Bhatti 
and Weber, 1979) suggested that it was a chymotrypsin-like, non-metallo, neutral serine 
protease, sequencing studies lead to the finding of the gene coding for the protease of 
adenovirus type 2 within the viral chromosome (Akusjarvi et a i,  1981; Hassel and 
Weber, 1978; Kruijer et a i,  1980; Yeh-Kai et al., 1983) and its subsequent translation 
into amino acid sequence, revealing a molecular weight of 23 kDa, and this was 
confirmed by tsl mutant studies (Weber and Houde, 1987).
An initial study claimed that the protease was specific for Gly-Ala bonds (Sung et 
al., 1983; Tremblay et al., 1983), although none of the peptides Gly-Ala, Ac-Gly-Ala or 
Ac-Gly-Gly-Ala-0NH2 was able to be cleaved by the protease (Tremblay et a i,  1983), 
this being explained in terms of the need of a secondary structure for the enzyme to bind 
to the substrate. Six viral substrates are acknowledged to be processed by the protease 
(Tremblay etal., 1983): pVI, pVII, pVIH, pTP, pllla and L2-11 kDa.
Based on the cleavage specificity suggested above, it was proposed (Chatterjee and 
Flint, 1987) that the protease is synthesised as a 23 kDa zymogen which by means of 
autocatalysis cleaves an Ala-Gly bond at amino acids 46 and 47 of the protease, thus 
maturing into a 19 kDa phosphorylated active form.
More detailed substrate specificity investigations (Anderson, 1990; Webster et a l, 
1989a) finally agree to a consensus cleavage sequence of (I,L,M)XGG-X or 
(I,L,M)XGX-G, with the cleavage occurring at the G-X or X-G bonds, respectively. 
Furthermore, more inhibition studies (Webster et a l,  1989b) propose for the first time 
that the protease is a cysteine rather than a serine protease. A protease deletion mutant 
lacking the first 9 N-terminal amino acids was shown not to be active (Anderson, 1990), 
dismissing the proposal of autocatalytic activation. Also, immunoblot titrations showed 
(Anderson, 1990) that each virion should contain about 10 protease molecules.
The first protease recombinant (Houde and Weber, 1990) still seemed to support the 
possibility of autocatalytic activation, and the same report proposes a serine protease 
catalytic triad of His-54, Asp-102 and Ser-160, based on the alignment of the protease 
sequences known by then.
In 1993, consensus was reached on a cysteine protease classification (Tihanyi et a l, 
1993; Webster et a l, 1993) with Cys-104 or Cys-122 as likely candidates for the active
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site thiol. Also, the autocatalytic proposal for activation was definitely abandoned 
(Tihanyi et a i ,  1993; Webster and Kemp, 1993), and instead a peptide was found 
(Mangel et a l ,  1993; Webster et al., 1993) to activate the protease, which was shown to 
be derived from the C-terminal of the viral protein pVI, with the sequence 
GVQSLKRRRCF. A thiol-disulphide exchange mechanism of activation was proposed 
(Webster et al., 1993) in which an internal disulphide bond rearrangement might involve 
the conserved Cys-104, Cys-122 and Cys-126, although the protease does not seem to 
contain any internal disulphide bonds (Tihanyi et al., 1993). Viral DNA (or any 
negatively charged polymer) also appears to contribute to the activation of the protease 
(Mangel et al., 1993; Mangel et al., 1996), although there is not complete agreement on 
this (Matthews and Russell, 1995; Webster et al., 1994).
In adenovirus infected HeLa cells, non-viral substrates, cytokeratin-7 and 
cytokeratin-18, were found (Chen et al., 1993; Zhang and Schneider, 1994) to be 
cleaved by the protease, which should contribute to the weakening of the cell mechanical 
integrity and thus promote host cell lysis as well as release of progeny virions.
As more protease sequences were published, it became apparent that the mechanism 
of activation involves one of the only two conserved cysteines, Cys-104 or Cys-122 
(Grierson et al., 1994; Rancourt et al., 1994), whereas the remaining one should belong 
to the active site.
Further studies on the tsl mutant revealed that the mutation at proline-137 to 
leucine produced a slight structural change which affected its solubility (Keyvani-Amineh 
et al., 1995a), and that the mutation did not affect enzyme activity but rather its 
packaging into the virion particles (Rancourt et al., 1995).
Investigations on the role of the protease in the virus entry into cells (Cotten and 
Weber, 1995; Greber et al., 1996) indicated that it might be in an inactive oxidised form 
whilst in the oxidising environment outside the host cell, whereas it should become active 
when it enters the reducing environment either in the endosome or the cytosol. The 
degradation of protein VI during virus entry is thought to be due to the protease, which 
would seem to violate its substrate specificity under some circumstances (Greber et al.,
1996; Matthews and Russell, 1995) by cleaving sites such as PEGR-G (Greber et al.,
1996). Interestingly, the ovine strain 287 protease was also discovered not to agree with ^
the consensus sequence (Vrati et al., 1996), cleaving sequences such as MRAT-G and |
NTGW-G. I
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Human adenovirus type 2 protease expressed in insect cells was also shown to be 
active in the absence of activating peptide (Keyvani-Amineh et a l ,  1995b), cleaving 
ovalbumin and baculovirus protease, whereas expression of protease mutants also in 
insect cells showed (Jones et a l,  1996) that cysteine-122 of the protease should be the 
active site thiol and cysteine-104 involved in the activation mechanism with the activating 
peptide, and these results were soon confirmed (Rancourt et a l, 1996).
More inhibition studies (Brown et a l ,  1996; Sircar et a l ,  1996) showed that 
cysteine inhibitors successfully depress the formation of infectious particles in vivo 
(Sircar et a l ,  1996), and bovine pancreatic trypsin inhibitor was thought (Brown et a l ,  
1996) to inhibit by precipitating viral DNA, one of the putative cofactors of enzyme 
activity (Mangel et a l, 1993). Also these studies led to a new protease count of about 50 
molecules per virion (Brown et a l,  1996). Some isoforms of the protease were described 
(Keyvani-Amineh et a l ,  1996), which seem to be related to its oxidation state and 
influence its activity.
Finally, in the summer of 1996 the tridimensional structure of the protease-peptide 
complex was published (Ding et a l ,  1996), confirming cysteine-122 to be the active site 
thiol and the activating peptide to be covalently bound to cysteine-104 in the protease.
1.2.2. Classification and Mechanism of Proteolysis
Proteases are classified according to the essential catalytic residues at their active 
sites (Bond and Butler, 1987). There are four distinct classes of proteases identified to 
this moment: serine (EC 3.4.21), cysteine (EC 3.4.22), aspartic (EC 3.4.23) and metallo- 
proteases (EC 3.4.24). The serine proteases present an unusually reactive serine side 
chain at the active site which attacks nucleophilically the carbonyl carbon of the peptide 
bond and involve an intermediate acylation of the serine. Cysteine proteases (formerly 
known as thiol proteases) work in a very similar fashion to that of serine proteases, but 
instead of a nucleophilic serine there is a cysteine at the active site, and the mechanism of 
cleavage is depicted in Figure 1.6 and Figure 1.7. Aspartic proteases (formerly known as 
acid proteases) contain two aspartic residues at the active site, and they are thought to 
work via acid-base catalysis (Bond and Butler, 1987). Metallo-proteases contain a metal 
ion (usually zinc) at their active site, which probably enhances the nucleophilicity of H 2 O 
as well as polarising the peptide bond, prior to a nucleophilic attack (Bond and Butler, 
1987).
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The usual approach for the identification of the protease class to which a certain 
enzyme belongs is by assaying the protease in the presence of several inhibitors known to 
block with a reasonable specificity a certain type of active site (Barrett, 1977). However, 
most inhibitors for serine proteases also inhibit cysteine proteases, and the first inhibition 
studies that led to the classification of the adenovirus protease as a serine protease 
(Bhatti and Weber, 1979) failed to verify whether this was the situation. Subsequent 
studies corrected this assertion (Webster etal., 1989b), and its classification as a cysteine 
protease is now generally accepted and verified in several independent studies (Brown et 
a i,  1996; Cotten and Weber, 1995; Greber et at., 1996; McGrath et al., 1996; Rancourt 
et a i ,  1994; Sircar et a i ,  1996; Tihanyi et a i,  1993; Weber and Tihanyi, 1994).
As mentioned above, the cleavage mechanism of a cysteine protease is based on a 
thiol nucleophilic attack on the carbonyl carbon of the peptide bond, followed by the 
acylation of the thiol group and release of the N-terminal free peptide chain:
^  JN -H
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Figure 1 .6- Mechanism of cleavage by a cysteine protease. The first step consists of the active site tliiol 
acylation, with the release of the free N-terminal chain.
The next step involves the hydrolysis of the thiol acyl:
ÇH2 f —
OH N^NH
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Figure 1.7 - Mechanism of cleavage by a c>^steine protease. The second step (déacylation) consists of the 
hydrolysis of the thiol acyl, with the release of the free C-terminal chain.
From the mechanism described above, it can be seen that the active site is composed 
of a reactive cysteine side chain coupled with a histidine side chain which functions as a 
proton acceptor and donor. Therefore, another means of identifying whether a certain
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protease is of the cysteine class is by comparing the sequences of the several known 
serotypes for that protease and searching for conserved cysteine residues which can be 
assigned to the active site. This is shown in Figure 1.8.
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Figure 1.8 - Alignment of protease sequences from 15 adenovirus serotypes with increased gap length 
penalty and manual adjustments based on DNA sequence alignment. Alignments created using the 
Pileup program of the University of Wisconsin GCG package. The single conserved histidine and the 
two conserved cysteines are higlilighted, as well as the glutamic/aspartic acid thought to be involved in 
the catalytic site. Sequences taken from N.C.B.L ENTREZ Browser 
(http://www3. ncbi. nlm.nih. gov/Entrez).
From the sequence alignment, no serines were found to be fully conserved, whereas 
two cysteines, Cys-104 and Cys-122, are conserved in all of the known serotypes, as
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well as the necessary His-54, again confirming the adenovirus to possess a cysteine 
protease.
1.2.3. Regulation of Activity: The Activating Peptide
First described in 1993 (Mangel et a i,  1993; Webster et al., 1993), deriving from 
the C-terminal of the viral protein pVI, the peptide GVQSLKRRRCF was found to 
enhance the activity of the protease by what was assumed to be a thiol-disulphide 
interchange in which it would presumably rearrange some intramolecular disulphide bond 
within the protease, thus exposing the active site thiol (Webster et al., 1993). This 
assumption was based on the finding (Webster et al., 1993) that the oxidised (dimeric) 
form of the peptide was more able to activate the protease, together with the fact that the 
peptide GVQSLKRRRAF was unable to cause any observable activation. Another 
interesting result (Webster et al., 1993) was that neither the peptide KRRRCF nor the 
unrelated peptides CKQDPFLRFGK or CQIRSATSFCHLKNM were able to activate 
the protease, suggesting a high specificity in the activation mechanism by the activating 
peptide. However, no further studies were made in order to elucidate the nature of this 
specificity, and this was the main objective of this project.
Other studies (Greber et al., 1996; Jones et al., 1996; Mangel et a l, 1996) only led 
to the conclusion that the peptide should bind to the protease, although no requirements 
for the specificity of the binding were ever determined.
L 2,3,1. Mechanism o f Activation
In a similar approach to that o f identifying what are the important residues in the 
protease, an alignment of the known activating peptide serotypes was produced in order 
to determine which are the conserved amino acids in most of the sequences. Although 
currently 14 serotypes are known (cf. Figure 1.9), at the start of this project only the 
human types 2, 5, 12, 40 and 41, together with the murine type 1, were published 
(Davidson et al., 1993; Weber and Tihanyi, 1994).
From the sequences known by then, several characteristics were common to all 
serotypes: (a) all peptides had the same length; (b) cysteine-10 was always present at the 
same position; (c) the consensus sequence was of the form GXXXXKRRRCX, which 
seemed to suggest a role for the four positively charged residues to the left of the 
cysteine. The relevance of all of the above characteristics was assessed in this project.
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Human type 2 IVGL-GVQSLKRRRCF
Human type 5 IVGL-GVQSLKRRRCF
Human t y p e 12 IVGL-GVKSLKRRRCY
Human t y p e 31 IVGL-GVKSLKRRRCYHuman type 40 IVGL-GVKSLKRRRCY
Human type 41 IVGL-GVKSLKRRRCY
Canine t y p e 1 IVGV-GLSNVKRRRCF
Canine type 2 rVGV-GLSNVKRRRCF
Equine type 1 IVGV-GLHGVKRRRCFY
Murine type 1 IMGL-GLQPIKRRRCF
Ovine strain 2 8 7 MTGD-GVNFNTRRYCY
Avian strain 127 MVGD-GVRYGSQRYCY
Avian type 1 LSGT-GVATATRRMCY
Avian type 10 LSGT-GVNVSSRRLCY
Figure 1.9 - Alignment of pVI C-terminal sequences from 14 adenovirus serotypes. Amino acids in 
b l u e  highlight the conserved residues, whereas the dash indicates tlie putative site of cleavage by the 
adenovirus protease. Sequences taken from N.C.B.L ENTREZ Browser 
(http://www3.ncbi.nlm.nih.gov/Entrez). Equine type 1 and avian type 10 sequences were obtained from 
translation of DNA sequences upstream from the hexon gene (accession numbers L79955 and U26221, 
respectively), where pVI is usually located, and as such are subject to confirmation.
1.2.3,2. Activation in Other Proteases
Many enzymes are synthesised as inactive precursors {zymogens, or proenzymes), 
subsequently activated by some mechanism which usually allows control over the activity 
o f the enzyme. Proteases are no exception, and perhaps the most well known examples 
are pepsin, trypsin and chymotrypsin, all synthesised as precursors which are then 
activated by proteolysis (Stryer, 1988). However, this activation process is irreversible, 
and the control over activity has then to be exerted by means of specific inhibitors.
Yet, there are other known mechanisms of protease activation or enhancement of 
activation, encompassing activation by ions, glycosaminoglycans, lipoproteins, pH 
change, etc., and these can usually be associated with several pathologies, which stresses 
the importance of proteases in the control of biological processes. For instance, the 
cytotoxicity of arsenic is thought (Yih and Lee, 1994) to be due to arsenite ions (AsOs^ ) 
being able to induce the activity of a cathepsin-B like protease. Rat mast cell protease 1 
seems to be active only when bound to heparin (Pejler and Maccarana, 1994), whereas 
apoliprotein(a) was reported (Pursiainen et al., 1994) to be activated when bound to 
lipoprotein(a), and this could be a factor determining the atherogenic potential of 
lipoprotein(a). Cathepsin-D in brain cells was found (Kohnken et a l ,  1995) to present 
pH-dependent reversible activation, suggesting that its intracellular localisation could 
play a role in Alzheimer’s disease. Tetanus and botulinum-B neurotoxins appear to be
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zinc proteases (Schiavo et al., 1992) which when activated by reduction of the interchain 
disulphide bond can cleave synaptobrevin, an integral membrane protein of small synaptic 
vesicles,
Several protozoan cysteine proteases also seem to be activated by proteolytic 
cleavage (Eakin et a i, 1992; Nene et al., 1990), but curiously the activity of at least one 
o f them (Lonsdale-Eccles et a i ,  1995) also appears to be enhanced by a kininogen-like 
moiety, to which usually is attributed cysteine protease inhibitor behaviour.
Also the solvent can be responsible for enhancement of activity: the addition of 
formamide to a chymotrypsin aqueous solution markedly enhances its proteolytic activity 
(Yamamoto and Kise, 1994), whereas tertiary amines have a similar effect in both 
subtilisin and chymotrypsin (Yamamoto and Kise, 1993).
Several virus proteases have also been reported to be activated either by a solvent 
change or by binding to another molecule, as well as by proteolytic maturation. Whilst 
both equine arthritis virus (Snijder et a i ,  1992) and murine coronavirus (Baker et al.,
1993) code for cysteine like proteases which are matured by autocatalysis, the protease 
o f herpes simplex virus type 1 interestingly presents an activity quite dependent on 
solvent changes (Hall and Darke, 1995), effected by kosmotropes (water structure- 
forming cosolvents) such as glycerol, sodium citrate or phosphate, which seem to induce 
a conformational change in the molecule.
The binding of other molecules to viral proteases has also been reported to activate 
them. These molecules can be of cellular origin, as in the case of poliovirus 2A protease 
being activated by the eukaryotic translation initiation factor 3 (Wyckoff et al., 1990), or 
of viral origin, such as reported (Wiskerchen and Collett, 1991) for the p80 protease of 
bovine viral diarrhoea virus which needs the presence of 133-kDa polyprotein for 
development of activity, or Sindbis virus nsP4 protease which appears to require the 
protein nsP3 for efficient proteolysis (de Groot et al., 1990).
Other examples in particular are known in the Flaviviridae virus family: yellow fever 
virus NS3 protease domain requires NS2B domain (Chambers et al., 1991), dengue virus 
type 4 NS3 protease domain needs NS2B domain (Falgout et al., 1993), and hepatitis C 
virus NS3 protease was shown to request binding to NS4A protein for efficient 
proteolytic activity (Butkiewiczer«/., 1996; Kim a/., 1996; Shimizu a/., 1996).
A final interesting example of activation is the human cytomegalovirus protease, a 
serine protease which was shown (Margosiak et al., 1996; Qiu et a i ,  1996; Shieh et al..
F
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1996; Tong et a i, 1996) to dimerise in order to achieve full proteolytic activity. 
Inhibition of activation has also been reported (Baum et a i ,  1996a; Baum et a i,  1996b) 
to be achieved by preventing disulphide bond formation, using l,r-(dithio-di-o- 
phenyiene)-6/5-(5-phenylbiguanide) or flavins, which corroborates the dimérisation 
mechanism as a means of activation.
Materials and Methods___________   ^
2. Materials and Methods
This chapter describes ail the techniques and methods used in this work, with a 
theoretical introduction explaining the principles underlying each technique.
2 .1. Production and Purification of Recombinant Proteases
The cloning of adenovirus proteases in E. coli provided with a more abundant 
source of material, as well as the ability of easily obtaining mutants for the study of the 
importance of selected residues on the activation/activity o f the protease. It also allowed 
the preparation of reasonable amounts of proteases from other adenovirus serotypes 
using their DNA as a template without having to resort to viral cultures.
Most of the mutants used in this work had been already cloned, and in such 
instances the transformed cells were used for culture and expression of the protease in 
the same way as for the cloned proteases.
Several purifications were attempted, which consisted on various combinations of 
the methods cited herein.
2.1.1. Production of Recombinant Protease
The original viral DNA was amplified from the protease gene using polymerase 
chain reaction (PCR). For this purpose, primers were synthesised flanking the protease 
gene, with some point mutations in order to create restriction sites which would later 
enable the insertion of the amplified gene into a plasmid vector.
The proteases were cloned using a pE T -llc  (plasmid for expression by T7 RNA 
polymerase) system (Novagen), which utilises the bacteriophage T7 RNA polymerase 
promoter to direct high level expression of cloned genes in E. coli (Rosenberg et al., 
1987). This vector contains a p-lactamase gene (which confers resistance to ampicillin; 
Amp'^ as a selectable marker (cf. Figure 2.1),
As standard laboratory stocks of E. coli do not produce T7 RNA polymerase, all 
DNA manipulations can be performed in any RecA', K12 A  coli strain normally used for 
cloning (such as XL 1-Blue, selected with tetracycline, Stratagene) without concern 
about background expression (Glover and Hames, 1995).
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pET-llc
Figure 2.1 - Schematic representation of the structure of the p E T -llc  plasmid: ori, origin of replication;
Amp'', (3-lactamase gene conferring ampicillin resistance: lad , la d  gene: pT7-/ac. T7-lac promoter: 
Xba I and BamR I. restriction enzyme cleavage sites (Glover and Hames, 1995).
When protein expression is required, the plasmid is transformed into a host strain 
(BL21, VompTrBinB) that contains a chromosomaily integrated gene for the T7 RNA 
polymerase, which is present as a bacteriophage DE3 lysogen, with the above gene under 
control of the lacUVS promoter. The BL21 host has the advantage of lacking the outer 
membrane protease {ompT) as well as the Ion protease (Glover and Hames, 1995), which 
may help in stabilising foreign proteins that are sensitive to endogenous protease activity. 
However, if the cloned protein is toxic the low level expression of the T7 RNA 
polymerase in the BL21(DE3) strain can be sufficient to prevent a stable transformation 
or propagation of the plasmid, and two solutions can used to circumvent this problem: 
the use of the Tl-lac  promoter in the pET vector, which will place the cloned protein 
under the control of lac, thus reducing its background expression in the absence of 
isopropylthiogalactopyranoside (IPTG); or alternatively, inhibiting T7 polymerase by 
expressing its natural inhibitor, T7 lysozyme, using a second plasmid that codes for this 
protein: pLysS, which produces small amounts of the above protein so that it does not 
inhibit induced levels of T7 polymerase. Furthermore, T7 lysozyme also cleaves a bond 
in the peptidoglycan layer o f E. coli, thus allowing cells to be lysed under mild conditions 
such as ffeeze-thawing.
The above system can be switched on by adding IPTG to the culture, thus inducing 
the expression of T7 polymerase, which will in turn trigger expression of the cloned 
gene.
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2.1.1.1. Agarose Gels
Agarose gels are used to separate DNA or RNA according to its molecular weight, 
much in the same way as SDS-PAGE (Method 2.2.1) separates proteins. However, 
unlike proteins DNA already has an overall negative charge, which allows 
straightforward electrophoresis of samples.
2 M Tris-acetate 0.05 M EDTA, pH 8, (TAE, 50x) electrophoresis buffer was 
prepared as a stock solution, which was diluted accordingly for use as chamber buffer.
Samples were prepared by adding 80 pi of sample to 20 pi of loading buffer (40% 
glycerol, 5xTAE, 50 mM EDTA, 5 units/ml RNAse (QIAGEN), 0.05% bromophenol 
blue). Agarose gels were prepared by making solutions of 1-2% agarose, 0.0005% 
ethidium bromide (from a 0.05% stock solution), dissolved by heating in microwave at 
full power for 2 min, and left to cool down to set. Samples were then loaded on the gel 
and run at a constant voltage of 100 V.
Separated bands were visualised using UV illumination of gel, and appropriate DNA 
was excised with the aid of a scalpel for further processing.
2.1.1.2. Polymerase Chain Reaction
This method is used to amplify from a given template a certain portion of DNA 
whose limits are defined by the oligonucleotide primers provided. There are three 
temperatures in each amplification cycle: the temperature required for DNA melting 
(dénaturation from double strand to single strand), followed by cooling for 
oligonucleotide primers to anneal with their target sequences, and a final optimum 
temperature for the primers to be extended with DNA polymerase. This cycle is then 
allowed to repeat for several times, so that the products of an amplification cycle can be 
used as templates for the next, thus allowing an exponential increase of the desired 
product (Sambrook a/., 1989).
Oligonucleotide primers were designed with the aid of the Macintosh application 
Amplify (Engels, 1992), and synthesised using a Beckman Oligo 1000 DNA Synthesizer, 
at a concentration of 30 pM.
Viral DNA (0.5-2 pg) was washed with 1 ml ethanol together with 0.5 ml of 
chloroform and 40 pi of 3M sodium acetate, left for 5 min and centrifuged at 13000 rpm 
for 5 min (MSE Micro Centaur). The supernatant was discarded, 1 ml of 70% ethanol 
was added, and the mixture was centrifuged again at 13000 rpm for 1 min. The
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supernatant was removed and the DNA pellet was left to dry, and resuspended in 250 ul 
HPLC filtered (0.2 pm) water.
A PCR mixture was prepared with 2 pi of the above DNA solution, 2 pi of each 
primer, 10 pi ofdNTP solution (0.5 mM dATP, 0.5 mM dCTP, 0.5 mM dGTP, 0.5 mM 
dTTP), 2 pi of 100 mM MgS0 4  (BioLabs), 10 pi of 1 Ox ThermoPol buffer (0.1 M KCl, 
0.1 M (NH4 )2 S0 4 , 0.2 M Tris-HCl, pH 8.8, 20 mM MgS0 4 , 1% Triton X-100, 
BioLabs), 1 pi of Vent DNA polymerase (in 0.1 M KCl, 0.1 mM EDTA, 10 mM 
Tris-HCl pH 7.4, 1 mM DTT, 0.1% Triton X-100, 50% glycerol, BioLabs) and 71 pi of 
HPLC filtered (0.2 pm) water. 100 pi of liquid paraffin (Boots) were overlaid on the 
solution to prevent evaporation.
This mixture was submitted to 35 cycles of 94°C for 1.5 min, 55°C for 1.5 min and 
72°C for 2 min, and a final 7 min at 72°C (Techno Programmable Dri-Block PHC-1). 
The mixture was then run on an agarose gel (Method 2.1.1.1) to extract the amplified 
segment.
2,1.13. UN A Gel Extraction Protocol
This procedure is used to extract DNA from agarose gels (Method 2.1.1.1) and 
purify it for further use. It is essentially the same as described in (QIAGEN, 1995b).
To the excised gel band, 3 volumes (pi) of buffer QXl (QIAGEN) were added per 
volume of gel band (assuming a density of 1 mg/pl), and this was incubated at 50°C for 
10 min. One gel volume of isopropanol was then added and mixed, and this was 
centrifuged through a QIAquick spin column (QIAGEN) for 1 min at 13000 rpm (MSE 
Micro Centaur). The flow-through was discarded and the column was centrifuged with a 
further 0.5 ml of buffer QXl for 1 min at 13000 rpm. The column was then washed by 
spinning with 0.75 ml of buffer PE (QIAGEN) for 1 min at 13000 rpm, the flow-through 
was discarded and the column centrifuged for an additional 1 min at 13000 rpm to 
remove any residual wash buffer.
The DNA was then eluted by spinning the column with 30 pi of HPLC filtered 
(0.2 pm) water at 13000 rpm for 1 min.
2.1.1.4. Restriction of Plasmid and Insert
This procedure aims at cutting the ends of the insert and the plasmid so that the ends 
of both match in one direction only, to ensure proper translation of the insert. For this
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purpose, different restriction enzymes are used for each end of the insert, as well as in 
the plasmid.
The insert was cut by mixing 25 pi of the DNA solution obtained by Method 2.1.1.3 
to 1 pi of each of the two restriction enzymes Xba I and BamH I (Promega) and 3 pi of 
Multicore buffer (Promega), and incubating at 37°C for 2 h.
The plasmid was cut by mixing 10 pi of the plasmid pE T -llc  solution (50 pg/ml, 
Novagen) to 1.5 pi of each of the two restriction enzymes Xba I and BamH I (Promega),
1.5 pi of Multicore buffer (Promega) and 0.5 pi of HPLC filtered (0.2 pm) water, and 
incubating at 37®C for 2 h.
The restricted insert and plasmid were run on an agarose gel (Method 2.1.1.1) and 
purified using Method 2.11.3.
2.1.1.5, Ligation of Insert
The ligation of the insert uses an enzyme, ligase, to join the ends of the insert 
obtained by PCR and plasmid (Method 2,1.1.2), whose ends were cut by restriction 
enzymes (Method 2.1.1.4).
To 9 pi of restricted insert, 1 pi of restricted plasmid (pET-llc, Novagen) and 7 pi 
of filtered (0.2 pm) HPLC water (Rathbum) were added and incubated at 45°C for 
5 min, followed by incubation on ice for another 5 min. Finally 2 pi of T4 DNA ligase 
buffer (Promega) and 1 pi of T4 DNA ligase (Promega) were added and left incubating 
at room temperature for 4 h.
As a control for religation of plasmid, a mixture of 1 pi of plasmid and 16 pi of 
filtered (0.2 pm) HPLC water (Rathburn) was used and subjected to the same treatment 
described above.
2, L 1.6, Transformation o f Cells
Transformation of cells consists of introducing a foreign plasmid inside the cell by 
permeabilising temporarily the cell wall to the passage of DNA.
A single colony of bacteria from a stock agar plate or glycerol was inoculated in 
1 ml of Luria-Bertani medium (LB: 1% bacto-tryptone, 0.5% bacto-yeast extract, 1% 
NaCl, pH 7.0 (Sambrook et al., 1989)) with 50 pg/ml carbenicillin (in the case of 
BL21(DE3) cells no antibiotic was used) and left growing overnight (-15 h) at 37°C. 
This was used to inoculate 50 ml of LB with antibiotic (see above) which was grown at 
37°C until the culture reached an optical density (OD) of 0.4-0.6 (600 nm). The cells
Materials and Methods___________________________________     27
were then centrifuged at 4°C, 3000 rpm for 10 min (lEC Centra-3R) and the supernatant 
was discarded.
The cell pellet was resuspended in 10 ml of filter sterilised (0.2 pm), ice cold 0.1 M 
MgCE, and centrifuged at 4°C, 3000 rpm for 10 min. Again the supernatant was 
discarded and the cells resuspended in 4 ml of filter sterilised (0.2 pm), ice cold 0.1 M 
CaCb, then left on ice for 30 min. The cells were then competent for 4-5 days, at their 
optimum after 24 h.
To 200 pi of competent cells 10 pi (containing at most 300 ng of DNA) of the 
ligation mixture (Method 2.1.1.5) was added and incubated on ice for 30 min, followed 
by incubation at 42°C for 90 s, and again on ice for 5 min. Aliquots of 30, 70 and 100 pi 
o f cells were then plated on agar plates (Method 2.1.1.7) containing antibiotic (see 
above).
2.1.1.7. Agar Plates
LB-Agar medium was prepared by adding 15 g of bacto-agar per litre of Luria- 
Bertani medium (cf. Method 2.1.1.6) and autoclaving, followed by the addition of 
50 p^m l carbenicillin when necessary (cf. Method 2.1,1.6). The agar was then poured in 
sterile plastic Petri dishes and left to set.
Cells were then spread on the plate at the required volume, left growing overnight 
(-15 h) at 37°C and then stored at 4°C, where they can be kept for about two weeks as a 
stock.
2.1.1.8. Mini-Prep
This protocol is used to check whether a certain bacterial strain has a plasmid 
successfully transformed into it. It is essentially based on (QIAGEN, 1993), with 
modifications.
Transformed cells were plated in agar plates with 11.8 pg/ml tetracycline (in the 
case of XL 1-Blue) as well as 50 pg/ml carbenicillin and left growing at 37°C overnight 
(-15 h). Single colonies were picked and inoculated in 5 ml LB (cf. Method 2.1.1.6), 
50 pg/ml carbenicillin, 11.8 pg/ml tetracycline (in the case of XL 1-Blue) and left 
growing at 37°C overnight (-15 h). They were then centrifuged at 3000 rpm for 5 min 
(lEC Centra-3R), the supernatant discarded and the cells resuspended in 0.3 ml of buffer 
PI (QIAGEN). Then, 0.3 ml of buffer P2 (QIAGEN) was added and the mixture 
incubated at room temperature for 5 min, followed by addition of 0.3 ml buffer P3
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(QIAGEN) and incubation on ice for 15 min, shaking occasionally. The precipitate was 
then centrifoged for 15 min at 13000 rpm (MSE Micro Centaur) and the precipitate 
discarded.
To the volume of supernatant 0.8 volumes of isopropanol were added and this was 
centrifuged again for 15 min at 13000 rpm, and the supernatant carefully removed. The 
pellet was washed with 0.5 ml 70% ethanol, centrifuged again for 15 min at 13000 rpm, 
the supernatant discarded and the DNA resuspended in 10 pi HPLC filtered (0.2 pm) 
water,
2.1.1.9. Maxi-Prep
This protocol is used for obtaining up to 500 pg of plasmid DNA, which can be 
further used for cell transformation, It is essentially as described (QIAGEN, 1995a).
Transformed cells were plated on agar plates with 11.8 pg/ml tetracycline (in the 
case of XL 1-Blue) and 50 pg/ml carbenicillin and left growing overnight (-15 h) at 
37°C. Single colonies were picked and inoculated in 5 ml LB (cf. Method 2.1,1.6), 
50 pg/ml carbenicillin, 11.8 pg/ml tetracycline (in the case of XL 1-Blue) and left 
growing at 37°C overnight (-15 h). They were then used (2 ml) to inoculate 500 ml LB, 
50 pg/ml carbenicillin, 11.8 pg/ml tetracycline (for XL 1-Blue), which was left growing at 
37°C overnight (-15 h).
Cells were then centrifuged at 4500 rpm for 20 min (Beckman J6-HC), the 
supernatant discarded and the pellet resuspended in 10 ml o f buffer PI (QIAGEN). To 
this mixture, 10 ml of buffer P2 (QIAGEN) were added, mixed gently, and left 
incubating at room temperature for 5 min. Then, 10 ml of ice cold buffer P3 (QIAGEN) 
was mixed gently and this was left to incubate for 20 min on ice. The precipitate was 
centrifuged at 4°C, 12000 rpm for 30 min (Beckman 12-21), the precipitate discarded 
and the supernatant again centrifuged at 4°C, 12000 rpm for 15 min, and any further 
precipitate again discarded.
A QIAGEN-tip 100 (QIAGEN) column was the equilibrated with 10 ml of buffer 
QBT (QIAGEN), allowing the column to empty by gravity flow. The supernatant 
previously obtained was then applied to the column and it was allowed to enter the 
column by gravity flow. The column was then washed twice with 30 ml of buffer QC 
(QIAGEN) and the DNA eluted with 15 ml of buffer QF (QIAGEN). To the eluted DNA
10.5 ml of isopropanol were added and the precipitated DNA was centrifuged at 4°C, 
10000 rpm for 30 min, with the supernatant being carefully discarded, and the DNA
Materials and Methods___________________________________________________ 59
pellet was washed with 5 ml of 70% ethanol and centrifuged at 4°C, 10000 rpm for 
15 min. The 70% ethanol was discarded and the precipitated DNA was redissolved in 
250 pi of HPLC filtered (0.2 pm) water.
2,1.1.10. Determination o f DNA Concentration and Purity
This procedure enables an approximate determination of the concentration of several 
kinds of DNA, based on their absorbance at 260 nm. The following table is used for the 
above purpose:
Table 2.1 - Conversion factors between absorbance at 260 mn and DNA concentration (Sambrook et a i.
1989).
Type of DNA Cone, (pg/ml)
Double stranded (ds) DNA A2 6 O nm X 50
Single Stranded (ss) DNA A260nm X 40
Oligonucleotides A2 6 O nm X 20
2.1.1.11. DNA Sequencing
-There are two main techniques for the sequencing of DNA: the method of chemical 
cleavage (Maxam and Gilbert, 1977) and the controlled interruption of replication 
(Sanger e /a/., 1977).
The first method is based on the radioactive labelling of DNA on one end of its chain 
followed by limited scission of the chain, using conditions specific for each nucleotide or 
pair of nucleotides. Thus, dimethylsulphate can damage adenine (A) and guanine (G) by 
méthylation, and these bases are then readily removed by heating at neutral pH, leaving 
the free sugar. The backbone can then be cleaved by heating in the presence of alkali, 
with concomitant elimination of the sugar. However, as méthylation of G occurs at a 
much faster speed than that of A, the above reaction yields almost only breakage at G 
nucleotides. But if the methylated purine is treated with dilute acid both kinds of purine 
are cleaved. In the case of cytosine (C) and thymine (T), these pyrimidines are removed 
by hydrazine, followed by cleavage of the backbone by piperidine. Yet, in the presence of 
2 M NaCl, the removal of T is suppressed. Therefore, if four lanes of a polyacrylamide 
gel are loaded with each of these reaction products (G, A+G, C, C+T), fragments can be 
separated depending on the place of cleavage, ordered according to the number o f bases 
they contain, which will enable the deduction of the nucleotide sequence on the original 
DNA.
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The principle underlying the second technique is the generation of DNA fragments 
by means of controlled interruption of enzymatic replication. This is achieved by means 
of extending oligonucleotide primers that complement the DNA to be sequenced by 
using DNA polymerase I, in much the same way as for PCR. However, for each different 
nucleotide lane there is in the incubation mixture a 2’,3’-dideoxy analogue of one of the 
nucleotides, whose incorporation blocks further extension of the new chain, due to the 
lack of the 3’-hydroxyl terminus needed for the formation of the phosphodiester bond. 
Hence, fragments of various lengths will be generated which can be separated 
electrophoretically as in the previous method. The labelling in this method, however, is 
done by using radioactively labelled deoxyribonucleoside triphosphates, or alternatively 
using a primer tagged with a fluorescent compound (Smith et al., 1986).
The sequencing was done automatically, based on the latter method, at the 
University of St. Andrews DNA Sequencing Facility using a Perkin Elmer ABI PRISM 
DNA Sequencer, using a solution of 12 pi containing 500 ng of the DNA to be 
sequenced and 3-5 pmol of the appropriate primer, which was amplified using a Perkin 
Elmer GeneAmp PCR System 2400, with a temperature program of 20 s at 96°C, 25 
cycles of 10 s at 96°C, 5 s at 50°C and 4 min at 60®C, and a final temperature of 4®C.
2,1.1.12. Glycerol Stocks
Glycerol stocks are used to keep bacterial strains stored indefinitely (Sambrook et 
ar/., 1989).
These are made by adding 1 volume of autoclaved 30% glycerol to 1 volume of 
bacterial culture in polypropylene containers, stirred to mix, and frozen at -70°C until 
required.
2.1.1.IS.Cell Culture, Induction and Harvesting
Two methods were used for growing cells: the first used conical flasks and the 
second used a fermenter (Microferm Fermentor, New Brunswick Scientific). The 
advantage of using conical flasks is that the volume of culture can be chosen, but it has 
the disadvantage of a poorer reproducibility of experimental conditions and poorer 
control of variables such as agitation and aeration.
Both methods started with an inoculation of 5 ml LB medium (cf. Method 2.1.1.6), 
50 pg/ml carbenicillin, with either a single colony of transformed E. coli from a stock 
plate or a glycerol stock. This inoculum was left to grow for 6-8 h at 37°C, and 1 ml of
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this was used to inoculate 2x250 mi M9 (18.7 mM NH4CI, 22,0 mM KH2PO4, 42.3 mM 
Na2HP0 4 , 0.4% glucose, 1 mM MgS0 4 , 50 pg/ml ampicillin/carbenicillin) in 2x2 1 (for 
the conical flasks method) or 2x500 ml M9 in 2x1 1 conical flasks (for the fermenter 
inoculum), which was left growing with constant shaking overnight (-15 h) at 37°C.
For the conical flasks method, the absorbance (600 nm) was checked, and if the 
value exceeded 0.6 the culture was diluted 1.3-5 in M9 medium and left to grow until the 
absorbance reached the desired value. When the absorbance (600 nm) was between 0.4- 
0.6 the culture was induced with 1 ml 0.25 M IPTG per 250 ml culture and left growing 
at 37°C for a ftjrther 5 h with constant shaking. The cells were then centrifuged at 
10000 rpm (Beckman J2-21), the supernatant discarded, the cell pellet resuspended in 
100 ml suspension buffer (50 mM Tris-HCl, 5 mM EDTA, 4% glycerol, pH 8), 
centrifuged again as before, the supernatant discarded and the cell pellet resuspended in 
6 ml of suspension buffer, stored in polypropylene tubes at -20°C until required.
For the fermenter method, the 1 1 inoculum was used to inoculate 101 of M9, the 
temperature set to 37°C, the drive speed set to 300 rpm, the aeration set to 12 p.s.i., and 
the cells were left to grow for -3  h, until the absorbance (600 nm) reached -0.6. Then, 
1.1 g/ml IPTG were added to the culture, the temperature was set to 25°C and the cells 
were left inducing for -5  h. The culture was then centrifuged at 4500 rpm for 20 min 
(Beckman J6-HC), the supernatant discarded and the cell pellet resuspended in 30 ml of 
suspension buffer, stored in polypropylene tubes at -20°C until required.
2.1.1.14. Analysis o f Protein Expression by SDS-PAGE
This procedure aims at assessing the increase of protein expression after induction, 
by taking samples of the induced culture at given time points and separating them by 
SDS-PAGE (Method 2.2.1.1). Typically, the induced protein can be identified as the 
band whose intensity increases noticeably with time.
Samples (1 ml) were centrifuged at 13000 rpm for 1 min and the supernatant 
discarded. The pellet was resuspended in 100 pi PBS (0.14 M NaCl, 2.7 mM KCl, 
10 mM Na2HP0 4 , 1.8 mM KH2PO 4 , pH 7.4 (Sambrook et a i,  1989)) and 20 pi of 
{3-MeOH were added. This was sonicated at an amplitude of 6.5 microns (MSE 
Ultrasonicator), boiled for 2 min and loaded onto the gel, which was run as per Method
2 . 2 . 1. 1.
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2.1.2. Purification of Protease
After expression, the protease is lodged inside the bacterial cells and it must be 
extracted and purified in order to be used. This process involves disruption of the cells, 
digestion of all the bacterial DNA and separation of the protease from the host proteins. 
The disruption of the cells is achieved by means of freeze-thawing together with the 
action of lysozyme, which degrades the peptidoglycan layer of E. coli. The step of DNA 
degradation is accomplished by the use of DNAse, an enzyme that degrades all DNA to 
oligonucleotides, thus facilitating its separation. A preliminary separation of the protease 
from the host proteins is achieved by centrifugation, as the protease remains in the 
supernatant. After the protease extraction follows its purification, by Fast Protein Liquid 
Chromatography (FPLC), using anionic and cationic exchange columns.
FPLC is a fast way of purifying proteins, as the mobile phase is driven through the 
stationary phase with the aid of pressure rather than by means of gravity flow. In ion 
exchange chromatography, analytes are separated according to their charge, and in the 
case of proteins this is pH dependent (one protein will have net positive charge below its 
isoelectric point and negative above it) (Harris and Angal, 1989). Therefore, a positively 
charged protein will bind to a cationic (negative) column but not to an anionic (positive), 
and different proteins will bind with different affinities to anionic or cationic columns. 
Once bound, a protein can be eluted by applying a high salt concentration to the column, 
which will exchange the charged protein by an ion, thus regenerating the column (Harris 
and Angal, 1989).
2.1,2.1. Extraction o f Protease
From the two methods used to produce the protease, via conical flask culture or 
fermenter (cf. Method 2.1.1.13), different size pellets are obtained. However, the 
extraction method is essentially the same, the only variation being due to the amounts of 
reagents used. Therefore, the following description applies to - 2  ml pellets originated 
from the conical flasks method. The differences regarding the fermenter pellets are 
indicated in (parenthesis).
To each 2 ml thawed cell pellet, 0.67 ml suspension buffer (cf. Method 2.1.1.13), 
6  mM (3-MeOH, were added, making it up to 4 ml with suspension buffer (to each 
-35 ml pellet. 5 pi 3-MeOH were added). To this mixture, 50 pi of 10 mg/ml lysozyme 
were added and incubated at 37°C for 15 min, followed by 3 steps of freeze-thawing
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(liquid nitrogen and 37°C). Then, 50 pi (200 pi) of 1 M MgS0 4  and 50 pi ( 100 pi) of 
2 mg/ml DNAse I (Boehringer Manheim) were added and the mixture incubated at 37°C 
for 15 min.
The suspension was then centrifuged for 1 0  min at 13000 rpm ( 15000 rpm) on a 
MSE Micro Centaur minicentrifuge (Beckman J2-21 centrifuge) and the precipitate 
discarded. The resulting solution was then further purified by FPLC.
In brief, the FPLC system used consisted of two pumps (P-500, Pharmacia) allowing 
a maximum pressure of 5 MPa connected to a gradient programmer (GP-250, 
Pharmacia) wliich enables the use of isocratic, stepwise and continuous gradients for the 
elution of proteins. Detection was performed at 280 nm using a UV detector (2238 
Uvicord SII, LKB Bromma).
2,1.2.2. FPLC with DEAF column
Diethylaminoethyl (DEAE) is a weak anion exchange group for ion-exchange 
chromatography. The strength of an ion-exchange group relates to the pH range in which 
the group remains ionised (Harris and Angal, 1989).
- C H - C H - N *
CH-CH3
Figure 2.2 - The structure of DEAE, a weak anionic exchange group.
This group will bind any protein whose net charge is negative at the operating pH. It 
was observed that the protease does not bind to this group at a pH o f 8 , whereas quite a 
few bacterial proteins do bind. Furthermore, the particular elution time of the protease 
enabled it to be separated fi-om most eluted proteins, as the protease migrates quite fast 
through DEAE.
The buffer used was either 25 or 50 mM Tris-HCl, pH 8.0, and depending on the 
sample volume one of two columns was used: a 30 x 1 cm column for the smaller 
samples and a 40 x 1.6 cm column for larger samples. In both the packing was DEAE- 
Sepharose Fast Flow (Sigma). Typical flow rates were 1-2 ml/min, depending on the 
purification procedure.
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2. L 2.3. FPL C with Heparin/CM column
Heparin and carboxymethyl (CM) are both cationic exchange groups, the first being 
a strong ion exchange group and the latter a weak (cf. Method 2.1.2.2).
co o - CH2OSO3-
-o-----------y-----o\ H  H /  \ H /O'
- o -
H OSO3- H NHSO3-
Figure 2.3 - The structure of heparin, a strong Figure 2.4 - The structure of CM, a weak cationic 
cationic exchange group. exchange group.
Once the protease has been separated from most proteins, and as it does not bind to 
positively charged groups, it should bind to negative groups. This was found to be the 
case. Therefore, running the DEAE purified protease through either or both these 
cationic exchange groups should enable a final separation of the protease from any 
remaining contaminants.
The buffer used was 25 mM Tris-HCl, pH 8.0, and two combinations of columns 
were tried; a mixed 1 0  mm internal diameter column with 2  cm heparin (Sigma) packed 
above 6.5 cm of CM-Sepharose (Sigma), and a 5 x 1 cm heparin column followed by a 
1 1 x 1 cm CM-Sepharose column. Typical flow rates were 1-2 ml/min, depending on the 
purification procedure. The protease was typically eluted at an isocratic gradient of 10% 
1 M NaCl, 25 mM Tris-HCl, pH 8.0.
2.2. Determination of Protein Concentration
Protein concentration was determined by comparison to solutions of known 
concentration of Soya bean trypsin inhibitor (SBTI), either by SDS-PAGE or using the 
Bradford reagent.
2.2.1. SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is the 
name given to a technique by which proteins are separated based on their molecular 
weight (Shapiro etal., 1967), improved by Laemmli (Laemmli, 1970).
This consists of denaturating the proteins by the action of an anionic detergent such 
as sodium dodecyl sulphate (SDS), which also binds to the main chain of proteins.
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conferring a large net negative charge to the protein, mercaptoethanol (P-MeOH) being 
also added to reduce any disulphide bonds. The SDS complexed protein has then a 
charge roughly proportional to its molecular weight, and it can be separated on an 
electric field,
In order to separate the proteins, a support must be provided, and this is 
accomplished by polyacrylamide gels, which can be synthesised by polymerisation of 
acrylamide using methylenebisacrylamide as a cross-linking reagent, in the presence of 
persulphate (Stryer, 1988) and N,N,N’,N’-tetramethylethylenediamine (TEMED), a 
photochemical catalyst (Pombeiro, 1983) which stabilises the formation of sulphate 
radicals (Sambrook et a l ,  1989):
CONH
H C = C H  + CONH — CH—CH~CH—OH—CH“ CH—OH—
CONH /  \  Y 2
H .C = C H  s o /  ÇONH CONH CONH2 -0 H~C H -C  H -C  H -C H -C  H—0 H -
Figure 2.5 - Reaction of acrylamide with methylenebisacrylamide forming polyacrylamide, caused by the
presence of persulphate.
The polymerisation reaction is inhibited by atmospheric oxygen. By varying the 
concentrations of acrylamide and methylenebisacrylamide, various pore sizes can be 
achieved that can be used to separate different ranges of molecular weights. Usually, a 
less concentrated mixture is used to prepare the stacking gel, whose role is to “order” the 
proteins, so that they can be separated more easily in the more concentrated separating 
gel that lies contiguously below the stacking gel (Pombeiro, 1983).
The mobility of most proteins under these conditions is linearly proportional to the 
logarithm of their mass, After being separated on the gel, they can be stained by either 
Coomassie blue (Chrambach et al., 1967; de St. Groth et al., 1963) or silver staining 
(Oakley ef a/., 1980; Switzer ef a/., 1979).
Whereas Coomassie blue, an anionic dye, stains by attaching itself to the NH?” 
groups of proteins in slightly acidic media, van der Waals forces keeping the reactants 
together (de St. Groth et al., 1963), the mechanism of staining with silver appears to be 
more complex, and possibly not fully understood. Also, there are several protocols for 
silver staining (see, for example, (Nielsen and Brown, 1984; Shevchenko et a i ,  1996; 
Wray et al., 1981) and references therein) which can be classified into three basic
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categories (Merril, 1990); diamine or ammoniacal silver stains, non diamine chemical 
development silver stains, and photoreduction silver stains. The essence of these methods 
seems to be the ability of silver to complex with charged groups in the proteins with its 
subsequent reduction: carboxyl groups complexing with silver ions (Wray et a i ,  1981), 
metallic silver precipitated by reduction with formaldehyde (Dion and Pomenti, 1983; 
Kurosaki et al., 1984) and/or silver ions complexing with any charged group (Dion and 
Pomenti, 1983; Nielsen and Brown, 1984) are but a few of the published possibilities.
In the method used, after the fixation of proteins to the gel, a sensitising agent (such 
as Na2 S2 0 4 ) is used which will precipitate microgranules of silver sulphide (thus creating 
latent images of bands (Shevchenko et al., 1996)), followed by addition of silver nitrate 
and formaldehyde. Development is done in an alkaline medium (NaaCOa), so that 
formaldehyde can reduce ionic silver to metallic silver (Merril, 1990), together with 
Na2 S2 0 4 . The development is stopped by acidifying with acetic acid.
2.2.1.1. SDS-PAGE Mini Gels
Mini gels were prepared using a Bio-Rad Mini Gel kit. Separating gel solutions had 
a final concentration of 2.1 M acrylamide (15% (w/v), from a 30% stock solution), 
5.6 mM methylenebisacrylamide (0.87% (w/v), from a 2% stock solution), 0.373 M Tris- 
HCl (from a 1 M, pH 8.7 stock solution) and 3.5 mM SDS (0,1% (w/v), from a 10% 
stock solution), 4,4 mM TEMED and 1,5 mM (NH4 )2 S2 0 g (from a 0.44 M (10% (w/v)) 
stock solution freshly prepared), which was topped with water saturated butanol until the 
gel set.
Stacking gel solutions had a final concentration of 0.72 M acrylamide (5.1% (w/v), 
from a 30% stock solution), 9.1 mM methylenebisacrylamide (0.14% (w/v), from a 2% 
stock solution), 0.125 M Tris-HCl (from a 1 M, pH 6.9 stock solution) and 3.5 mM SDS 
(0,1% (w/v), from a 10% stock solution), 17 mM TEMED and 2.2 mM (NH4 )2 S2 0 g 
(from a 0.44 M (10% (w/v)) stock solution freshly prepared).
Samples (15-20 pi) were added to 5 pi of Magic Mix (0.35 M SDS, 0.25 M Tris, 
25% (v/v) glycerol, 0.05% bromophenol blue) and boiled for 2-5 min. They were then 
loaded onto the gel, and a constant current of 40 mA was applied per gel, which ran for 
-40  min.
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2.2.1.2. Coomassie Blue Staining
Gels were stained with -20  ml of a solution of 2.5 g of Coomassie Brilliant Blue 
R250 in 45% (v/v) methanol, 10% (v/v) acetic acid, 45% (v/v) water, for 10-15 min, and 
destained several times with 10-30 min -20  ml washes of an aqueous solution of 25% 
(v/v) methanol and 7.5% (v/v) acetic acid.
2.2.1.3. Silver Staining
Gels stained with Coomassie Blue (Method 2.2.1.2) were washed 3 times for 20 min 
in 30% (v/v) ethanol, then washed twice for 15 min with water. They were then soaked 
for 1 min in 1.4 mM Na2 S2 0 4 , washed twice for 1 min in water, shaken for 30 min in a 
solution 1 2  mM AgNOs, 1 mM HCHO, followed by a 1 min wash with water. It was 
then washed with a solution 0,57 M Na2 C0 3 , 6  mM HCHO and 20 pM Na2 S2 0 4  until 
bands developed.
It was then washed with 3.5% acetic acid for 10 min for the developing to stop and 
washed 4 times for 30 min with water.
-2.2.2. Bradford Reagent
This method is based in the binding of Coomassie blue to proteins (Bradford, 1976), 
as described in the Coomassie blue staining (Method 2.2.1). The binding of the dye to 
protein causes a shift in the absorption maximum of the dye from 465 to 595 nm, and it 
is the increase of absorbance at the latter wavelength that is monitored (Bradford, 1976).
2.2.2.1. Procedure for Bradford Reagent
Several dilutions of protein standards (SBTI) were prepared for a standard curve. 
To 0,8 ml of standards or sample 0.2 ml of Dye Reagent Concentrate (Bio-Rad) were 
added and vortexed. After 5 min the absorbance at 595 nm was read against a reagent 
blank. The absorbance was plotted against concentration of standards and sample 
concentration was read from the standard curve.
2.3. Western Blotting
Western Blotting consists of transferring electrophoretically proteins from a 
SDS-PAGE gel (Method 2.2.1) onto to a polyvinylidene difluoride (PVDF) membrane in 
such a way that a faithful replica of the original gel pattern is obtained (Burnette, 1981; 
Towbin et al., 1979). These bound proteins can then be marked with a specific antibody
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against which a second antibody is directed. The second antibody can then be either 
radioactively labelled or conjugated to fluorescein or peroxidase. The specific protein can 
finally be detected by either autoradiography or the peroxidase reaction product (Leong 
and Fox, 1990), respectively.
Peroxidase reaction was the method used, in which luminol, reacting with a peroxide 
in the presence of an oxidising agent such as peroxidase in a basic media, is oxidised with 
the concomitant production of light (Roswell and White, 1978):
o
+ 2Hp  ^ + 20H- 4H^O + + hvo e r o x id a s e
NHNH^  O
Figure 2.6 - Oxidation of luininol with the production of liglit.
If the blot is to be reacted again with the antibodies, it has to be stripped of the 
previous antibodies first.
2.3,1. Western Blotting Procedure
A blotting sandwich was assembled as follows: lower (positive) electrode, four 
layers of filter paper soaked in transfer buffer (48 mM Tris, 39 mM glycine, 20% (v/v) 
methanol, 0.13 mM SDS), polyvinylidene difluoride (PVDF) or nitro-cellulose 
membrane, SDS-PAGE gel (Method 2.2.1), four layers of filter paper soaked in transfer 
buffer and upper electrode (negative). This was run at a constant current of 50 mA for 
1 hour.
The resulting blotted membrane was then washed for 10 min with 20 ml blocking 
buffer (500 ml of PBS (0.14 M NaCl, 2.7 mM KCl, 1 0  mM Na2HP0 4 , 1 . 8  mM KH2 PO4 , 
pH 7.4 (Sambrook et a i,  1989)), 25 g of Boots dried milk powder and 500 pi of 
polyoxyethylenesorbitan monolaurate (Tween 20), microwaved at full power for 2 min), 
followed by incubation with the first antibody (5 pi in 20 ml blocking buffer) for 30 min 
at room temperature.
The membrane was then rinsed with 10 ml blocking buffer, washed for 10 min with 
2 0  ml of blocking buffer, rinsed again with 1 0  ml of blocking buffer, again washed for 
1 0  min with 2 0  ml of blocking buffer and finally rinsed once again with 1 0  ml of blocking 
buffer.
Materials and Methods __________________________________________________ Æ
The membrane was then incubated with the second antibody (Amersham peroxidase 
conjugated anti-rabbit IgG (4 pi in 20 mi blocking buffer) for 30 min at room 
temperature, washed again as above and rinsed with PBS.
The blot was then washed for 1 min in a mixture of Amer sham reagents 1 (2.5 mM 
luminol (Fluka) from a 250 mM stock solution in dimethyl sulphoxide (DMSO, Sigma),
0.396 mM p-coumaric acid from a 90 mM stock solution in DMSO, and 0 . 1  M Tris-HCl 
from a 1 M stock solution of Tris-HCl pH 8.5) and 2 (0.0192% (v/v) H2 O2 and 0.1 M 
Tris-HCl from a 1 M stock solution of Tris-HCl pH 8.5), drained and placed between 
two acetate sheets, and X-ray film (Fuji Medical X-Ray Film RX) was exposed to the 
blot for 1-5 min, and developed with a Kodak M3 5 X-OMAT Processor.
2.3.2. Stripping of Western Blot from Antibodies
PVDF membranes with antibodies previously bound were stripped by incubating the 
membrane at 70°C for 30 min in 0.10 M (3-MeOH, 69 mM SDS, 62.5 mM Tris-HCl 
(from a 1 M, pH 6.9 stock solution), followed by washing with PBS.
2.4.- Peptide Synthesis and Purification
The concept of solid phase peptide synthesis was first proposed by Merrifield 
(Merrifield, 1963), marking a radical change on the field of peptide synthesis. The 
elimination of excess reagents and by-products, as well as the solubility and purification 
of peptides, became much more simplified, as all unreacted products were easily washed 
away, and the growing peptide chain did not have to be soluble. The method was quickly 
improved (Merrifield, 1964a; Merrifield, 1964b) by changing the amino protecting 
groups to enable milder reaction conditions, and the resulting method was widely 
adopted to synthesise peptides successfully. The adoption of the Fmoc chemistry ensued 
to try and resolve some of the weaknesses of Merrifield’s method, mainly by introducing 
milder reacting conditions and by enabling a monitoring of the process (Atherton and 
Sheppard, 1989). This technique is continuously being improved in several ways, 
through prediction of difficult couplings (Van Woerkom and Van Nispen, 1991), 
optimisation of cleavage cocktails (Sole and Barany, 1992), various methods for 
monitoring coupling (Flegel and Sheppard, 1990; Salisbury et a l ,  1990; Young et a l,
1990) and use of more specific catalysts (Carpino, 1993).
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A curious future alternative for synthesising peptides could be the use of proteases 
(Schellenberger and Jakubke, 1991) by adjusting appropriate physicochemical reaction 
parameters, thus exploiting the intrinsic reversibility of hydrolytic reactions.
2.4.1. Peptide Synthesis
All peptides were synthesised using the chemical method of fluorenyl- 
methoxycarbonyl-polyamide (Atherton and Sheppard, 1989), using a Cambridge 
Research Biochemicals’ Pepsynthesiser II. The above is a two step method that consists 
o f a N-terminai elongation of a peptide linked to a polyamide resin by addition of C- 
terminal activated, side chain protected amino acids, followed by the N-terminal 
deprotection of the newly attached amino acid. The N-terminal protection, whose 
purpose is to prevent cross-reactions, consists of a fluorenylmethoxycarbonyl (Fmoc) 
group (Atherton et a i ,  1981). The activation at its C-terminal is achieved by means of a 
pentafluorophenyl ester (Opfp) group, which will react with the N-terminal of the 
peptide linked to the resin, catalysed by 1-hydroxybenzotriazole (HOBt) (Carpino, 
1993):
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-polyamide
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-polyamide + HO— — F
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Figure 2.7 - Reaction of Fmoc protected amino acid, Opfp activated, with polyamide coupled peptide.
catalysed by HOBt.
The polyamide resin holds the growing peptide chain, enabling the excess reagents 
to be washed from the reaction medium, which in turn allows the deprotection step to be 
performed, in which piperidine removes the Fmoc group from the N-terminal of the 
peptide chain:
CH—OCO-NH-CH—C —NH—CH—C— • ■ •— polyamide
& & I  &
0
NH-— CH— C—NH—CH—C—  • — NH 2 I I I I 2R, O R, O OH, CO.
0
CH—N
Figure 2.8 -Deprotection reaction of Fmoc protected peptide chain. The released dibenzofulvene- 
piperidine adduct absorbs at 330 nm. enabling its detection b>^  spectrophotometry.
In certain peptides, the deprotected N-terminal is required to be acetylated, in order 
not to contain any free amino groups. That can be achieved by reacting acetic anhydride
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with the peptide chain in the presence of pyridine (Van Woerkom and Van Nispen,
1991):
,o
 ^ \  NH?— CH—C------------polyamideO  + I ji
CH3 ^  °  -CHgCOO-o
CH C O —NH—CH—C------------ polyamide ^ I 1R O
Figure 2.9 - Acetyiation reaction of the N-terminal of a peptide chain with acetic anhydride
Dimethylformamide (DMF) is the solvent commonly used in solid phase peptide 
synthesis as it is a good solvating agent for both the resin and the Fmoc peptides, and it 
keeps both the resin and the growing peptide in an extended, mobile and unhindered 
conformation (Atherton and Sheppard, 1989). However, in order to minimise undesirable 
side reactions, this reagent must be reasonably pure, namely free of amines like 
dimethylamine, which can cause a significant loss of Fmoc protecting groups, leading to 
a double insertion of amino acids, In order to detect for the presence of this contaminant, 
Sanger’s reagent ( 1 -fluoro-2,4-dinitrobenzene, FDNB) (Sanger, 1945) is used (Figure 
2 . 1 0 ), and its removal is achieved by using molecular sieves to trap it.
NO CH  ^
Figure 2.10 - Reaction of FDNB with dimethylamine. The product absorbs at 381 nm, enabling its
detection spectrophotometrically.
In order to monitor the progress of the coupling reaction, the method of Counterion 
Distribution Monitoring (Salisbury et al., 1990; Young et a i ,  1990) was used. This 
method continuously monitors the total population of amino fimctions on the support 
resin using the distribution of a very small quantity of a reporter dye between these 
groups and cations in solution. As the medium is acidic, due to the presence of the 
catalyst HOBt, the amino groups bound to the resin are protonated, as well as a tertiary 
amine like diisopropylethylamine, and an inert anionic dye such as quinoline yellow will 
distribute itself among all available cations. However, as the coupling proceeds the 
number of free amines in the support resin decreases and the number of dye anions
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bound as counterions is displaced into solution, which will increase the absorption of the 
solution. This will reach a theoretical maximum when the reaction is complete.
Therefore, both the coupling reaction and the deprotection step can be monitored 
spectrophotometrically, the first by measuring the increase in absorbance due to 
quinoline yellow (measured at 436 nm, (Salisbury et a i ,  1990)) and the latter by 
measuring the absorbance of the released dibenzofulvene-piperidine adduct (measured at 
330 nm, cf. Figure 2.8 (Atherton et al., 1988)). Figure 2.11 shows a typical trace of the 
absorbance change for a complete cycle of coupling and deprotection.
Mixing Reaction Completion Deprotection
s«
436 nm 330 nm
Time
Figure 2 .11- Scheme of a typical trace of coupling and deprotection reactions, obtained
spectrophotometrically.
Once the peptide chain is synthesised, the peptide must be cleaved from the resin, 
and the side chain protecting groups must be removed. All side chain protecting groups 
were designed to be cleaved by the same conditions, so that they can all be removed at 
the same time;
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Figure 2 .12 - Side chain protecting groups of amino acids used in peptide synthesis. The dashed line
indicates the cleavage site.
Both the cleavage of the peptide from the resin and the removal of the side chain 
protecting groups are done at the same time by acidic cleavage, using trifluoroacetic acid 
(TFA) (Atherton et a i ,  1988), after washing the resin with a mildly acidic reagent such 
as acetic acid, as any residual DMF has a pronounced inhibitory effect on acidolysis 
(Atherton and Sheppard, 1989). The advised solvent washing sequence is t-amyl alcohol, 
acetic acid, t-amyl alcohol and diethyl ether, the intermediary t-amyl alcohol being 
necessary to avoid the exothermic mixing of DMF with acetic acid (Arshady et al., 
1981). The final ether is used in order to easily dry the resin.
In the process of cleavage, the protecting groups released might react again with the 
free side chain groups. In particular, methionine, cysteine, tryptophan and possibly 
tyrosine appear to be most at risk of reacting with the released carbonium ions (Atherton 
and Sheppard, 1989). Therefore, in the presence of these groups scavengers should be 
added to the reacting medium, such as anisole (a good scavenger for tBu 
trifluoroacetate) and ethanedithiol (the most efficient scavenger for tBu triftuoroacetate, 
it also scavenges Mtr groups, minimising alkylation of Trp by Arg(Mtr)) (Applied 
Biosystems, 1990). Whereas all the protecting groups based on an alkoxybenzyl linkage 
are cleaved by acids relatively fast (trifluoroacetic acid, room temperature, 0.5-2 h 
(Atherton and Sheppard, 1989)), as well as the linkage of the peptide chain to the resin.
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the Mtr protecting group of arginine (cf. Figure 2.12) requires longer cleavage times, as 
well as particular scavengers such as phenol in order to react with the released 
arylsulphonyl cleavage product (Atherton and Sheppard, 1989). Three or four arginines 
will typically require overnight reaction times, in which it is advisable to monitor the 
cleavage by removing samples to check whether all the Mtr groups are completely 
removed.
Once the cleavage is deemed to be finished, the peptide should be separated from 
the resin by means of filtration and the reaction mixture should be evaporated at reduced 
pressure, in order to wash and precipitate the peptide using ethyl ether. Several washes 
with ethyl ether are recommended so that all residual acid is removed. A final 
resuspension of the dried peptide in water followed by ffeeze-drying of the peptide 
should provide with a reasonably clean peptide.
2.4.1.1. Reagent Preparation
DMF from Rathburn was treated with 50 g of molecular sieves from Sigma per 2.5 1 
for 10-14 days. The sieves were activated by heating in a furnace at 200°C for 2 h. All 
DMF was filtered using a 0,2 pm pore nylon filter. It was then tested for the presence of 
amines by using 0.1% (w/v) FDNB in ethanol mixed in equal volumes with DMF, leaving 
at room temperature for 30 min, and then reading absorbance at 381 nm. All DMF with a 
reading above 0.15 was rejected, and treated fiirther with sieves until a satisfactory test 
was obtained.
All syntheses used PEG-PS resins from Millipore with the first amino acid already 
coupled. Resin loadings ranged from 0.10-0.21 meq/g, and of these, 0.5-1 g was used 
depending on the amount of peptide required. These were suspended in DMF and 
inserted in Omnifit columns.
All Fmoc amino acid O p^  esters weights were calculated so as to be in a 4-fold 
excess of the resin loading, and were dissolved in 1 ml DMF, 1 M HOBt, 0.8 mM 
diisopropylamine and 0.1 mM quinoline yellow (quinoline yellow solution), which was 
kept as a stock at 4°C, and made fresh every second day. All reagents were from Aldrich.
2.4.1.2. Semi-Automated Peptide Synthesis
The Cambridge Research Biochemicals’ Pepsynthesiser II is a machine controlled by 
computer (Apple lie), in which both the steps of coupling and deprotection are done 
automatically, the new amino acid addition being the only manual step. It was connected
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to a spectrophotometer which enabled the monitorisation of the coupling and 
deprotection procedures, as described above (cf. Figure 2.11). The program used to 
control of reagents flow was the following:
Step Action Time (min) Description
1 FLOW A 5 Wash with DMF
2 FLOW B 15 Deprotection with 20% piperidine in DMF
3 FLOW A 10 Wash with DMF
4 CALL 0 Wait for operator
5 FLOW S 5 Add new amino acid in quinoline yellow solution
6 RFCIRC 25 Coupling reaction (left on pause for at least 1 h)
7 FLOW S 1 Wash loading line
8 FLOW A 5 Wash with DMF
9 RECIRC 0.5 Clear lines and pump of excess reagents
10 FLOW A 5 Wash with DMF
11 REPEAT Repeat the cycle
Every synthesis started on step 1, with each new amino acid being added at step 5 
and left reacting for at least 1 h.
If acétylation was required, 0.53 M acetic anhydride, 12 mM pyridine in 1 ml of 
DMF were added at step 5 and left reacting for at least 1 h.
After the last amino acid was added and coupled, the program was left running until 
step 4, so that the last coupled amino acid was deprotected. The peptide coupled resin 
was then washed sequentially on a sintered filter with: -25 ml DMF, -10  ml t-amyl 
alcohol, -10  ml glacial acetic acid, -10  ml t-amyl alcohol and finally twice with -25 ml 
of diethyl ether, and dried by using reduced pressure to pull all the washes through the 
filter.
2.4.1.3. Peptide Cleavage from Resin and Removal o f Side Chain Protecting 
Groups
For each gram of resin, 40 ml of TFA from Rathburn, 1 ml of ethanedithiol and 1 ml 
of anisole both from Aldrich (0 . 6 6  ml of ethanedithiol, 0.66 ml of anisole and 0.66 ml of 
phenol in the case of a peptide containing Arg(Mtr)) were mixed gently together in a 
round bottom flask at room temperature.
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In order to evaluate the progress of the cleavage and removal of the side chain 
protecting groups, 1 0 0  pi samples were taken from the reaction mixture and put into a 
0.5 ml eppendorf, and the mixture was evaporated with the help of a gentle stream of 
nitrogen. The remaining residue was then dissolved in 1 0 0  pi of HPLC water and 
extracted four times with 200 pi of ether, the latter being discarded. The resulting sample 
was then analysed using Method 2.7.1. If only one peak (or one major peak) was 
observed, then it meant that the reaction had terminated.
After the completion of the reaction, the mixture was filtered to separate from the 
resin and washed twice with -10  ml of TFA. The filtrate and washings were evaporated 
to approximately 1 ml of solution in a rotary evaporator at reduced pressure, with a 
water bath at a temperature of-45°C . To the remaining solution -20  ml of ether were 
added in order to precipitate the peptide, which was left to settle, and the supernatant 
ether was carefully discarded. This procedure was repeated about five times, to try and 
wash the peptide as thoroughly as possible from any remaining impurities and solvents. 
After the last extraction, the ether was completely dried off by gently stirring the flask in 
the water bath, and the resulting peptide powder was dissolved in 1-5 ml of water and 
freeze-dried overnight. This resulted in a reasonably clean peptide, which was then 
further purified.
Z 4.1.4. M ini Method Peptide Synthesis
This method was designed to produce smaller amounts of peptide without recurring 
to the use of the Pepsynthesiser II. Basically, the chemistry used was the same as for the 
previous methods (Methods 2.4.1 . 1  to 2 .4.1.3) as well as the reagents, the only 
difference lying on the amount of reagents used and the support where the peptide was 
synthesised. This consisted of a polyethylene box where some perforations were made in 
order to fit Mobicols (Bioscience Services) flow-through columns in which about 75 mg 
of resin could be introduced, with an extra hole to which a vacuum line could be fitted. 
The amino acid weights used were 30-40 mg per coupling.
Each coupling step consisted of:
1. Washing 3 times the resin with DMF, sucking the column dry after each wash.
2. Filling the column with 20% piperidine in DMF and sucking dry, with another 
filling of the same reagent being allowed to percolate through the column.
3. After sucking dry the column, washing 4 times with DMF, sucking the column dry 
after each wash.
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4. Adding the amino acid dissolved in 300 pi DMF and 100 pi of a 1 M solution of 
HOBt in DMF to the resin, mixing it by using a plastic Pasteur pipette, allowing 
the peptide to react for at least 45 min at 35°C, and restarting a new step.
After all the amino acids were added, the last was deprotected by performing the 
above steps 1-3, and the resin was then washed twice with 0.5 ml of the following 
sequence of reagents: DMF, t-amyl alcohol, glacial acetic acid, t-amyl alcohol. It was 
then washed 4 times with 0.5 ml of ether and dried under vacuum.
The cleavage mixtures were the same as per Method 2.4.1.3, but a total amount of 
200 pi was used, and the reaction times were also the same. The resin was then washed 
with 200 pi TFA, the washings being collected into an eppendorf tube and this 
evaporated with a stream of nitrogen. To the residual solution -500 pi of ether were 
added to precipitate the peptide, which was then washed 5 times with ether, allowing the 
peptide to settle down and discarding the supernatant between each wash. After the final 
wash, the ether was vaporised using a stream of nitrogen and the peptide was dissolved 
in water and freeze-dried.
2.4.2. Peptide HPLC Purification
Preparative reverse-phase High-Performance (or High Pressure, as it is also known) 
Liquid Chromatography (HPLC) is a technique currently used to purify peptides 
(Atherton and Sheppard, 1989). The designation of reverse-phase is due to the stationary 
phase (the solid packing), being hydrophobic, presenting a lower polarity than the mobile 
phase, which is the reverse of the normal situation of a stationary phase with a higher 
polarity than the mobile phase (Pombeiro, 1983).
The eluent is usually a solvent of high polarity such as water in which low polarity 
solutes such as peptides tend to bind to the low polarity stationary phase, being eluted 
when increasing amounts of a lower polarity solvent such as acetonitrile are flowed 
through the column. The stationary phase usually consists of silica or polymer beads.
The high pressure has the advantage of enabling the separation of solutes with high 
resolution and in a relatively short time, in comparison to traditional chromatographic 
techniques (Pombeiro, 1983).
2.4.2.1. Reverse-phase HPLC
The HPLC system used was from Gilson, with two pumps model 303 delivering a 
pressure of up to -400 bar, with a manometric module model 802 to keep the working
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pressure range between 0-250 bar and a Holochrome UV detector selected for 226 nm. 
in order to detect for peptide absorbance. Pump A delivered a solution of 0.1% TFA in 
filtered water and pump B delivered 0.1% TFA in filtered acetonitrile.
The columns used were a Bio-Rad RSL CIS HL, with a length of 250 mm and an 
internal diameter of 4.6 mm, with a particle size of 5pm, for samples of a concentration 
of up to 1 0  mg/ml, and a Capital HPLC Ltd Spherisorb ODS2-Sb5-20061 with a length 
of 250 mm and an internal diameter of 10 mm, with a particle size of 5pm, for more 
concentrated samples.
Peptides were dissolved in 0.1% TFA, filtered (0.2 pm) and applied to the column 
equilibrated with 0.1% TFA in water. The maximum sample load was 2 ml. The gradient 
profile used to purify the peptides was as follows:
II
0 10 20 30 40
Time (min)
Figure 2 .13- Gradient profile of reverse-phase HPLC purification.
The flow rate was 1 ml/min for the Bio-Rad column and 4 ml/min for the Capital 
HPLC column. The peptides were eluted usually at 30-40% acetonitrile. The fractions 
collected were then analysed for purity using Method 2.7.1, and the appropriate fi-actions 
pooled and freeze-dried. The final peptides were considered to be virtually pure (only 
one peak shown on capillary electrophoresis analysis. Method 2.7.1).
2.5. Peptide and Protein Sequencing
The method commonly used for peptide and protein sequencing is based on the 
Edman degradation procedure (reviewed in (Han et al., 1985)). This consists of three 
steps: the coupling of phenylisothiocyanate (PITC), which can be activated with methyl- 
piperidine, to the N-terminal of the peptide or protein (Figure 2.14), followed by the
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removal of the first amino acid by acidic cleavage (Figure 2.15), and a final step of 
conversion of an unstable thiazolone to a more stable phenylthiohydantoin (PTH, Figure 
2.16).
The first step should be performed under mild alkaline conditions (pH in the range 
9-9.5), in order to avoid side reactions such as the hydrolysis of PITC with the 
consequent formation of aniline, which could react with excess PITC and form 
diphenylthiourea (DPTU), a compound that can interfere in the posterior identification of 
PTH-amino acids (Han et al., 1985),
The buffer solution should also be aldehyde-free, as side reactions between 
aldehydes and a-amines tend to form Schiff bases and related products, which can 
reduce the yield of the expected phenylthiocarbamyl-peptide.
N = C = S  + H^N—C - C —NH—C - C ^  
O O
Ri
NH—C—NH—C—C—NH—C—C *^ II I I8 0 0
Figure 2.14 - Edman degradation; the coupling of PITC with the peptide chain.
After the coupling reaction, the excess PITC, solvents and by-products should be 
removed, to follow with the cleavage step.
The acidic cleavage is usually performed using anhydrous trifluoroacetic acid, and 
care should be taken to avoid the acid catalysed hydrolysis of the peptide bonds by 
ensuring the absence of water in the solvent.
1^ Ra
NH—C—NH—C—C—NH—C—C '^I I I8 0 0
H+ n - M '
Figure 2 .15- Edman degradation: the cleavage of the phenyltliiocarbamyl peptide bond via cyclisation
in acidic media.
The final step ensures that the unstable anilino-thiazolinone derivatives of the amino 
acids are converted into more stable PTH-amino acids, and this is usually achieved by 
heating at 80®C for 10 min in 1 M HCl.
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))—NH"'^ O
HN-
Figure 2.16 - Edinan degradation: the conversion of the unstable thiazoiinone derivative to a more stable
PTH derivative.
The stable PTH derivative is then extracted and run on an HPLC system, where it 
elutes at a characteristic time which is matched with PTH-amino acid standards in order 
to determine which amino acid was in the original chain.
The most important side reactions consist of the amide groups of PTH-Asn and 
PTH-Gln being partially hydrolysed to PTH-Asp and PTH-Glu, and both PTH-Ser and 
PTH-Cys being decomposed during the conversion through a p-elimination, as well as 
PTH-Thr.
In automated Edman degradation, polybrene ( 1,5-dimethyl-1,5-diazaundeca- 
methylene-polymethobromide) is used as a film-stabilising carrier for the sequencing of 
proteins and peptides, which allows the reduction of wash-out of peptides.
2.5.1. Peptide Sequencing
Sample preparation consisted essentially on fixing the peptide to a membrane treated 
with polybrene (BioBrene Plus, Applied Biosystems) and loading it to the protein 
sequencer.
All the peptide sequencing was done at the University of St. Andrews using an 
Applied Bio systems Procise 491 Protein Sequencer.
2.5.2. Protein Sequencing
The protein sequencing methodology used involved separating the protein of interest 
by means of SDS-PAGE (similar to Method 2.2.1), followed by wet blotting (similar 
principle to Method 2.3) to transfer the protein to a PVDF membrane, and staining with 
amido black (similar principle to Coomassie Blue, Method 2.2.1.2 (Merril, 1990)) in 
order to visualise the protein band to sequence from the blot. The band can then be cut 
and loaded directly to the protein sequencer.
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The gels are made essentially as per Method 2.2.1, but instead of using 
methylenebisacrylamide as a cross-linking agent, piperazine di-acrylamide (PDA) is used 
in order to reduce N-terminal blocking (Bio-Rad, ).
Mini gels were prepared using a Bio-Rad Mini Gel kit. Separating gel solutions had 
a final concentration of 1.8 M acrylamide (12.5% (w/v)), 17 mM PDA (from a 30% 
(w/v) acrylamide, 41 mM PDA filtered (0.2 pm) stock solution, stored at 4°C in the 
dark), 0.375 M Tris-HCl, 3.5 mM SDS (from a 1.5 M Tris-HCl, 14 mM SDS, pH 8 . 8  
stock solution), 3.3 mM TEMED and 1.6 mM (NH4 )2 S2 0 g (from a 0.44 M (10% (w/v)) 
stock solution freshly prepared), which was topped with water saturated butanol until the 
gel set. Once set, the water saturated butanol was replaced by a 0.375 M Tris-HCl, 
3.5 mM SDS solution and left at 4°C overnight.
Stacking gel solutions had a final concentration of 0.70 M acrylamide, 2.8 mM PDA 
(from a 30% (w/v) acrylamide, 41 mM PDA filtered (0.2 pm) stock solution, stored at 
4°C in the dark), 0.375 M Tris-HCl, 3.5 mM SDS (from a 1.5 M Tris-HCl, 14 mM SDS, 
pH 8 . 8  stock solution), 6 . 6  mM TEMED and 3.3 mM (NH4 )2 S2 0 g (from a 0.44 M (10% 
(w/v)) stock solution freshly prepared).
The gels were pre-run for 1 h at 15 mA per gel until sample buffer (25% (v/v) 
glycerol, 0.10 M SDS, 62.5 mM Tris-HCl, 0.05% bromophenol blue, 0.71 M p-MeOH 
(added just before use), pH 6 .8 ) loaded in one lane reached the running gel, with a 
negative electrode buffer of 0.125 M Tris-HCl, 3.5 mM SDS, 0.05 mM glutathione 
(from a 10 mM stock solution freshly prepared), pH 6 .8 , and a positive electrode buffer 
of 75 mM Tris-HCl, 0.576 M glycine, 3.47 mM SDS.
Buffers were then replaced by 75 mM Tris-HCl, 0.576 M glycine, 3.47 mM SDS, 
0.08 M sodium thioglycollate (from a 1 0 0  mM stock solution freshly prepared) for the 
negative electrode buffer, and 75 mM Tris-HCl, 0.576 M glycine, 3,47 mM SDS as the 
positive electrode buffer. Samples (15-20 pi) were added to 5 pi of sample buffer (see 
above), boiled for 2-5 min and loaded onto the gel, and a constant current of 2 0  mA was 
applied per gel, which ran for -40  min.
A blotting sandwich was then assembled as follows: negative electrode, fibre pad 
soaked in transfer buffer (10 mM 3-[cyclohexylaminoj-1 -propanesulfbnic acid (CAPS), 
1 0 % (v/v) methanol), one sheet of filter paper soaked in transfer buffer, polyvinylidene 
difluoride (PVDF) membrane (previously soaked in methanol for -2  min, then in transfer 
buffer), the above gel (soaked in transfer buffer for at least 1 0  min with several buffer
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changes), one sheet of filter paper soaked in transfer buffer and positive electrode. This 
was run at a constant current of 300 mA for 2 h, with a cooling container that was 
changed after one hour. The resulting blotted PVDF membrane was then stained for 30 s 
with amido black stain (0.1% (w/v) amido black, 40% (v/v) methanol and 1% (v/v) 
acetic acid) and destained with several washes of distilled water. The appropriate band 
was cut with the aid of a scalpel and loaded to the protein sequencer.
All the protein sequencing was done at the University of St. Andrews using an 
Applied Biosystems Procise 491 Protein Sequencer.
2.6. Mass Spectrometry
Mass spectrometry is a technique that enables the determination of the molecular 
weight of molecules.
Basically, a mass spectrometer consists of a ion source where ionisation of the 
sample occurs, followed by ion separation through an electric and/or magnetic field. The 
separated ions are then detected and its mass-to-charge ratio is recorded (Rose and 
Johnstone, 1982).
All mass spectrometry was carried out at the University of Aberdeen using a Vestec 
Lasertec benchtop laser desorption time-of-ftight mass spectrometer. Laser desorption is 
an ionisation method in which polar non-volatile molecules (including salts) are coated 
onto a metal surface in a thin layer which is then subjected to a short but intense laser 
pulse that causes thermal desorption of alkali ions present as impurities in the metallic 
probe or added intentionally to the sample. These ions become attached to molecules to 
yield cationised species which are then accelerated out of the ion source. Little 
fragmentation of the molecules is observed, which enables the analysis of amino acids, 
peptides, nucleotides and oligosaccharides (Rose and Johnstone, 1982).
In ion separation by time-of-flight there is no magnetic separator and ions are 
separated by making use of their different velocities after acceleration through a 
potential. The ion velocity is mass dependent and therefore if ions are accelerated and 
then allowed to pass along a field-free region, the ions will arrive at the detector at 
different time intervals depending on their velocities, hence on their masses. Unlike other 
separation methods, this has no mass range limitations, thus allowing detection of ions of 
very high molecular weight (Rose and Johnstone, 1982).
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Samples (typically 1 mg/ml for peptides and 50-200 pg/ml for protease) were diluted 
1:10 with 0.1% (v/v) trifluoroacetic acid, and 0.5 pi was mixed with 0.5 pi o f matrix 
solution (1% (w/v) sinapinic acid (3,5-dimethoxy-4-hydrocinnamic acid) in 0.05% (v/v) 
trifluoroacetic acid) in 50% (v/v) acetonitrile. Spectra were an average of 64 scans.
2.7. Determination of Peptide Concentration
Peptide concentrations were determined either by quantitation of N-terminal amines 
by reaction with fluorescamine and compared to standard curves of peptides of known 
concentrations or by comparison of electropherogram areas resulting from capillary 
electrophoresis, again compared to areas of peptides of known concentration.
2.7.1. Capillary Electrophoresis
Classical electrophoresis is a process in which charged molecules are separated 
based on their movement through a fluid under the influence of an applied electric field 
(Weinberger, 1993). In capillary electrophoresis, samples are separated into their 
components by their respective mass-to-charge ratios, size and chemical interaction (Bio- 
Rad, 1996). Each analyte migrates electrophoretically inside an electrolyte-filled capillary 
past an absorbance detector and its light absorption generates a signal proportional to its 
concentration:
Capillary
UV \  Detector
Figure 2 .17- Scheme of capillary electrophoresis. The sample in the left vial is inserted into the 
capiilaiy and separated by an electric field. The separated analytes are detected at the other end of the
capillary.
In order to achieve both a good separation and resolution in a short time, voltage 
field strengths of over a thousand volts per centimetre can be applied. Capillary 
electrophoresis combines the high resolution of traditional gel electrophoresis (cf.
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Method 2.2.1) with the sensitivity, ease of use and high speed of HPLC (cf Method 
2.4.2.1).
The technique used to separate the analytes was Capillary Zone Electrophoresis 
(CZE). This technique consists of pre-concentrating the sample (sample stacking) by 
injecting it from a low-conductivity matrix into a run buffer which has a substantially 
higher conductivity (Bio-Rad, 1996; Weinberger, 1993). The samples must present a 
positive charge in order to migrate to the negative electrode, so they must be kept in a 
buffer at low pH. The output of capillary electrophoresis is called an electropherogram, 
which displays the absorbance of the outcoming analytes as a function of their elution 
time.
2 7.1.1. Sample Preparation and Analysis
All the samples had a volume of either 50 or 100 pi, and were composed 1:1:8 
respectively of the actual sample, filtered (0.2 pm) phosphate buffer (Bio-Rad) at pH 2.5 
and filtered (0.2 pm) HPLC water. These were run in a BioFocus 3000 capillary 
electrophoresis system, with a pressure injection of 20 PSI x s, at a constant voltage of 
10 kV using coated capillary cartridges of either 17 cm x 25 pm or 24 cm x 25 pm, 
running from the positive to the negative electrode in a phosphate buffer, pH 2.5 
(Bio-Rad). The absorbance was read at a single wavelength of 200 nm. All equipment 
was from Bio-Rad. All electropherograms were collected by an IBM compatible PC, 
using the Bio-Rad software package BioFocus V3.10 for Windows 3.1x, on .BFF format 
(BioFocus File) files.
2  7, i. 2  Spectra Integration
All electropherograms (spectra) were analysed using the Bio-Rad software package 
Integrator V3.01, where the BFF files were converted to .ACQ files (Acquisition) and 
integration was performed using manual baseline editing of the observed peaks. The 
output reports comprised the elution times of each peak together with its height and 
area, and the areas were given both in absolute and percentual forms.
2.7.2. Fluorescamine Assays
This assay is based on the fact that fluorescamine reacts with primary amines 
(Udenfriend et al., 1972; Weigele et a i ,  1972) (more recent reports show that it reacts
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also with secondary amines, although not yielding a fluorescent compound (Nakamura et 
al., 1980)):
RNH2
NH
O
R—N
OH
COON
Figure 2.18 - Reaction of fluorescamine with a primary amine (Stein et at., 1974).
Fluorescamine is not fluorescent, but the fluorescent reaction product with a primary 
amine has ?iex=390nm and A,em=475 nm (Udenfriend et a i, 1972). Moreover, 
fluorescamine is readily hydrolysed in water and its hydrolysis products are not 
fluorescent. However, the reaction of fluorescamine with primary amines is much faster 
than its hydrolysis, allowing it to label the primary amines prior to the complete 
degradation of the excess reagent.
The observation that fluorescamine does not react with guanidine or creatine leads 
to the conclusion that arginyl groups do not contribute with amine groups for the 
fluorescamine reaction (Bohlen et al., 1973). Instead, lysinyl groups do react with 
fluorescamine (Bohlen et ah, 1973; Schwabe, 1973; Singh and Sonar, 1988; Stein and 
Udenfriend, 1984) although in some circumstances this seems not to happen (Nakai et 
ah, 1974). This should depend on the pH conditions of the assay, as well as the pKa of 
the amino groups (de Bernardo et ah, 1974), since unprotonated amines are expected to 
react due to its nucleophilic character whereas a protonated amine like ammonia is 
known not to react (Udenfriend et ah, 1972).
2.7,2.1. Assay for Peptide Concentration using Fluorescamine
A solution of 0.72 mM of fluorescamine (Sigma) in acetone was prepared and kept 
at room temperature in a flask covered by tin foil to protect from light. To 2 ml of PBS 
buffer (0.14M  NaCl, 2.7 mM KCl, 10 mM Na2HP0 4 , 1.8 mM KH2PO4 , pH 7.4 
(Sambrook et ah, 1989)) 10-20 pi of the peptide solution were added and as the solution 
was stirred 0.5 ml of fluorescamine solution were added. The fluorescence of the 
resulting solution was measured on a Hitachi F-1050 Fluorescence Spectrophotometer
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with Xex^375 nm and A-em=480 nm found to be the optimal working wavelengths 
(Cabrita, 1992).
2.8. Chemical Modifications to Peptides
The chemical modifications made to peptides consisted only on either fully reducing 
any disulphide bridge between cysteines of the peptide, or promoting the full 
dimérisation of those cysteines to cystines. These were based on pH control, necessary to 
ensure that the thiol group was ionised to thiolate, as this is the reacting species in 
oxidation-reduction interchange (Kolthoff et al., 1955).
2.8.1. Oxidation (Dimérisation) of Peptide
The peptide was dissolved in 0.1 M NaHCOg and left stirring at room temperature 
overnight. It was then purified using reverse-phase HPLC (Method 2.4.2.1).
2.8.2. Reduction of Peptide
The peptide was dissolved in 0.1 M NaHCOa and a 3-fold excess of dithiothreitol 
(DTT) in regard to disulphide bridges was added. The solution was then bubbled with 
nitrogen for 2 min and stirred at room temperature for 45 min. 0.2 M acetic acid was 
then added to the solution until a pH of 4-5 was reached, and the peptide was purified by 
reverse-phase HPLC (Method 2.4.2.1).
2.9. Proteolysis Assays
All these assays were based on the digestion of synthetic peptides (Method 2.4.1) 
whose sequence niiinics the established consensus sequence (Anderson, 1990; Webster et 
al., 1989a).
2.9.1. Digestion of Peptides LSGAGFSW and Ac-LRGAGRSR
The design of these peptides was based on considerations of solubility and relative 
susceptibility to digestion. It is known (Webster et al., 1989a) that the peptide 
MSGAGFSW is a good substrate for the protease, and the substitution of methionine to 
leucine was aimed at a more stable substrate (methionine can undergo chemical changes 
during synthesis), and fiarther substitutions of serine, phenylalanine and tryptophan to 
arginine tried to improve solubility whilst still keeping the consensus sequence. The 
acétylation of the N-terminal was used to provide with a possible substrate for
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fluorescamine assays (Method 2.7.2), since the result of digestion would release a new 
free amino group which could be titrated with the above reagent (Evans and Ridella, 
1984).
The equations for substrate digestion by the protease are respectively:
LSGAGFSW -> LSGA + GFSW Eqn. 2.9.1
and:
Ac-LRGAGRSR —> Ac-LRGA + GRSR Eqn. 2.9.2
As the protease is not active at low pH (Webster et al., 1989b), dropping the pH of 
the assay mixture was the method used to stop the reaction in order to take time 
samples.
The reaction conditions are a modification of a previous assay (Webster et a i,  
1989b). In a typical assay, the recombinant protease (10 pi of 0.02-0,06 mg/ml) was
incubated with a solution of the activating peptide or its equivalent (10 pi of 0.25-
1 mg/ml) and buffer (25 pi of 50 mM Tris-HCl, 10 mM EOT A, pH 8, 2 mM p-MeOH) 
at 37°C for 15 min, followed by the addition of the substrate (5 pi of 2 mg/ml of 
synthetic peptide) equilibrated at 37°C. Samples (5 pi) were taken at required time points 
and analysed using Method 2.7.1.
2.9.2. Digestion of (LRGG)2-Rhodamine
This substrate was based on a previously reported method (Mangel et a l ,  1993). 
The substrate digestion by the protease can be described as follows:
L e u - A r g - G l y G l y N H ^ _ ^ / - x . _ ^ 0 ^ ^ / ^  ,N H 'G ly G ly A rg -L eu  Lew Arg-GlyGlyNI
Figure 2.19 - Protease cleavage of (LRGG)2-rhodamine. Both the intermediary monoamide and the final
rhodamine 110 are fluorescent.
This assay provided a continuous measurement of digestion kinetics, quite useful for 
following kinetics of activation of the protease. Rather than the kinetics of cleavage of
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substrate by a fully activated protease, the aim of this assay was to follow the kinetics of 
activation of the protease
In a typical assay, 100 pi of (LRGG)2 -rhodamine substrate solution (0.03 mM) were 
mixed with 5 pi of solution of the activating peptide or its equivalent (1 mg/ml), 300 pi 
of buffer (25 pi of 50 mM Tris-HCl, 10 mM EDTA, pH 8, 2 mM p-MeOH) and 190 pi 
of HPLC water, and incubated at 37°C for 10 min, and 5 pi of protease (0.02- 
0.06 mg/ml) were added, monitoring the fluorescence with a Perkin-Elmer Luminescence 
Spectrometer LS 50 B, with %ex=492 nm and Xem=523 nm, with a 5 nm slit width.
2.9.3. Inhibition Assays
Inhibition assays were intended to assess the ability of several peptides to inhibit 
activation of the protease with the activating peptide, rather than being directed at the 
catalytic site of the protease. Therefore, the assays consisted of adding a possible 
inhibitor to the protease followed by the addition of the activating peptide, and assaying 
for protease activity by digestion of a synthetic peptide, as in Method 2.9.1.
In a typical assay, the recombinant protease (10 pi of 0.02-0.06 mg/ml) was 
incubated with a solution of the possible inhibiting peptide (10 pi o f 0.25-1 mg/ml) and 
buffer (25 pi of 50 mM Tris-HCl, 10 mM EDTA, pH 8, 2 mM P-MeOH) at 3 7 T  for 
15 min, followed by the addition o f the activating peptide (10 pi of 0,25-1 mg/ml) and 
incubation of another 15 min at 37°C. The substrate (5 pi of 2 mg/ml of synthetic 
peptide) equilibrated at 37°C was then added and samples (5 pi) were taken at required 
time points and analysed using Method 2.7.1.
2.10. Determination of the pK@ vaiues of the Activating Peptide
A diprotic acid dissociates its protons according to the following scheme (Edsall et 
a/., 1958):
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Figure 2.20 - Scheme of the ionisation of a diprotic acid, illustrating the meaning of the four 
“microscopic” constants. The symbol H on the left of HAH is the acidic proton denoted as (1), the one
on the riglit is (2).
Each of the above constants, such as k\, is defined by the relation 
k\ = (H")(‘AH)/(HAH), etc., where (ET) denotes the hydrogen ion activity, etc. The 
notation used is that of Hill (quoted in (Edsall et a i ,  1958)), in which the last numeral in
the subscript denotes the group that donates a proton in the process, while the numerals
that precede it indicate the groups already deprotonated, if any.
In an ordinary titration, in which pH is determined as a function of the mean number 
of protons removed from the diprotic acid by addition o f a base, the values of the 
microscopic constants can not be determined directly. However, two “macroscopic” 
constants can be determined, and according to the scheme:
hah — ^  (-AH + HA-)  ^  A2-
Figure 2.21 - Scheme of the ionisation of a diprotic acid, illustrating the “macroscopic” constants.
There are several methods available for determining these macroscopic constants 
(see, for instance (Parke and Davis, 1954; Simms, 1926a; Simms, 1926b)). Furthermore, 
relations have been described between the macroscopic and microscopic constants 
(Ryklan and Schmidt, 1944):
(H -)[(-A H ) + (H A -)l 
' " ------  (HÂÏÏ)--------- Eqn. 2.10.1
Another important relation comes from Eqn, 2.10.1 and Eqn. 2.10.2:
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When the two ionisable protons are indistinguishable, k\ = kj and the macroscopic 
constants (also denominated “apparent dissociation constants”) suffice to describe the 
acid/base behaviour of the molecule. If, however, those protons come from distinct 
groups, their lability will be different and macroscopic constants can only be used if one 
of the protons is much more ionisable than the other, so that k\ »  ki and K \~ k \.  In the 
opposite case, when k\ and kj are within the same order of magnitude, the microscopic 
constants have to be used.
In the latter situation, the above equations are insufficient to determine the four 
microscopic constants, one additional relation being needed in order to obtain 
independent checks of the values for the microscopic constants. Two main approaches 
can be employed: (a) convert one of the acidic groups in HAH to an alkyl derivative 
RAH, or HAR’, where R and R’ generally denote methyl or ethyl groups, or (b) using a 
method that enables the determination of the extent of ionisation of only one of the 
groups, be it by spectrophotometry, nuclear magnetic resonance (NMR), Raman 
spectroscopy, etc.
Using the first approach, it is assumed that the effect of the group RA- on the 
ionisation of hydrogen is equivalent to that of HA' If the hydrogen HAH is the acidic 
hydrogen of a carboxyl group and RAH its monoester, this is known as the principle of 
Wegscheider (referenced in (Edsall et a i,  1958)). Therefore, when this equivalence 
applies, the pK value of HAR’ is equal to that of pAri in Figure 2.20, and that of RAH is 
equal to p^2 . The other values can then be determined with the aid of the above 
equations.
In the second approach, if the extent of ionisation of only one group can be 
determined by some method, postulating that it is the hydrogen HAH of Figure 2.20 a 
function a\ can be defined that represents the fraction of ionised H as follows (Edsall et 
al., 1958):
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(HAH) +( AH) + (H A -) + (A'" ) 
(H “) + A:,^,, (H y Eqn. 2.10.4l + (^ ,+ A :2 )/(H ')4 -A ,^ ,,,(H l'
The following function M\ can then be readily defined as;
^  ( H i K  .  M 2 E K 6 &  = M E 2 ± M l
l - a ,  (H*) + *, (H ") + *2
or, in logarithmic form,
pM, = p H - l o g - ^  = - l o g * ' ( " ^ ( + y "  Eqn. Z 10.61 —a , (H ) + /t2 (H ) + ^2
It follows from Eqn. 2.10.4 and Eqn. 2.10.6 that when (H") -^+qo, a i ^  0 and 
pA/i -> pA"i, and when (H") 0, ai -> 1 and pMi —>■ p^2 i. The function pMi is then
completely determined by the ratios ^ 1 /^ 2 1  and kjlh. The character of the function 
defined by Eqn. 2.10.6 is illustrated in detail by the curves shown in Figure 2.22. These 
curves are calculated taking pA:2 i - pA:i = 1 and therefore the intercepts at ai = 0 and 
« 1  = 1 coincide in all the curves. The different curves correspond to different values of 
the ratio kdh . Similar families of curves are obtained for other values of p^2 i - p^i. It is 
apparent from Figure 2.22 that, if k2 »  k\, the value of pMi rapidly rises to a value near 
to p^2 i with the increase of a\. Therefore, in this case the determination o f ^kzi by 
extrapolation is straightforward but the converse for pAri is not true, the extrapolation 
being reasonably uncertain. In the same manner, if k2 «  h ,  the values of pMi remain 
close to pÂTi until a\ approaches 1, when the curve suddenly raises to reach pA:2 i. Hence, 
in this case the extrapolation for the determination of pk\ is accurate but the estimation 
of pA:2 i remains difficult. However, if k\ and ^ 2  are within the same order of magnitude 
(the ratio k d h  lying between 5 and 1/5) both the above constants can be determined with 
reasonable accuracy.
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Figure 2.22 - The function pA/j represented as a function of the fractional ionisation a\. The zero of the 
ordinate scale is taken as pA</i = p^i and all the curv^es correspond to an assumed value of 
p^2i - p/o = 1 pH unit. The number attached to each curve represents the corresponding value of the ratio
kdki (after (Edsall e/fl/.. 1958)).
Once k\ and ^ 2 1  have been determined, it is possible to take these two constants as 
known quantities and to solve for kz. There are several ways of estimating this (Edsall et 
al., 1958). The approach taken was to computer generate a family of curves for several 
values of k2, and evaluate visually which is the best fit, as the equations are non-linear 
and a least-squares fit is not possible, and the use of more complex fitting algorithms 
seemed unnecessary, given the required accuracy and the experimental error involved. 
Furthermore, a visual evaluation already enables an accuracy of 0.1 pH units.
2.10.1. Experimental Determination of the pKa values
There are several ways of detecting the fraction of ionised cysteines: by 
spectrometry, as the thiolate anion absorbs at a wavelength of 230-240 nm whereas the 
thiol group does not (Benesch and Benesch, 1955; Coates et al., 1969; Gorin and Clary, 
1960); by NMR, by observing the change in the chemical shift o f the thiol group with its 
ionisation (Rabenstein, 1973; Shrager et al., 1972), etc. The spectrophotometric method 
was the one chosen, due to its simplicity.
Peptides were dissolved in a constant (I = 0.1) ionic strength buffer (0.05 M acetic 
acid, 0.05 M 2-(N-morpholino)-ethanesulphonic acid (MES), 0.1 M Tris, (Ellis and 
Morrison, 1982)), the pH lowered with the addition of 1 M HCl, and this solution was 
titrated with either 0.5 or 1 M NaOH with constant mixing, with measured values of pH
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and absorbance at 238 nm being recorded for several volumes of added NaOH. Values of 
pH were measured at room temperature using a Jenway 3010 pH Meter, with the 
electrode being calibrated with buffers of pH 4.0 and 7.0 (Russell), and absorbance was 
measured using a LKB Ultraspec II Biochrom spectrophotometer, readings being 
corrected for the increase in volume.
2.11. Determination of the Oxidation State of the Activating Peptide
Essentially, two methods were used; capillary electrophoresis (Method 2.7.1) and 
Ellman’s reagent. The first method is based on the observation that the oxidised 
(dimeric) form of the peptide has a higher electrophoretic mobility than its reduced 
counterpart, thus appearing first on an electropherogram. The second method is 
described below.
2.11.1. Ellman’s Reagent
Ellman’s reagent 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) (Ellman, 1959; 
Jocelyn, 1987) reacts with thiols, as aromatic disulphides are easily reduced by thiol- 
disulphide interchange:
■ss NO, S -<  >— NO,
+ 2R S- -------- ► R SSR  + 2
HOOC COOH COOH
Figure 2.23 - Reaction of DTNB with thiolate anions. The resulting aromatic thiol absorbs at 412 nm.
Though with protein thiols the mixed disulphides are stable products, non protein 
thiols are themselves quickly reduced. In any circumstance, the overall stoichiometry is 
one aromatic thiol generated for each biological thiol originally present.
Care should be taken when handling DTNB, as although it is stable indefinitely when 
kept in the dark at 0°C, it rapidly develops a yellow colour if exposed to light at room 
temperature. Also, if the pH locally reaches 9 the disulphide is hydrolytically cleaved 
with formation of yellow thiol (Jocelyn, 1987).
Once it is allowed to react with the biological thiol, the absorbance at 412 nm should 
be read after at least 2 minutes, and this remains constant over the next 8 minutes. 
Reasons for decline of absorption include autoxidation of the aromatic thiol, and increase 
is due to slow hydrolysis (Jocelyn, 1987).
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2A 1.1.1. Procedure for Determination of Thiol Groups with DTNB
From a stock solution of 10 mM DTNB in PBS (0.14 M NaCl, 2.7 mM KCl, 10 mM 
Na2HP0 4 , 1.8 mM KH2PO4, pH 7.4 (Sambrook et a i,  1989)), 6.7 pi were added to 1 ml 
of protein/peptide solution, and absorbance was read at 412 nm after 2-3 min, against a 
blank of DTNB and buffer.
2.12. Determination of Initial Rates of Digestion
Usually, for the determination of the initial rate of digestion, this rate is commonly 
considered to be approximately linear until about 10% of the substrate is digested 
(Eisenthal and Danson, 1993) (although some consider that the ideal situation would be 
less than 1% (Cornish-Bowden, 1995)), and a plot of number of molecules of substrate S 
digested against time t of digestion will yield a linear relationship between this two 
variables. The initial rate v of cleavage will then be the slope of that line.
However, the method used to determine the percentage of substrate digestion SISq 
(Method 2.7.1) was not sensitive enough to determine accurately little amounts of 
digestion such as less than 10%. Therefore, an analytical equation which describes a 
general digestion curve of a substrate had to be used. The following was obtained by 
manipulating mathematically simple kinetic equations, though there are several ways of 
obtaining the same result (Cornish-Bowden, 1995).
All digestions of substrate in Method 2.9.1 can be described with the following 
equation:
S - ^ P  Eqn. 2.12.1
where S  is the substrate and P  are the products of digestion. Although in a digestion 
there are two molecules of products from the cleavage of each molecule of substrate (see 
Method 2.9.1), that is irrelevant for the following determinations if we consider it to be 
an irreversible reaction. Furthermore, although these are hydrolysis reactions, as water is 
in large excess, this results in an overall pseudo first order reaction.
So, for an first order reaction (Perry and Green, 1984), its rate v is defined as the 
variation of substrate concentration dS  that is consumed in the time interval dt. This is 
described mathematically by:
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dSV -   Eqn. 2.12.2dt
On the other hand, the rate v of an irreversible first order reaction is only 
proportional to the substrate concentration:
v = kS Eqn. 2.12.3
The constant k is termed rate constant and it is independent of the substrate 
concentration. The initial rate will then be the product of the rate constant by the initial 
concentration of substrate 6'o. In order to determine k, Eqn. 2.12.2 and Eqn. 2.12.3 can 
be equalled (Wesley, 1969):
; C - ^ k S  Eqn. 2.12.4dt
Integration of Eqn. 2.12.4 yields:
In = ~kt Eqn. 2.12.5
which is an equation of the form y  = Ax, with y - I n  (SlSo) and %= A So, a plot of 
In (SISq) against t will yield a straight line of slope -k that, when replaced in Eqn. 2.12.3 
together with the initial substrate concentration, will calculate the initial rate of digestion.
Finally, by rewriting Eqn. 2.12.5 we can get an analytical equation that describes the 
dependence o f percentage of substrate digestion with time:
—  =  e"* ' Eqn. 2.12.6
2.12.1. Experimental Determination of Initial Rates
Digestion assays were performed as described in Method 2.9.1, and analysed using 
Method 2.7.1. The integrations obtained by Method 2.7.1.2 were then treated with 
Microsoft Excel 5.0 as illustrated in the following example:
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Table 2.2 - Example of data treatment of digestion assays.
A B C
1 Time (min) S/SO ln(S/SO)
2 5 0.9083 -0.096181
3 10 0.8228 -0.195042
4 15 0.7412 -0.299485
5 20 0.6645 -0.40872
6 30 0.5251 -0.644167
Cells C2 to C6 contain the formula =ln (B2) to ==ln (B6) respectively. A linear 
regression was then performed:
Table 2.3- Example of calculation of a linear regression in order to calculate the rate constant.
slope {-k)\ 
standard error: 
correlation coefficient r :
F statistic:
regression sum of squares:
G
2 -0.020862
3 0.000357
4 0.995305
5 848.0609
6 0.177867
where cells G2 to G6 contain the Excel array formula 
{=LINEST {C2 :C6, A2 :A6, FALSE, TRUE) }. The slope in G2 is equal to -k, so 
A: = 0.021 min'\ By using this value in Eqn. 2.12.6, we can plot the analytical curve that 
fits best the experimental data:
1 TI0.8 t
0.6 iI
0.4 I  
0.2 t
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Figure 2.24- Grapliical result of the fitting of experimental data with Eqn. 2.12.6.
Results and Discussion
3. R esults and D iscussion
The main objective of this work was to try and understand how the activating 
peptide GVQSLKRRRCF converts the adenovirus protease from an inactive to an active 
form. In order to achieve this purpose, several characteristics of the activating peptide 
were studied.
This chapter starts with some general experimental observations made throughout all 
the work regarding certain characteristics of the recombinant protease (3.1). It then 
follows to the activating peptide, in trying to assess what are the relevant properties of 
the peptide which enable it to somehow render the protease active: the importance of the 
cysteine residue (3.2), the effect of N-terminal truncations in the peptide on its activation 
properties (3.3), which led to an assessment of the importance of the N-terminal residues 
(3.4), and the influence of the environment around the cysteine (3.5). From the results 
obtained by these investigations, the idea of inhibition of activation arose and was 
followed further (3.6). Finally, an attempt was made to clone a protease from an avian 
adenovirus in E. coli (3 .7).
Also, it was deemed necessary to include a few considerations on some of the 
methodologies used (3.8), in order to evaluate their validity and applicability.
3 .1. The Adenovirus Recombinant Protease: General Features
While working with the recombinant protease in vitro, several characteristics of this 
enzyme were observed that made it a difficult protein to work with, and these are 
discussed.
The recombinant protease is very sensitive to temperature changes, and repeated 
ffeeze-thawing turns it inactivatable, that is, the addition of the activating peptide 
GVQSLKRRRCF is then unable to render the protease active. Also, if left at room 
temperature, it gradually loses the ability to be activated. This inactivation seems to j
depend on the concentration of mercaptoethanol present, which would suggest that this 
process is associated with some oxidation of the protease. Furthermore, the mere mixing j
o f the protease after thawing in order to homogenise the solution does affect its ability to 1
be activated, another fact that could be explained in terms of oxidation. For all o f the i
above reasons, the attainment of a constant and reproducible digestion rate for the I
protease proved to be an almost impossible task. i
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However, once the protease is allowed to incubate with the activating peptide, it 
then becomes reasonably stable to any of the above perturbations and remains active for 
at least 8 hours (maximum period observed) without showing any signs of loss of 
activity. Interestingly enough, it has been observed (Jones et a l ,  1996) that increasing 
concentrations of activating peptide allow a more efficient activation of the protease, as 
well as that a subsequent reduction of the activating peptide concentration reduces the 
activity of the protease once this is activated (Iqbal, unpublished results). However, after 
the peptide is allowed to incubate with the protease, the addition of further peptide does 
not seem to enhance the activity of an already activated protease. In other words, before 
activation the protease is sensitive to the concentration of activating peptide, whereas 
after it is activated it is sensitive only to a reduction of the activating peptide 
concentration.
Another interesting observation is that dithiothreitol (DTT) inhibits the recombinant 
protease activation when added before, whereas if DTT is added after the activation, it 
actually stimulates activity (Webster et a l, 1993). On the other hand, viral protease 
(already activated) seems to be stimulated by both DTT and cysteine up to an optimal 
concentration of 0.5-2 mM, followed by a decrease in activation for higher 
concentrations of these reagents (Webster et a l,  1993). Certainly, different protease 
preparations seemed to show a different susceptibility to reducing reagents, as well as 
stability at room temperature. Curiously, whereas some protease preparations seemed to j
present an activity (after activation) directly proportional to their protease concentration, 
some others did suffer a dramatic decrease in activity once diluted.
Finally, the recombinant protease was also observed to form dimers (Vaughan, 
personal communication), in a fixed proportion to the amount of monomer present, the 
two forms liable of being separated by a non-reducing SDS-PAGE. Attempts made to try 
and identify via which cysteine(s) these dimers occur have been unsuccessful, and it is 
possible that dimérisation occurs through several combinations of available cysteines. An 
interesting observation (Vaughan, unpublished results) is that the incubation of a 
protease dimer with the activating peptide reduces the amount of dimerised form to what 
seems to be the monomer possibly bound to the activating peptide.
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3.2. Importance of Cys~10 in the Native Activating Peptide
The observation that the peptide GVQSLKRRRAF did not activate the adenovirus 
protease led to the assumption that the cysteine residue in position 10 of the activating 
peptide could be involved in a thiol-disulphide interchange with the protease (Webster et 
a i,  1993), In order to try and elucidate what was the nature of this interaction, several 
peptides were synthesised in which the cysteine was substituted by other amino acids. 
Three amino acid substitutions were tried: alanine, providing a side chain similar in 
length to a cysteine, though apolar, which was the original substitution that rendered the 
activating peptide non functional (Webster et a i, 1993); serine, quite similar to cysteine 
in both polarity and structure, although not as reactive and not allowing the formation of 
disulphide bridges; aspartate, a residue analogous in structure and function to a sulphenic 
acid (RSOH), which has been observed to contribute to redox control involving cysteine 
residues (Abate et al., 1990).
3.2.1. Residue Substitutions of Cys-10
Two peptides were synthesised, GVQSLKRRRSF and GVQSLKRRRDF as 
described in Method 2.4.1, using the semi-automated synthesis. Method 2.4.1.2; 
GVQSLKRRRAF had been synthesised previously (Webster et a i, 1993).
Preliminary experiments were made with non-purified peptides (used immediately 
after the freeze-drying that follows synthesis), attempting to activate the protease for 
10 min before the addition of substrate by incubating the protease (0.02 mg/ml) with 
each of the peptides at 37°C (Method 2.9.1). The substrate LSGAGFSW was then 
allowed to digest for 30 min at several concentrations (0.15, 0.12, 0.089, 0.059, 0.030 
and 0.015 mM), of each of the peptides. Time samples were taken and analysed using 
capillary electrophoresis (Method 2.7.1.1). The results are shown in Figure 3.1:
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Figure 3.1- Effect of cysteine substitution in the activating peptide on activation of the adenovirus 
protease. Curves correspond to a 30 min digestion of the substrate LSGAGFSW. The peptides are not
purified.
These results show that cysteine is the only residue that effectively enables the 
activation of the protease. However, in order to try and explain the reasonably high 
activation with some of the peptides at higher concentration they were further purified by 
HPLC (Method 2.4.2.1), to discard any contaminants remaining after the synthesis and 
cleavage.
After purification, peptide samples were analysed with capillary electrophoresis 
(Method 2.7.1.1) in order to check for purity, as the presence of more than one peak 
would indicate evidence of a contaminant. As a reference, typical percentages of 
acetonitrile for migration of the peptides (4.6 mm x 25 cm CIS column), as well as 
migration times on capillary electrophoresis (CE) are shown in Table 3.1.
Table 3 .1 - Typical values of purification parameters for several peptides. Migration times for CE are
given for a 24 cm x 25 pm capillary.
Peptide Percentage of acetonitrile 
for peptide elution
Migration time 
on CE (min)
GVQSLKRRRCF 35-45 3.3
GVQSLKRRRAF 40-50 3.5
GVQSLKRRRSF 40-50 3.5
GVQSLKRRRDF 40-50 3.8
When these purified peptides were used to activate the protease in the same manner 
as described above, the results obtained were as follows;
Results and Discussion___________________________________________________ 82
100
80 -  ------------------------------c  -^G V Q SLK RR RCF
’I  60 ^  r-GVQSLKRRRAF
&Q 40 +
^  ^  GVQSLKRRRDF
20 t  -----------------------------
GVQSLKRRRSF
0  4— < -
0 0.05 0.1 0.15
Peptide Concentration (mM)
Figure 3.2 - Effect of cysteine substitution in the activating peptide on activation of the adenovirus 
protease. Curves correspond to a 30 min digestion of the substrate LSGAGFSW. Purified peptides.
As well as showing a more distinctive difference between GVQSLKRRRCF and the 
remaining peptides, stressing the importance of the cysteine in activation, these results 
also showed that impure peptides must contain a common contaminant which seems to 
help in activation. One possibility might be ethanedithiol, a scavenger used to remove 
tBu and Mtr groups, as it also contains thiol groups. All non-purified peptides present a 
characteristic odour which can be ascribed to this contaminant.
3,2.2. Oxidation State of Cysteine
Previous results indicated that the activating peptide needs to be in the oxidised 
(dimeric) form in order to efficiently activate the protease (Webster et al., 1993). 
Measurements of initial rates showed a 10 fold increase of that value when oxidised 
activating peptide was used instead of the reduced version, which enabled the conclusion 
that the oxidised form should be the active molecule.
The above observation led to the assumption that the activating peptide was 
catalysing the oxidation/reduction of specific cysteine/cystine residues in the protease by 
a mechanism of thiol-disulphide interchange. A model was devised where the protease 
was synthesised as an inactive form in which the active site cysteine was involved in an 
intramolecular disulphide bridge, and the role of the activating peptide was to form a 
new disulphide bond leaving the active site cysteine as a free thiol (Webster et a i ,  1993):
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Figure 3.3 - The proposed mechanism of activation of the protease via a tliiol-disulphide interchange.
The activating peptide (AP) would promote the rearrangement of an internal disulphide bridge within 
the protease molecule wliich would release the active site cysteine thiol {S).
In the above model, the activating peptide would act presumably by setting the 
appropriate redox potential to allow for the interchange to occur.
In order to evaluate how determinant the oxidation state is, and to provide with 
some better insight into the mechanism of activation, some experiments were conducted 
with oxidised and reduced versions of the activating peptide, in which its ability to 
activate the protease was assessed.
The activating peptide was prepared in the reduced (Method 2,8.2) or oxidised form 
(Method 2.8.1). The presence of free thiols in each preparation was assayed (Method
2.11.1.1) to check that the peptides remained in the appropriate redox state, and this was 
verified by CE (Method 2.7.1.1), as the oxidised activating peptide migrates faster than 
its reduced counterpart. The two forms were then dissolved in either 5 mM P-MeOH (to 
prevent the reduced peptide from oxidation) or in HPLC water (for the oxidised form) at 
a concentration of ~1 mM. These solutions were then used in activity assays (Method
2.9.1), with 10 pi of protease (0.05 mg/ml) being activated with 10 pi of either of the 
above activating peptide solutions, and 25 pi of assay bulfer (without P-MeOH in the 
case of the reduced peptide, in order to keep the P-MeOH concentration constant in both 
assays). The substrate Ac-LRGAGRSR was then used to determine initial rates of 
digestion (Method 2.12.1).
It was found (Hawkins, 1997) that the initial rate using the oxidised peptide relative 
to that found using the reduced peptide was 1.15 + 0.16, that is, the difference in 
activation between the two forms is not significantly different (p < 0.05). The cause for 
this was later found out to be that after the 15 min incubation period, both peptides were 
found mainly in the reduced form, most certainly due to the presence of p-MeOH.
More attempts were made (Reid, 1997), this time also trying to assess the influence 
of the peptide concentration in its activating properties. Again, the preparation of both
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the reduced and oxidised forms were as described above, although it was chosen to 
dissolve the purified peptides only immediately prior to assaying, in order to try and keep 
their redox state unchanged. The results are shown in the following graph (protease 
concentration of 0.05 mg/ml):
c1
3
2.5
2
1.5
1
0.5
0
0.1 10 1001
Cone. (mM)
— Oxidised GVQSLKRRRCF r - Reduced GVQSLKRRRCF
Figure-3.4 - The influence of the activating peptide (GVQSLKRRRCF) concentration and redox state in
the activation of the adenovirus protease.
These results show again that there seems not to be any definite difference between 
the two forms within the peptide concentration range of 0.5-11 mM, considering that the 
results were not repeated in order to evaluate their statistical significance. However, the 
decrease in activation observed at higher concentrations was unexpected and could 
possibly have been caused by the presence of an impurity in the peptide solutions that 
only becomes apparent at higher concentrations.
Therefore, from the above results no difference between the oxidised and reduced 
forms of the peptide were found. The fact that the assay buffer contained (3-MeOH must 
have contributed to this apparent lack of difference between the oxidised and reduced 
peptides. However, if (3-MeOH was removed from the assay buffer, the protease 
presented a very variable degree of activation. Therefore the evaluation of which redox 
form of the peptide is the most effective activator of the protease was inconclusive.
3.2.3. pKa of Cysteine
A striking feature of the native activating peptide (GVQSLKRRRCF) is the 
presence of three consecutive arginines to the left of the cysteine presumed to be
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involved in the interaction to the protease. Furthermore, this sequence is reasonably well 
conserved within the several known serotype sequences of pVI (cf. Figure 1.9).
It has been reported that positively charged groups adjacent to a cysteine can 
enhance the formation of a specific reversible disulphide bond (Snyder et a i,  1981; 
Snyder et a i ,  1983). This finding, together with the aforementioned observation of a 
high conservation of arginines nearby the cysteine, lead to the possibility that these 
arginines were responsible for a reactivity enhancement of the cysteine, eventually by 
lowering its pKa below the typical value of 8.5 (Stryer, 1988).
The formation of a disulphide bond, concomitant with the oxidation of the thiol
group, is thought to proceed in the following two steps (Benesch and Benesch, 1955):
RS —> RS e Eqn. 3.2.1
RS + RS —> RSSR Eqn. 3.2.2
A lower pKa would facilitate the formation of the bond by increasing the rate of the 
reaction in Eqn. 3.2.1, causing the reaction in Eqn. 3.2.2 to be the limiting step.
Therefore, the determination of the pKa of the cysteine was the consequent step, in 
order to try and evaluate whether the cysteine had an unusually low pKa value which 
could explain the role of so many conserved arginines.
The determination of the pKa value for the cysteine thiol is not straightforward in the 
case of the activating peptide, due to the presence of other ionisable groups, such as the 
carboxyl at the C-terminal, the three arginines, the serine hydroxyl group, the amino 
groups at the N-terminal and in lysine-6 . Although the carboxyl group loses its proton at 
such a low pH (typically with a pKa of 3.1 (Stryer, 1988)) that it should ionise 
completely prior to any other group, and the arginines deprotonate at such a high pH 
(typically with pKa values of 12.0 (Stryer, 1988)) that they should ionise only after the 
complete deprotonation of amines and thiols, the situation is not so distinct between 
amino and sulfhydryl groups (Benesch and Benesch, 1955). The ionisation equilibria can 
be best described as follows:
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Figure 3.5 - The ionisation equilibria involved in the deprotonation of the activating peptide 
(GVQSLKRRRCF), Only the ionisable groups are represented for simplicity. The numbering of the 
microscopic equilibrimn constants is based on the notation of Hill, cited in (Edsall et al., 1958). The 
amino terminal is group 1, the amino lysine is group 2 and the cysteine thiol is group 3. The carbox\i
group was not numbered for simplicity.
The system described in Figure 3.5 is too complex for the equilibrium constants 
involved to be determined using Method 2.10 directly. Therefore, use was made of both 
the principle of Wegscheider and thioiate absorption measurements (cf. Method 2.10) in 
order to measure some of the constants involved so that the remaining unknowns could 
then be determined.
The approach taken was then to titrate peptides in which one of the amino groups 
was blocked and following their absorbance at 238 nm so that the ionisation of the thiol 
group could be monitored. It can be seen from Figure 3.5 that if the peptide 
Ac-GVQSLKRRRCF is titrated, the constants kn, A1 3, k \23 and k m  can be determined by 
using Method 2.10, as the acetylated N-terminal should be equivalent to a non- 
protonated amino group (principle o f Wegscheider). By a similar reasoning, the titration 
of the peptide GVQ SLARRRCF should yield the constants ^2 1 , ^2 3 , km  and ^2 3 1 . These 
two determinations yield a value for km , which can be used as a guideline for the 
reliability of the results, or in case of experimental error it can provide with an estimate 
of what the real value should be, by matching the two values obtained from the titrations.
Using this approach, seven of the twelve equilibrium constants can be determined. In 
order to obtain the remaining five constants, an extension of Method 2.10 was devised, 
which can be applied to the titration of GVQSLKRRRCF, provided that values for the 
above constants are defined.
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Equations corresponding to Eqn. 2.10.4 and Eqn. 2.10.6 can be written for the 
system described in Figure 3.5 as follows:
/  ( H -  ) +  ) /  ( H "  ) '  4- /  ( H " ) '
1 + (^1 +^2 + ^ 3 ) /  (H ) + (itiA:j2 + AtjA:j3 + / (H"") + ^ 1^,2 ^ 1 2 3
Eqn. 3.2.3
+ ^ 2 ^ 2 3 ) ^ (H ") +pMj = -  lo g   ^ - f .....  Eqn. 3.2.4
It then follows from Eqn. 3.2.3 and Eqn 3.2.4 that when (lU) +0 0 , % - 4  ^0 and 
pMs p^3 , and when (IT) -> 0, ^ 3  -> 1 and pMs —> ^km . From these equations and a 
plot of PM3 vs. « 3 , the values of A3 and km  can be determined, and the latter can be 
made to adjust to the previously obtained values for this constant. The unknown values 
in the above equations are then k\ and A2 , but these are related by the equation 
ki k \2  = A2 A2 1 and therefore assigning a value to one of them will define the other. The 
remaining two constants, A31 and A3 2 , can also be calculated by using similar equations, 
such as Ai Ai3 = A3 A31 and A2  A2 3 = A3 A3 2 , which means that all the constants can be 
determined, using a process similar to that described in Method 2.10. Eventually, for a 
better agreement of all the constants, several iterations had to be made, so that ail the 
values coincided for the three different titrations.
After these constants were determined, some other peptides were also titrated to 
assert about the influence of the residues around the cysteine on its acidity. For this 
purpose, the peptides GVQSLKRRRCA, GVQSLKRRCRF and GVQSLKRCRRF were 
also titrated and equilibrium constants determined.
All peptides were synthesised as described in Method 2.4.1, using the semi­
automated synthesis. Method 2.4.1.2, and purified by HPLC (Method 2.4.2.1).
3.2.3.1. The Titration o f the Buffer Solution
When titrations were performed, an unexpected decrease of absorbance was 
observed between pH values of 3 and 6 (cf. Figure 3.6) which could not be explained in 
terms of thiol ionisation.
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Figure 3.6 - Example of titration curve of a peptide (Ac-GVQSLKRRRCF). illustrating the unexplained 
decrease in absorbance between pH 3 and 6. Absorbance values are corrected for the increase in volume.
A search for the source of this behaviour led to the titration of the buffer solution 
alone. This revealed to be the cause of the decrease in absorbance, which in fact was due 
to the buffer also absorbing at 238 nm. The absorbance profile of the buffer at a pH 
ranging from 2 to 12 is shown in Figure 3,7.
It then became obvious that the buffer absorbance profile had to be subtracted from 
every peptide titration absorbance curve. For this purpose, an analytical description of 
the buffer absorbance profile had to be obtained, in order to be able to subtract the buffer 
absorbance at any pH value. However, the profile shape did not resemble any easily 
describable curve, and a choice was made to adjust separate curves for different pH 
ranges. Each of these separate curves was adjusted using least-squares fitting, and the 
following analytical curves were obtained for the several pH ranges: 
pH: 1.75 -4.22 A = 0.1413 - 0 .1396/pH - 0.02317xpH Eqn. 3.2.5
pH: 4,23 -6.02 A = 0.1530 - 0.03653xpH+ 1.965xlO'\pH^ Eqn. 3.2.6
pH: 6.03 - 11.37 A = 0.07509 - 14309/pH^ Eqn. 3.2.7
pH: 11.38-12.5 A = 0.1101 - 0.003541xpH + 3.631xlO‘^ *^ xpH^ ° Eqn. 3.2.8
Each curve is represented in Figure 3.7, with Eqn. 3.2.5 and Eqn. 3.2.7 represented 
in red and Eqn. 3.2.6 and Eqn. 3.2.8 represented in black.
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Figure 3.7 - Titration of the buffer solution. Crosses (+) represent experimental readings for absorbance 
corrected for increase in volume. The dashed lines represent the analytical fitting curves for various pH
ranges (see text for explanation).
When the buffer absorbance profile is subtracted, the resulting curve has a 
substantially different aspect (cf. Figure 3.8), with the absorbance decrease at the pH 
range of 3 to 6 disappearing, together with a levelling of the right end of the titration 
curve, at high pH.
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Figure 3.8 - Titration curve from Figure 3,6 before (dashed line) and after subtraction (solid line) of 
buffer absorbance. Notice the disappearance of the decrease in absorbance between pH 3 and 6.
The subtraction of the buffer absorbance did not always produce a perfect levelling 
of both ends of the titration curve, and this made it more difficult to attribute a maximum
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and a minimum required for the calculations described in Method 2.10, which then had to 
be chosen as to produce the best fitting among the several curves obtained. This 
contributed in some instances to minimise the scattering of the experimental data.
3.2.3.2. The Titration of Ac-GVQSLKRRRCF
The peptide Ac-GVQSLKRRRCF was titrated as described in Method 2.10.1, the 
buffer absorbance was subtracted using the equations stated in 3.2,3.1 and the ionisation 
fraction aj. was calculated for each experimental point using the following equation:
=  (Ai - Amin)/(Amax ” Amin) Eqn. 3.2.9
in which Ai is the absorbance at 238 nm, Amin is the minimum absorbance of the 
titration curve and Amax the absorbance maximum. These limit values were in some 
instances adjusted in order to obtain a better fitting of the several curves. The function 
pMa was then calculated using Eqn. 2.10.6 for each value of % and plotted against « 3 , 
and a theoretical curve was fitted to the points as described in Method 2.10, also taking 
into consideration the titration curves obtained in 3.2.3.3 and 3.2.3.4. The result o f the 
fitting is shown in Figure 3.9. This fitting yielded the values pA:i2  = 9.0, pA^ = 8.65, 
P^i23 = 9.55 and pA: ,3 2  = 9.9 for the constants of the equilibria in Figure 3.5.
1
t  k  X XX
Figure 3.9 - The fimction pM vs. a  for the peptide Ac-GVQSLKRRRCF. The different symbols 
represent experimental data from 5 titrations and the dashed line is the theoretical curve obtained using
Eqn. 2.10.6.
Although the experimental data are quite scattered, the theoretical curve for this 
situation seems to describe the general trend. Using Eqn. 2.10.4, a theoretical curve
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could be fitted to the experimental data for titration to check for the goodness of fitting, 
as shown in Figure 3.10.
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Ü 0.6
X..
pH
Figure 3 .10 - Titration curve for the peptide Ac-GVQSLKRRRCF. The different symbols represent 
experimental data from 5 titrations and the dashed line is the theoretical curve obtained using Eqn.
2.10.4.
Again in the above plot the scattering of experimental data is evident, but the 
theoretical curve seems to describe the trend reasonably well. From the constants 
obtained above, the deprotonation profile for the lysine amino group can also be 
calculated and compared to that of the cysteine:
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Figure 3.11 - Deprotonation profiles of the cysteine tliiol (dashed line) and the lysine amino group (solid
line) for the peptide Ac-GVQSLKRRRCF.
From these curves it can be observed that the cysteine thiol does not ionise at an 
unusually low pH, although it is somewhat less basic than the lysine amino group. In fact,
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the corresponding values of pku, pAn, pkm  and pk \^2  for cysteine, which also contains 
an amino group as well as the thiol group, have been determined (Benesch and Benesch, 
1955), and are reproduced in the following table:
Table 3.2 - p^ values for the peptide Ac-GVQSLKRRRCF and cysteine. Values for cysteine taken from
(Benesch and Benesch. 1955).
p k Ac-GVQSLKRRRCF Cysteine
p k u 9.0 8.86
P^13 8.65 8.53
P^ 123 9.55 10.03
p/tl32 9.9 10.36
The above table shows a remarkable similarity between the values, which seems to 
indicate that the cysteine has an ionisation pattern similar in both compounds, that is, 
with a thiol group not unusually acidic, although with an amino group more basic in 
cysteine than in the peptide Ac-GVQSLKRRRCF.
3.Z3.3, The Titration o f GVQSLARRRCF
The peptide GVQSLARRRCF was also titrated as described in Method 2.10.1, the 
buffer absorbance was subtracted using the equations stated in 3.2.3.1 and the ionisation 
fraction % was calculated for each experimental point using Eqn. 3.2.9. In the same 
manner described above (cf. 3.2.3.2), the function pAA was then calculated using Eqn.
2.10.6 for each value of % and plotted against and a theoretical curve was fitted to 
the points as described in Method 2.10, also taking into consideration the titration curves 
obtained in 3.2.3.2 and 3.2.3.4. The result o f the fitting is shown in Figure 3.12. This 
fitting yielded the values p^2 i = 10.7, p^ 2 3  = 8.85, pkm  = 9.55 and pA:2 3 i =11.4 for the 
constants of the equilibria in Figure 3.5.
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Figure 3,12- The function pM vs. a  for the peptide GVQSLARRRCF. The different symbols represent 
experimental data from 5 titrations and tlie dashed line is the theoretical curve obtained using Eqn.
2 . 10 .6 .
The above plot shows a good agreement between the experimental data and the 
theoretical curve for « 3  < 0.6, although it then deviates for higher values. This is a 
consequence of keeping the values o f the equilibrium constants for the three titrations 
coherent. Again, using Eqn. 2.10.4, a theoretical curve could be fitted to the 
experimental data for titration to check for the goodness of fitting, and this is shown in
Figure 3.13.
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Figure 3 .13- Titration curve for the peptide GVQSLARRRCF. The different symbols represent 
experimental data from 5 titrations and the dashed line is the theoretical curve obtained using Eqn.
2.10.4.
In this representation, the theoretical curve does seem to describe the general trend, 
although the collection of more experimental points in the pH range between 10 and 11.5
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could have benefited the determination of these constants. From the constants obtained 
above, the deprotonation profile for the N-terminal amino group can also be calculated 
and compared to that of the cysteine:
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Figure 3.14 - Deprotonation profiles of the cysteine thiol (dashed line) and the N-terminal amino group
(solid line) for the peptide GVQSLARRRCF.
From the curves above it can again be noted that the cysteine thiol does not ionise at 
an unusually low pH. Unexpectedly, the N-terminal amino group is quite basic, only 
starting to deprotonate when the thiol is almost completely ionised. Using the same 
reasoning as in 3.2.3.2, the corresponding values of p^2 i, p^2 3 , p^i23 and pAiisi can also be 
compared to those for cysteine in the following table:
Table 3.3 - p/: values for the peptide GVQSLARRRCF and cysteine. Values for cysteine taken from
(Benesch and Benesch. 1955).
pA: GVQSLARRRCF Cysteine
P^2I 10.7 8.86
P^ 23 8.85 8.53
9.55 10.03
PA^231 11.4 10.36
This time, the table shows some similarity only for the value of p^2 3 , that 
corresponds to the ionisation of the thiol group when the amino group is still protonated, 
which still shows that the thiol group in the peptide is not unusually acidic.
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3.2.3.4. The Titration of GVQSLKRRRCF
The peptide GVQSLKRRRCF was also titrated as described in Method 2.10.1, the 
buffer absorbance was subtracted using the equations stated in 3.2.3.1 and the ionisation 
fraction % was calculated for each experimental point using Eqn. 3.2.9.
However, as this peptide has three ionisable groups, the equations developed in 
3.2.3 had to be used. The function pMs was then calculated using Eqn. 2.10.6 for each 
value of « 3  and plotted against %, and a theoretical curve was fitted to the points using 
Eqn. 3.2.4 as described in 3.2.3, also taking into consideration the titration curves 
obtained in 3.2.3.2 and 3.2.3.3. The result of the fitting is shown in Figure 3.15. This 
fitting yielded the remaining values pA:i = 7.2, p^2=5.5, p/rg = 7.15, p^3 i = 8.7 and 
p^ 3 2  = 7.2 for the constants of the equilibria in Figure 3.5.
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Figure 3 .15- The function pM vs. a  for the peptide GVQSLKRRRCF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.4.
It can be seen from the above figure that a very good agreement between the 
experimental data and the theoretical curve was obtained. Therefore, the constants 
obtained using the method described in 3.2.3 seem to be reasonably reliable. Using Eqn
3.2.3, a theoretical curve could be fitted to the experimental data for titration to check 
again for the goodness of fitting, and this is shown in Figure 3.16.
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Figure 3 .16- Titration cur\^e for the peptide GVQSLKRRRCF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.3.
The above graph shows a tight fitting of the theoretical curve to the experimental 
points, thus providing with another way of confirming the validity of the constants 
obtained. Again fi’om these values deprotonation profiles can be calculated for the N- 
terminal and lysine amino groups, as well as for the cysteine thiol:
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Figure 3 .17- Deprotonation profiles of the lysine amino group (— ), the c\ steine thiol (- 
N-terminal amino group (-----) for the peptide GVQSLKRRRCF,
-) and the
The curves above indicate three interesting results: (a) the cysteine thiol once more 
does not seem to present an unusual pattern of ionisation; (b) the high basicity of the 
N-terminal amino group does not seem to be affected by the presence of another 
ionisable group, as compared to its behaviour in the peptide GVQSLARRRCF (cf.
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Figure 3.14), this leading to this amino group being always protonated at physiological 
pH; (c) on the other hand, the lysine amino group suffers a remarkable increase in acidity 
when the N-terminal amino group is present, as compared to its behaviour in the peptide 
Ac-GVQSLKRRRCF (cf. Figure 3.11).
The whole set of constants determined for the peptide GVQSLKRRRCF is 
presented in the following table;
Table 3.4 - p/c values for the peptide GVQSLKRRRCF (cf. Figure 3.5),
pA: GVQSLKRRRCF
p k i 7.2
p k 2 5.5
p h 7.15
p k \ 2 9.0
p k u 8.65
p k i i 10.7
P^23 8.85
P^31 8.7
p^32 7.2
pA:i23 9.55
p k \ 3 2 9.9
p^ 231 11.4
3.2.3.S. The Titration of GVQSLKRRRCA
The determination of the equilibrium constants for this peptide had to rely on certain 
assumptions. As the only difference between the peptide GVQSLKRRRCF and this 
peptide rests on the C-terminal residue, a replacement that does not add any charge to 
the molecule, it was assumed that only the thiol involving constants {h, kn, kjs and km , 
cf. Figure 3.5) would change, all the others remaining constant. By using this hypothesis, 
only these constants had to be recalculated, all the remaining being equal to the 
corresponding constants in the peptide GVQSLKRRRCF. This implied only one degree 
of freedom in the determination, which meant that if a value was attributed to one o f the 
equilibrium constants, the others would be consequently defined.
Taking k3 as the independent equilibrium constant, the other constants could be 
calculated using the following equations:
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k\y — kj. k^\ / k\ 
ki3 ~ k-\ ki.2 / 1<2
Eqn. 3.2.10 
Eqn. 3.2.11
k \2Z =  k \ 2 kx22 /  k \ 2  Eqn. 3.2.12
The peptide GVQSLKRRRCA was also titrated as described in Method 2.10,1, the 
buffer absorbance was subtracted using the equations stated in 3.2.3.1 and the ionisation 
fraction % was calculated for each experimental point using Eqn. 3.2.9. In the same 
manner described above (cf. 3.2.3.4), the function pMs was then calculated using Eqn.
2 .1 0 . 6  for each value of « 3  and plotted against « 3 , and a theoretical curve was fitted to 
the points using Eqn. 3.2.4 as described in 3.2.3. The result of the fitting is shown in 
Figure 3.18 and the resulting constants are presented in Table 3.5.
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Figure 3 .18- The function pM vs. a  for the peptide GVQSLKRRRCA. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical ciuve obtained using Eqn.
3.2.4.
A very good agreement between the experimental data and the theoretical curve is 
apparent firom the above figure. This seems to support the assumptions made above. 
Using Eqn. 3.2.3, a theoretical curve could be fitted to the experimental data for titration 
to provide with an alternative test for the goodness of fitting, and this is shown in Figure 
3.19.
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Figure 3.19 - Titration cur\e for the peptide GVQSLKRRRCA. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.3.
Having confirmed with the above graph a remarkable fitting of the theoretical curve 
to the experimental points, deprotonation profiles can again be calculated for the N- 
terminal and lysine amino groups, as well as for the cysteine thiol:
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Figure 3.20 - Deprotonation profiles of the lysine amino group (—). the cysteine thiol (------ ) and the
N-terminal amino group (-----) for the peptide GVQSLKRRRCA.
As expected from the assumptions made above, the deprotonation curves for both 
the amino groups remained constant as compared to those corresponding to the peptide 
GVQSLKRRRCF. Even the curve corresponding to the ionisation of the cysteine thiol is 
only slightly shifted towards lower pH values, indicating that the substitution of the 
phenylalanine for an alanine in the activating peptide makes the thiol slightly less basic.
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Table 3.5 - p/c\ alues for the peptide GVQSLKRRRCA (cf. Figure 3.5).
P^__ GVQSLKRRRCA
p^l 7.2
P^2 5.5
P^3 7.05
P^12 9.0
P^13 8.55
P^ 21 10.7
P^23 8.75
P^31 8.7
P^32 7.2
p k \2 3 9.45
P^132 9.9
P^ 23l 11.4
3.2.3.Ô. The Titration of GVQSLKRRCRF
As with the previous peptide, also the determination of the equilibrium constants for 
the peptide GVQSLKRRCRF had to rely on certain assumptions. However, in this case 
the difference between this and the peptide GVQSLKRRRCF is a shift of one of the 
ionisable groups (the thiol) within the molecule, which will be expected to affect most 
equilibrium constants, as it has already been observed previously that the insertion o f an 
ionisable group is liable to affect the ionisation of other groups. Therefore, it was 
assumed that only constants k2, ku  and ^ 2 1  would not change as compared to those of 
the peptide GVQSLKRRRCF, since these are the only equilibria which involve species 
with a non ionised thiol group (cf. Figure 3.5), that should therefore have an equivalent 
behaviour regardless of the relative position of the cysteine within the molecule. By using 
this hypothesis, eight constants had to be recalculated, with four degrees of freedom in 
the determination.
The choice of four independent equilibrium constants with which to attribute values 
was based on the observation of Eqn, 3.2.4. As mentioned before (cf. 3.2.3), when 
(KT) -> +0C, a 3 -> 0 and pAA -> pAs, and when (FT) ^  0, as -> 1 and pMs pA^s, so 
the plot of the experimental pM values will provide with an estimate for values of h  and 
k\2i- Thus, these two could be used as independent constants, and the two remaining 
necessary constants were arbitrarily chosen to be A23 and Arsi.
The dependent constants were then calculated using the following equations:
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A'i3 =  /c? k n  /  k \
k \3 ,2  — k u  k \2 3  /  k u  
km  — A'21 Ati23 / A"23
Eqn. 3.2.13 
Eqn. 3.2.14 
Eqn. 3.2.15
k u  =  k \^ k u 2 /  At231 Eqn. 3.2.16
Also the peptide GVQSLKRRCRF was titrated as described in Method 2.10.1, the 
buffer absorbance was subtracted using the equations stated in 3.2.3.1 and the ionisation 
fraction « 3  was calculated for each experimental point using Eqn. 3.2.9. In the same 
manner described above (cf. 3.2.3.4), the function pMg was then calculated using Eqn. 
2 . 1 0 . 6  for each value of % and plotted against and a theoretical curve was fitted to 
the points using Eqn. 3.2.4 as described in 3.2.3. The result of the fitting is shown in 
Figure 3.21 and the resulting constants are presented in Table 3.6.
10
9.5
9
♦  A8a .
8
7,5
7
0 0.2 0.4 0.6 0.8 1
a
Figure 3.21 - The function pM vs. a  for the peptide GVQSLKRRCRF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical cmve obtained using Eqn.
3.2.4.
This figure allowed the confirmation that the experimental data and the theoretical 
curve are closely related. Using Eqn. 3.2.3, a theoretical curve could also be fitted to the 
experimental data for titration, enabling a second confirmation of the goodness of fitting, 
and this is shown in Figure 3.22.
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Figure 3.22 - Titration curve for the peptide GVQSLKRRCRF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.3.
With the constants obtained, deprotonation profiles could be calculated for all the 
ionisable groups, as depicted below;
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Figure 3 .23 - Deprotonation profiles of the lysine amino group (—), the cy steine thiol (------ ) and the
N-terminal amino group (— ) for the peptide GVQSLKRRCRF.
When compared to the peptide GVQSLKRRRCF (cf. Figure 3.17), the above figure 
shows that, whereas the lysine amino group retains its acidity unchanged, the N-terminal 
amino group actually becomes more basic, albeit slightly, and the cysteine thiol becomes 
slightly less basic.
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Table 3.6 - pÀ'values for the peptide GVQSLKRRCRF (cf. Figure 3.5).
pA GVQSLKRRCRF
pki 7.2
Vkj 5.5
P^ 3 8.5
P^ 12 9.0
pku 8 . 8
pkii 10.7
P^ 23 8.5
P^ 31 7.5
P^ 32 5.5
P^ 123 9.5
pku2 9.7
pkiii 11.7
3,2,3.7, The Titration of GVQSLKRCRRF
The assumptions made and method used for the calculation of the equilibrium 
constants for this peptide were identical to those for peptide GVQSLKRRCRF (cf. 
3.2.3.6).
This peptide was also titrated as described in Method 2 .1 0 .1 , the buffer absorbance 
was subtracted using the equations stated in 3.2.3.1 and the ionisation fraction « 3  was 
calculated for each experimental point using Eqn. 3.2.9. In the same manner described 
above (cf. 3.2.3.4), the function pMs was then calculated using Eqn. 2.10.6 for each 
value of % and plotted against and a theoretical curve was fitted to the points using 
Eqn. 3.2.4 as described in 3.2.3. The result of the fitting is shown in Figure 3.24 and the 
resulting constants are presented in Table 3.7.
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Figure 3.24 - The function pM vs. a  for the peptide GVQSLKRCRRF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.4.
As with the previous peptide, again from the above figure a good agreement 
between the experimental data and the theoretical curve can be observed. Using Eqn.
3.2.3, a theoretical curve could be fitted to the experimental data for titration to allow 
for another judgement on the goodness of fitting, and this is shown in Figure 3.25.
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Figure 3.25 - Titration cuive for the peptide GVQSLKRCRRF. The different symbols represent 
experimental data from 3 titrations and the dashed line is the theoretical curve obtained using Eqn.
3.2.3.
The above graph shows a good fitting of the theoretical curve to the experimental 
points, although the points for pH below 6 show some considerable scattering, which 
imposed a careful assignation of the curves minima. Again from these values
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deprotonation profiles could be calculated for the N-terminal and lysine amino groups, as 
well as for the cysteine thiol;
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Figure 3.26 - Deprotonation profiles of the lysine amino group (—), the cysteine tliiol (------ ) and the
N-terminal amino group (— ) for the peptide GVQSLKRCRRF.
Again in comparison to the peptide GVQSLKRRRCF (cf. Figure 3.17), the above 
figure shows that, whereas the lysine amino group retains its acidity unchanged, the 
N-terminal amino group actually becomes even more basic (increasing even in relation to 
the peptide GVQSLKRRCRF), and the cysteine thiol becomes slightly less basic (again 
to a greater extent than in the peptide GVQSLKRRCRF).
Table 3.7 - p/r values for the peptide GVQSLKRCRRF (cf. Figure 3.5).
p/f GVQSLKRCRRF
p^l 7.2
P^ 2 5.5
P^3 9.0
P^ 12 9.0
P^13 9.3
P^ 21 10.7
P^23 8.3
P^31 7.5
P^32 4.8
P^123 9.5
P^I32 9.2
P^231 11.9
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3.2.3.8. Final Considerations on the Titration Results
The titration results provide a better understanding of the acid-base behaviour of the 
activating peptide. The initial assumption that the array of arginines close to the peptide 
would alter significantly the acidic character of the cysteine thiol group was shown not to 
be true. Also, although the equilibria description in Figure 3.5 provides with a more 
accurate account of the deprotonation equilibria, a somewhat simpler description of the 
deprotonation can be used, since it can be observed (cf. Figure 3.17) that for the 
activating peptide each ionisable group deprotonates at distinct pH ranges. Therefore, an 
alternative simpler description would be as follows:
NH, NH, NH, NH,
— NH,+ Ki
HS HS
COOH
-NH,-*- K2
HS
000 -
s-
000 -
-NHg ^4
000-
NH,
*8-
-NH,
000 -
Figure 3.27 - Simplified description of the deprotonation of the peptide GVQSLKRRRCF, Tlie species 
depicted represent the predominant species only, altliough the macroscopic constants represent 
deprotonation steps of the molecule, regardless of where the proton is coming from.
In the above description, the macroscopic constants can be shown to be related to 
the microscopic constants represented in Figure 3.5 as follows (excluding K\, for which 
no determinations were made):
Eqn. 3.2.17
^ 1 ^ 1 2  ~F ^2^23 Eqn. 3.2.18
"231 Eqn. 3.2.19
Taking into consideration the values in Table 3.4, it is a straightforward process to 
show that K2 » ki, K3 % k23 and K 4 % k2 3 i, as it would be expected if the simplification 
stated above was true, This enables the assignation of a macroscopic pK to each of the 
ionisable groups within the peptide (with the exception of the carboxyl group):
Remits and Discussion 107
Table 3.8 - Macroscopic piT values of tlie ionisable groups of the peptide GVQSLKRRRCF, with 
exception of the C-tenninal carboxyl group.
G roup P f
Lysine-6 amine 5,5
Cysteine-10 thiol 8.85
N-terminal amine 11.4
Therefore, a discussion in terms of “independent” ionisable groups is possible for the 
effect of mutations of residues within the activating peptide,
Reanalysing the data for the peptide GVQSLKRRRCA, it can be seen that this 
mutation leads to a decrease of 0.1 pH units in the pK of the thiol group in relation to the 
peptide GVQSLKRRRCF, while keeping the other pÆ values constant (cf. Figure 3.28). 
This seems to indicate that the phenylalanine does not play any relevant role on the 
acidity of the cysteine thiol group. The fact that the other pÆ values remain constant is a 
reflection of the postulate used for the determination of the constants.
0.9 -
0.7 --
0.3 - 
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Figure 3.28 - Comparison of the deprotonation curves of the peptides GVQSLKRRRCF (solid lines) and 
GVQSLKRRRCA (dashed lines). The black lines correspond to the lysine amine, the purple to the 
cysteine thiol and the dark blue to the N-terminal amine.
When the cysteine is shifted along the arginines, there is a reasonable increase in 
acidity of the thiol group, with a decrease of 0.35 pH units for the peptide 
GVQSLKRRCRF, and of 0.55 pH units for GVQSLKRCRRF (cf. Figure 3.29), 
consistent with the aforementioned observation that charged neighbouring groups affect 
the acidity of the cysteine group, although this result does indicate that the cysteine in the 
activating peptide is actually reasonably basic rather than unusually acidic, which is
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exactly the opposite effect of what was expected to be observed if the arginines had the 
reactivity enhancement initially sought for.
0.9
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Figure 3.29 - Comparison of the deprotonation curves of the peptides GVQSLKRRRCF (----),
GVQSLKRRCRF (------ ) and GVQSLKRCRRF (—). The black lines correspond to the lysine amine, the
purple to the cysteine thiol and the dark blue to the N-terminal amine.
Again, the fact that the lysine amine has a constant pÆ is a result of the constraints 
imposed for the calculation of the equilibrium constants, although it makes sense that a 
group that is completely deprotonated before any other group (other than the C-terminal 
carboxyl) in the molecule will not be affected by small changes of pÆ of groups that only 
deprotonate at a reasonably higher pH,
Finally, although the array of arginines close to the cysteine appears not to affect its 
pK, it is plausible that these could be responsible for the unusually very low pK  o f the 
lysine amino group. Also, the very high pK  o f the N-terminal amino group falls within 
the range of the usual pK  values for arginine groups, which implies that the initial 
assumption that these would only deprotonate after the complete deprotonation of the 
amines and thiol cannot be applied, and therefore the equilibria depicted in Figure 3.5 
should be much more complex, not enabling the mathematical treatment used herein. 
Therefore, the only reliable pK  values determined are those for the cysteine, as there is 
experimental evidence for these.
3.3. Influence o f Activating Peptide Length on Activation
The peptide KRRRCF, which corresponds to the last six residues of the full length 
activating peptide, was found to be unable to activate the adenovirus protease (Webster 
et a l ,  1993). This observation suggested that there had to be some role of the peptide
Results and Discussion /OP
length in activation. Therefore, several peptides were synthesised in order to evaluate 
what was the minimum length requirement for adequate activation of the protease.
3.3.1. Importance of GV in Activation
Four peptides were synthesised, LKRRRCF, SLKRRRCF, QSLKRRRCF and 
VQSLKRRRCF as described in Method 2,4.1, using the semi-automated synthesis. 
Method 2.4.1.2; KRRRCF had been previously synthesised. All peptides were purified by 
HPLC (Method 2.4.2.1) and as a reference typical percentages of acetonitrile for elution 
of the peptides (4.6 mm x 25 cm CIS column), as well as migration times on capillary 
electrophoresis (CE) are shown in Table 3.9. The peptide molecular weights were 
confirmed by mass spectrometry (Method 2.6) and their sequence was confirmed by 
Method 2.5.
Table 3.9 - Typical values of purification parameters for several peptides. Migration times for CE are
given for a 24 cm x 25 pm capillary.
Peptide Percentage of acetonitrile 
for peptide elution
Migration time 
on CE (min)
VQSLKRRRCF 40-50 3,4
QSLKRRRCF 45-50 3.3
SLKRRRCF 45-50 3.1
LKRRRCF 45-50 3.1
KRRRCF 40-45 2.9
The first approach to the study of these peptides was to perform concentration 
assays, in the same manner as with the peptides with substitutions in the cysteine. The 
protease (0.02 mg/ml) was therefore incubated with each of the peptides at 3TC  
(Method 2.9.1) for 10 min before the addition of substrate. The substrate LSGAGFSW 
was then allowed to be digested for 30 min at several concentrations (0.15, 0.12, 0,089, 
0.059, 0.030 and 0.015 mM), of each of the purified activating peptides. Time samples 
were taken and analysed using capillary electrophoresis (Method 2.7.1.1), The results are 
shown in Figure 3.30:
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Figure 3.30 - Effect of activating peptide length on activation of the adenovirus protease. Curves 
correspond to a 30 min digestion of the substrate LSGAGFSW. Purified activating peptides.
These preliminary results indicated that the first two N-terminal residues, glycine and 
valine, had a definite role in the activation process of the protease. The following step 
was to quantify the difference between the activation of these peptides, For that purpose, 
kinetic assays were made in order to obtain values for the initial rates of the digestion 
reaction.
3.3.2. Determination of the Initial Rates of the N-terminal Truncated 
Peptides
The kinetic assays consisted on following the digestion curve of LSGAGFSW with 
time (as described in Method 2.12.1 and discussed in 3.8.3) when the protease was 
activated with each of the N-terminal truncated peptides and comparing it to the 
activation with the original activating peptide.
The determination of the initial rates of digestion demanded the use of a curve fitting 
strategy (Method 2.12) due to the limitation of the method used to determine the time 
points of digestion (capillary electrophoresis. Method 2.7.1.1), which did not allow to 
quantify accurately low amounts of digestion. Several initial rate determinations were 
made for each peptide activation in order to obtain statistically significant values for the 
final values.
3.3.2.L The Peptide VQSLKRRRCF
Kinetic assays were done essentially as described in Method 2.9.1, In a typical assay, 
three substrate digestions were followed with time, where the protease (0.06 mg/ml) was
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activated in duplicate by the peptide VQSLKRRRCF, and activated by 
GVQSLKRRRCF in a control assay. Time points were plotted against its correspondent 
percentage of substrate digestion and a curve was fitted using Method 2.12. The results 
are presented in the following table (duplicate assays are displayed where two identical 
rates of digestion are found for the control peptide):
Table 3.10 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide VQSLKRRRCF (IRio) together with the 
initial rates of the control peptide GVQSLKRRRCF (XRn). The first column indicates the concentration 
of peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc.: 5 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative initial
rate.
Conc.
(mM)
IRii
(%/min)
r n IHio
(%/min)
rlo IRio/lRu
0.037 0.01128 0.99984 0.00242 0.97560 0.215
0.037 0.00829 0.93833 0.00200 0.94571 0242
0.15 0,07947 0.98941 0.02097 0.94202 0.264
0.15 0.11863 0.99577 0.04060 0.98968 0 342
0.037 0.01128 0.99984 0.00387 0.98800 0J43
0 037 0.02599 0.98825 0.00960 0.98294 0 369
0.037 0.01910 0.99029 0.00714 0.96683 0.374
0.037 0.00829 0.93833 0.00318 0.99818 0.384
0.15 0.11863 0.99577 0.04957 0.98323 0.418
0.15 0.07947 0.98941 0.03341 0.97852 0.420
0.037 0.01599 0.96870 0.00684 0.95220 0.428
0.037 0.01599 0.96870 0.00764 0.98279 0.478
0.037 0.01319 0.98735 0,00633 0.99536 0.480
0.15 0.08540 0.99441 0.04109 0.97740 0.481
0.15 0.08540 0.99441 0.04427 0.97429 0.518
0.037 0.01319 0.98735 0.00686 0.98690 0.521
0 037 0.01910 0.99029 0.01037 0.98324 0.543
0.037 0.03418 0.99591 0.02026 0.99812 0.593
0.15 0.07658 0.97816 0.04647 0.95889 0^07
(1037 0.03418 0.99591 0.02211 0.99484 0.647
0.037 0.02599 0.98825 0.01814 0.99250 0.698
0.15 0.09830 0.99466 0.07234 0.97038 0.736
0.15 0.09830 0.99466 0.07595 0.97374 0.773
0.15 0.07658 0.97816 0.06285 0.97380 0.821
The first remark to be made regards the notorious variability found in the initial rate 
for the activated protease with any of the peptides. This is certainly due to the instability 
of the protease regarding repeated freeze-thawing whilst being reused (cf. 3.1). Also, the 
correlation coefficient is always greater than 0.90, indicating a close agreement between
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the experimental points and the theoretical curve. However, the final relative initial rate 
of digestion is reasonably constant, regardless of the concentration of peptide used for 
activation, allowing for a statistical treatment of the data. An histogram depicting the 
distribution of the relative initial rate allows a better illustration of the average value to 
be calculated;
0.40 0.50 0.60
Relative initial Rate
Figure 3.31 - Histogram depicting the distribution of the relative initial rate IRio/IRi,.
From the histogram, an average can be estimated to lie between 0.40-0.45. These 
values led to a final determination of an average value of 0.49 + 0.17 (standard 
deviation) for the relative initial rate of protease cleavage when activated with the 
peptide VQSLKRRRCF as compared to the peptide GVQSLKRRRCF. Therefore, this 
peptide is still able to activate the protease, albeit only with half of the efficiency of the 
original activating peptide, which suggests a role of the N-terminal glycine in the 
activation mechanism.
The Peptide QSLKRRRCF
Again, kinetic assays were done essentially as described in Method 2.9.1. In a typical 
assay, three substrate digestions were followed with time, where the protease (0.06 or 
0.1 mg/ml) was activated in duplicate by the peptide QSLKRRRCF, and activated by 
GVQSLKRRRCF in a control assay. Time points were plotted against its correspondent 
percentage of substrate digestion and a curve was fitted using Method 2.12. The results 
are presented in the following table (duplicate assays are displayed where two identical 
rates of digestion are found for the control peptide):
Results and Discussion 1 1 2
Table 3 .11- Experimentally determined v alues for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide QSLKRRRCF (IR9) together with the initial 
rates of the control peptide GVQSLKRRRCF (IR,;). The first column indicates the concentration of 
peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative initial
rate.
Conc.
(mM)
IRn
(%/min)
r i i JUR.9
(%/min)
r ' 9 IR 9 /IR 11
0.15 0,10074 0.99192 0.00169 0,96602 0.017
0.15 0.12871 0,97184 0.00263 0.95126 0.020
0.15 0,06186 0,97466 0,00155 0.91595 0.025
0.15 0.06186 0,97466 0,00157 -0.25010 0.025
0.15 0.12871 0.97184 0.00342 0,99171 0,027
0.15 0,10074 0.99192 0,00272 0.94370 0TG7
0.15 0,11909 0,98792 0.00355 0.98022 0.030
0.15 0,14347 0,98552 0.00568 0.97872 0.040
0.15 0,14347 0,98552 0.00617 0.99012 0.043
0.15 0,10656 0,99264 0,00474 0.93982 0.045
0.15 0,11408 0.99271 0.00528 0.95972 0.046
0.15 0,11909 0,98792 0,00591 0.95957 0.050
0.15 0,11408 0,99271 0,00661 0.97445 0.058
0.15 (X10656 0,99264 0.00659 0.97167 0.062
0.037 0,01500 0.98818 0.00124 0.99569 0.083
0.037 0.00812 0.96384 0,00073 0.98983 0,090
0.18 0.03496 0,99615 0.00378 0,99042 0.108
0.18 0.01057 0,98228 0.00142 0.99933 0T34*
0.037 0,01500 0.98818 0.00206 0,99134 0T37*
0.18 0,03496 0.99615 0.00477 0.96606 0 137"
0.037 0,01589 0,98845 0.00252 0.98884 0 158"
0.037 0.01069 0.99482 0.00184 0.96240 0.172"
0 18 0.01029 0,99317 0.00184 0.97711 0.179"
0.037 0,00770 0.96415 0,00141 0.97266 0 183"
0.037 0.00812 0.96384 0.00150 0.99824 OH&r
0T8 0.01029 0.99317 0.00214 0.92229 0.208"
0.037 0.01069 0.99482 0.00227 0.99614 0 .2 1 2 "
0.18 0.01057 0.98228 0.00272 0.98001 0.258"
0.037 0.00770 0.96415 0.00215 0.94425 0.280"
0.037 0,01589 0.98845 0,00458 0.97647 0.288"
- Discarded values in the average calculation.
Once more in these determinations a remarkable variability is found in the initial rate 
for the activated protease, as well as a value for the correlation coefficient constantly 
above 0.90, with one exception. However, in this case the final relative initial rate of 
digestion is not very constant. The causes leading to this occurrence can be attributed to 
the method used for determination of the values for the percentage of digestion. A first
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point to note is that the peptide QSLKRRRCF was not expected to activate very 
efficiently the protease, as revealed by the preliminary studies (cf. 3.3.1), On the other 
hand, initial digestion rates of less than 0.005 % digested substrate/min arise from 
digestion points below 10 % of substrate digestion, which is very near to the limit of 
detection of the method used (cf. discussion in 3.8.3). Therefore, the results for low 
initial rates were misleading, and a more concentrated protease was used in order to 
obtain more reliable results, An histogram depicting the distribution of the relative initial 
rate allows a better illustration of the average value to be calculated, depicting the 
scattering of higher relative initial rates due to loss of sensitivity of the method 
(corresponding in the quotient I R g / I R n  to a variable value of I R n  with a reasonable 
constant low value of I R 9);
0.01 0.05 0,09 0.13 0.17
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Figure 3.32 - Histogram depicting the distribution of the relative initial rate IRç/IRu. The void bars 
correspond to values discarded in the average calculation.
From the histogram, an average can then be estimated to lie between 0.03-0.05, 
taking into consideration the above arguments for discarding the higher values. This led 
to a final determination of an average value of 0.047 ± 0,027 for the relative initial rate 
of protease cleavage when activated with the peptide QSLKRRRCF as compared to the 
peptide GVQSLKRRRCF. This value should be considered rather as a maximum, 
consistently with the low initial rates obtained when the protease was activated with the 
peptide QSLKRRRCF, which might still lie within the detection limits of the method 
used for these determinations. These results seem to indicate that the presence of the 
residues glycine and valine in the N-terminal are determinant in the activation process of 
the protease.
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3.3.2.3, The Peptide SLKRRRCF
Once again, kinetic assays were done essentially as described in Method 2.9,1. In a 
typical assay, three substrate digestions were followed with time, where the protease 
(0.06/0,1 mg/ml) was activated in duplicate by the peptide SLKRRRCF, and activated by 
GVQSLKRRRCF in a control assay. Time points were plotted against its correspondent 
percentage o f substrate digestion and a curve was fitted using Method 2.12. The results 
are presented in the following table (duplicate assays are displayed where two identical 
rates of digestion are found for the control peptide):
Table 3.12 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide SLKRRRCF (IRg) together with the initial 
rates of the control peptide GVQSLKRRRCF (IRn). The first column indicates the concentration of 
peptide used in tlie assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last colmim indicates the relative initial
rate.
Conc.
(mM)
IRu
(%/min)
r n ERs
(%/min)
r s IRs/IRu
0,15 0.12815 0.99627 0.00303 0.94653 &024
0,15 0.07025 0.99804 0.00193 0,97575 0.027
0.15 0,14925 0.97736 0.00427 0.96935 0.029
0,15 0.12815 0.99627 0.00392 0.97551 0.031
0,15 0.12264 0.99838 0.00390 0.82152 0T82
0,15 0,07025 0.99804 0.00224 0.94382 0,032
0.15 0.15668 0.99644 0,00695 0,96895 0,044
0.15 0.06370 0.86419 0.00285 0.98054 0.045
0.15 0,06611 0.55708 0,00307 0.95940 0.046
0.15 0.15668 0.99644 0.00747 0.98019 0.048
0.15 0.12264 0.99838 0.00595 0.98364 0TM9
0,15 0.06611 0.55708 0.00325 0.96606 0,049
0,15 0.14925 0.97736 0.00762 0.92186 0,051
0,15 0.06421 0 99929 0.00325 0.95514 0.051
0,15 0.06421 0.99929 0.00372 0.99955 0.058
0,15 0,54545 1 0.04900 0.99865 0.090*
0,15 0,54545 1 0,05252 0.99194 0.096"
0,15 0.06370 0.86419 0.00710 0 98722 O .l l f
0,18 0.02936 0.99966 0.00437 0.99047 0 149"
0 18 0.02936 0 99966 0.00633 0.99856 0.216"
0T8 0.02038 0.98904 0,00443 0.97525 0.218"
018 0.02164 0.98993 0.00518 0.95017 0.239"
0.18 0.02038 0,98904 0,00695 0.98986 0.341"
0,18 0.02164 0.98993 0.00817 0.98640 0.378"
- Discarded values in the average calculation.
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As with the previous peptides, the initial rate for the activated protease is found to 
be quite variable, as well as a value for the correlation coefficient lying steadily above 
0.90, again with one exception. In one case, this value reaches 1 due to the fact that only 
one point was used to determine the adjustment curve, as the protease was extremely 
active, and complete digestion of substrate can not be used in the calculation due to 
having to compute a logarithm of zero. As with the peptide QSLKRRRCF, the final 
relative initial rate of digestion is not very constant, the causes leading to this occurrence 
being similar to the ones pointed out for that peptide. Therefore, again the results for low 
initial rates are misleading, and a more concentrated protease was used in order to obtain 
more reliable results. The following histogram depicting the distribution of the relative 
initial rate illustrates the average value to be calculated, depicting the scattering of higher 
relative initial rates due to loss of sensitivity of the method (once more corresponding in 
the quotient IRg/IRii to a variable value of IRu with a reasonably constant low value of 
% ) :
Dag.__ . n,n. , ,___,n, ,n:
0.01 0.05 0.09 0.13 0.17 0.21 0.25 0.29 0.33 0.37
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Figure 3.33 - Histogram depicting the distribution of the relative initial rate IRg/IR,,, The void bars 
correspond to values discarded in the average calculation.
From the histogram, an average can then be estimated to lie between 0.03-0.05, 
taking into consideration the above arguments for discarding the higher values. This led 
to a final determination of an average value of 0.041 ± 0.011 for the relative initial rate 
of protease cleavage when activated with the peptide SLKRRRCF as compared to the 
peptide GVQSLKRRRCF. As with the peptide QSLKRRRCF, the value for the relative 
initial rate should be considered rather as a maximum, consistently with the low initial 
rates obtained when the protease was activated with the peptide SLKRRRCF, which 
again might still lie within the detection limits of the method used for these 
determinations. What these results suggest is that any shorter peptide, lacking the N-
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terminal glycine and valine, will not be able to activate the protease, which had already 
been shown to be true in the case of the peptide KRRRCF (Webster et al., 1993).
3.3.3. Non-Complementarity of GVQSL and KRRRCF
From the previous results, it became apparent that the residues glycine-1 and 
valine-2 were determinant for the activation of the protease with the peptide 
GVQSLKRRRCF. In order to try and elucidate whether the peptide molecule acted as a 
whole or in a concerted manner, with more than one molecule being necessary to fully 
activate the protease, some assays were performed using a mixture of the peptides 
GVQSL and KRRRCF.
The peptide GVQSL was synthesised as described in Method 2.4,1, using the semi­
automated synthesis. Method 2.4.1.2; KRRRCF had been previously synthesised. It was 
then purified by HPLC (Method 2.4.2.1) and typical percentages of acetonitrile for 
elution of GVQSL were of 40-45% (4.6 mm x 25 cm C l8 column), and its migration 
time on capillary electrophoresis (CE) was of 7.1 min (24 cm x 25 pm capillary).
Activity assays were done essentially as described in Method 2.9.1, and the results 
are summarised in the following table;
Table 3.13 - Protease activation with GVQSL and KRRRCF (30 min digestion).
Peptide Concentration (mM) % digestion
GVQSLKRRRCF 0.074 100
GVQSL 0.074 0
KRRRCF 0.074 0
GVQSL + KRRRCF 0.037 0
These results show that the peptide GVQSLKRRRCF acts as a whole in the 
activation mechanism, which suggests that the N-terminal region of the peptide has some 
concomitant role in activation.
3.4. Importance of N-terminal region of Activating Peptide
The results shown in 3.3.2 stress the importance of the N-terminal region of the 
activating peptide GVQSLKRRRCF in the activation of the protease, namely the role of 
the two first residues, glycine-1 and valine-2. The next step was to assess the specificity 
required for these residues in the activation mechanism. Again some peptides were 
synthesised, with some alterations in those residues: valine was mutated to alanine, a side 
chain similar in hydrophobicity although not branched; and to threonine, a side chain
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similar in structure to valine but hydrophilic. Glycine was also acetylated in the N- 
terminal in order to eliminate the positive charge. The ability of these peptides in 
activating the protease was then evaluated.
3.4.1. Determination of the Initial Rates of the N-terminal Mutated Peptides
Three peptides were synthesised, GAQSLKRRRCF, GTQSLKRRRCF and 
Ac-GVQSLKRRRCF, as described in Method 2.4.1, using the semi-automated synthesis. 
Method 2.4.1.2. All peptides were purified by HPLC (Method 2.4.2.1) and as a reference 
typical percentages of acetonitrile for elution of the peptides (4.6 mm x 25 cm CIS 
column), as well as migration times on capillary electrophoresis (CE) are shown in Table 
3.14. The peptide molecular weights were confirmed by mass spectrometry (Method 2.6) 
and their sequence was confirmed by Method 2.5, with the exception of the peptide 
Ac-GVQSLKRRRCF, which could not be sequenced due to being N-terminal blocked.
Table 3.14 - Typical values of purification parameters for the peptides GAQSLKRRRCF, 
GTQSLKRRRCF and Ac-GVQSLKRRRCF. Migration times for CE are given for a 24 cm x 25 pm
capillary.
Peptide Percentage of acetonitrile Migration time
for peptide elution on CE (min)
GAQSLKRRRCF 40-45 3.7
GTQSLKRRRCF 40-45 3.6
Ac-GVQSLKRRRCF 40-45 4.3
The kinetic assays consisted on following the digestion curve of LSGAGFSW with 
time (as described in Method 2.12.1 and discussed in 3.8.3) when the protease was 
activated with each of the N-terminal truncated peptides and comparing it to the 
activation with the original activating peptide.
As stated before, the determination of the initial rates o f digestion demanded the use 
of a curve fitting strategy (Method 2.12) due to the limitation of the method used to 
determine the time points of digestion (capillary electrophoresis. Method 2.7.1.1), which 
did not allow to quantify accurately little amounts of digestion (cf. 3.8.3). Again, several 
initial rate determinations were made for each peptide activation in order to obtain 
statistically significant values for the final values.
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3.4,LL The Peptide GAQSLKRRRCF
Once more, kinetic assays were done essentially as described in Method 2.9.1. In a 
typical assay, three substrate digestions were followed with time, where the protease 
(0.06 mg/ml) was activated in duplicate by the peptide GAQSLKRRRCF, and activated 
by GVQSLKRRRCF in a control assay. Time points were plotted against its 
correspondent percentage of substrate digestion and a curve was fitted using Method
2.12. The results are presented in the following table (duplicate assays are displayed 
where two identical rates of digestion are found for the control peptide):
Table 3 .15- Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide GAQSLKRRRCF (IR2a) together with the 
initial rates of the control peptide GVQSLKRRRCF (IRu). The first column indicates the concentration 
of peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative initial
rate.
Conc.
(mM)
LRii
(%/min)
r 'li
(%/min)
r^A IR2a/ERii
0.15 0.01018 0.97545 0.00120 0.97502 0.118
0.18 0.01066 0.95073 0.00181 0.98667 0.170
0.18 0.03440 0.98847 0.00691 0.96337 0.201
0.15 0.05352 0 99646 0.01233 0.98106 0.230
0.18 0.03440 0.98847 0.00857 0.96912 0.249
0T5 0.01043 0.99610 0.00298 0.98372 0.286
0.15 0.02090 0.96148 0.00653 0.94099 0.312
0.15 0.00791 0.98073 0.00259 0.96028 0.328
0.15 0.02014 0.96412 0.00726 0.93341 0.360
0.15 0.03049 0.99430 0.01109 0.94534 0364
0 15 0.02014 0.96412 0.00770 0.99001 0.382
0.15 0.00791 0.98073 0.00305 0.96836 0.386
0.18 0.02228 0.98468 0.00928 0.99328 0.416
0.15 0.05352 0.99646 0.02329 0.99634 &435
0.18 0.02228 0.98468 0.00984 0.99372 0.442
0.15 0.00906 0.95198 0.00435 0.97731 0.481
0.15 0.01043 0.99610 0.00505 0.95070 0.485
0.15 0.04747 0.98128 0.02517 0.99562 0.530
0.15 0.03305 0.98649 0.01757 0.99791 0.532
0.18 0.01066 0.95073 0.00586 0.99692 0.550
0.15 0.03305 0.98649 0.01866 0.99820 0.564
0.15 0.00906 0.95198 0 00536 0.96646 0.592
0.15 0.04747 0.98128 0.02873 0.98135 0.605
As with the previous assays, the initial rate for the activated protease with any of the 
peptides varies to a noticeable extent, again due to the instability of the protease
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regarding repeated ffeeze-thawing whilst being reused. Also, the correlation coefficient is 
always greater than 0.90, indicating a close agreement between the experimental points 
and the theoretical curve. However, the relative initial rate of digestion obtained after the 
calculations is reasonably constant within certain limits, regardless of the concentration 
of peptide used for activation, allowing for a statistical treatment of the data. An 
histogram depicting the distribution of the relative initial rate allows a better illustration 
of the average value to be calculated;
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Figure 3.34 - Histogram depicting the distribution of the relative initial rate IR2a/IRii.
From the above histogram, an average can be estimated to lie between 0.30-0.40. 
For the determination of the average, no values were discarded as all the data seem to lie 
within the apparent pattern for a normal distribution, albeit quite flat and scattered. This 
led to a final determination of an average value of 0.39 ± 0,14 for the relative initial rate 
of protease cleavage when activated with the peptide GAQSLKRRRCF as compared to 
the peptide GVQSLKRRRCF, This value seems to indicate that a branched side chain in 
the second residue of the activating peptide is a requirement for a more effective 
activation of the protease.
3,4.L2. The Peptide GTQSLKRRRCF
As with the previous peptides, kinetic assays were done essentially as described in 
Method 2.9.1. In a typical assay, three substrate digestions were followed with time, 
where the protease (0.06 mg/ml) was activated in duplicate by the peptide 
GTQSLKRRRCF, and activated by GVQSLKRRRCF in a control assay. Time points 
were plotted against its correspondent percentage of substrate digestion and a curve was 
fitted using Method 2.12. The results are presented in the following table (duplicate 
assays are displayed where two identical rates of digestion are found for the control 
peptide):
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Table 3.16 - Experimentally determined v alues for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide GTQSLKRRRCF (IR2T) together with the 
initial rates of the control peptide GVQSLKRRRCF (IRn). The first column indicates the concentration 
of peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together with the 
correlation coefficient obtained using Method 2,12.1. and the last column indicates the relative initial
rate.
Conc.
(mM)
IRii
(%/min)
r n ER2T
(%/rain)
r"3T IR 2T/IR11
0.15 0.01133 0.98164 0.00291 0.95609 0.257
0.15 0.01011 0.98184 0.00277 0.97950 0.274
0.15 0.00593 0.98647 0.00174 0.99153 0.294
0.15 0.00373 0.97594 0.00118 0.97975 0.318
0.15 0.01133 0.98164 0.00439 0.96493 0.387
0.15 0.01989 0.99706 0.00781 0.95833 0.393
0.15 0.01011 0,98184 0.00433 0.98233 0.428
0.15 0.01989 0.99706 0.00883 0.96019 0.444
0.18 0.02445 0.99339 0.01289 0.99101 0.527
0,18 0.02445 0.99339 0.01411 0,99162 0.577
0.15 0.00806 0.98981 0.00654 0.97038 0.811*
Discarded value in the average calculation.
I t  can again be observed that the initial rate for the activated protease with any of 
the peptides is varying, for the same reasons already stated. Also, the correlation 
coefficient is always greater than 0.95, indicating an excellent agreement between the 
experimental points and the theoretical curve. The relative initial rate of digestion values 
obtained afi:er the calculations are much less variable, regardless of the concentration of 
peptide used for activation, allowing for a statistical treatment of the data. Only one 
point was found to lie reasonably distant from the others, which led to its discarding 
(a  = 0 .r ,  criteria of Dixon (Dixon and Massey, 1957)). An histogram depicting the 
distribution of the relative initial rate allows a better illustration of the average value to 
be calculated:
a  represents the probability of the discarded point belonging to the average and not being due to 
some error associated with its experimental determination (Dixon and Massey. 1957).
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Figure 3.35 - Histogram depicting the distribution of the relative initial rate DR.2t/IRi i. The void bar 
corresponds to tlie value discarded in the average calculation.
It is not completely clear from the above histogram where the average lies, for the 
initial rate of digestion with this peptide. For the determination of the average, it was 
assumed that all the data lay within the pattern for a normal distribution, in spite of the 
unusual distribution of the data points, which can be due to a reduced number of 
experiments, as compared to other peptides. Yet, this still allowed a final determination 
o f an average value of 0.39 ± 0.11 for the relative initial rate of protease cleavage when 
activated with the peptide GTQSLKRRRCF as compared to the peptide 
GVQSLKRRRCF. The above value suggests that the side chain of the second residue, 
besides having to be branched, should also be hydrophobic in order to enable an efficient 
activation of the protease.
3.4.L3, The Peptide Ac-GVQSLKRRRCF
Also for this peptide kinetic assays were done essentially as described in Method
2.9.1. In a typical assay, three substrate digestions were followed with time, where the 
protease (0.06 mg/ml) was activated in duplicate by the peptide Ac-GVQSLKRRRCF, 
and activated by GVQSLKRRRCF in a control assay. Time points were plotted against 
its correspondent percentage of substrate digestion and a curve was fitted using Method
2.12. The results are presented in the following table (duplicate assays are displayed 
where two identical rates of digestion are found for the control peptide):
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Table 3.17 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide Ac-GVQSLKRRRCF (IR ac) together with 
the initial rates of the control peptide GVQSLKRRRCF (IRn). The first column indicates the 
concentration of peptide used in the assay, the following four columns the initial rates obtained with the 
respective peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together with 
the correlation coefficient obtained using Method 2.12.1. and the last column indicates the relative
initial rate.
Conc.
(mM)
IRii
(%/min)
r n IRac
(%/min)
r^ Ac IRac/IRii
0.15 0.01090 0.99031 0.00338 0.98527 0.310
0.15 0.01090 0.99031 0.00348 0.95136 0.319
0.15 0.02050 0.98791 0.00828 0.98440 0.404
0.15 0,01880 0.99737 0.00781 0.97149 0.416
0.15 0.01880 0.99737 0.00862 0.95616 0.459
0.15 0.00783 0.95468 0.00370 0.98793 0.472
0.15 0.02050 0.98791 0.01017 0.99226 0.496
0.15 0.00871 0.97358 0.00436 0.98196 0.501
0.15 0.00871 0.97358 0.00492 0.97349 0.565
0.15 0.00880 0.95452 0.00539 0.98532 0.612
0.15 0.00783 0.95468 0.00539 0.99817 0.688
0.15 0,00880 0.95452 0.00654 0.97576 0.743
The same observations previously made regarding protease activity variability and 
good fitting of the experimental data to the theoretical curve, expressed in correlation 
coefficient values always greater than 0.95, also apply to these results. The relative initial 
rate of digestion values obtained after the calculations are exhibiting once more a very 
moderate variation, regardless of the concentration of peptide used for activation, 
allowing for a statistical treatment of the data. As previously, an histogram depicting the 
distribution of the relative initial rate illustrates the average value to be calculated:
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Figure 3.36 - Histogram depicting the distribution of the relative initial rate IRa</IRii.
In this histogram, the highest frequency of values is within the interval 0.45-0.50, 
indicating a first approximation to the value of the average to be calculated. Considering
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a normal distribution, this allowed a final determination of an average value of 
0.50 + 0.14 for the relative initial rate of protease cleavage when activated with the 
peptide Ac-GVQSLKRRRCF as compared to the peptide GVQSLKRRRCF. Again this 
reveals the importance of the N-terminal residues and their specificity, as a change in the 
polarity of the amino group decreases activity to half of its original value with the 
ordinary peptide. This also suggests that peptides with an extended peptide chain along 
the N-terminal should not be as effective as the cleaved peptide in activating the 
protease, raising the possibility that pVI is not as effective as the cleaved C-terminal in 
the activation process. This was studied further below.
3.4.2. N-terminal Prolongation with Consensus Sequence
The previous results, in which the acétylation of the activating peptide in its 
N-terminal, yielding the peptide Ac-GVQSLKRRRCF, caused a reduction in activation 
when compared to the native peptide, raised the question of how the activating peptide is 
released from pVI in the first instance. Certainly, previous studies (Webster et at., 1993) 
showed that pVI was able to activate the protease, but the effectiveness of this activation 
had not been assessed. Moreover, as the activating peptide is cleaved from pVI by the 
protease, it was possible that the mechanism of activation was concomitant with the 
cleavage of the peptide, with the C-terminal of pVI binding to the protease in such a way 
that the cleavage site was positioned in the active site and the C-terminal cysteine of pVI 
close to the cysteine of the protease with which it dimerises (cysteine 104), as illustrated 
by the following scheme;
JVGUGVQSLKRRRCF
VQSLKRRRCF
Figure 3.37 - Scheme illustrating a possible mechanism of activation concomitant with the cleavage of 
the C-tenninal of pVI. The binding of the activating peptide would cause a conformational change in the 
active site by pushing together the residues involved in catalysis, thus converting the protease to its 
active conformation. The putative active site cysteine (C) and histidine (H) are also depicted.
In order to test for this hypothesis, several peptides were synthesised, with the 
following sequences: IVGLG VQSLKRRRCF, IV ALGVQ SLKRRRCF and
VVGLGVQSLKRRRCF. Whilst the first peptide corresponds to the C-terminal 15
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residues of pVI, including a cleavage site that matches the consensus sequence for the 
protease, the latter two comprise point mutations in amino acids that alter the consensus 
sequence, rendering it uncieavable by the protease, or which will be cleaved in spite of 
not presenting a consensus sequence, should the above model be verified. Also, if the 
hypothesis above was true and the peptides were not cleaved, the latter peptides would 
inhibit the protease, by blocking the active site and preventing other substrates from 
reaching it.
3,4.2.1. The peptides (I, V) V(G, A) LG VQSLKRRRCF
The above three peptides were synthesised as described in Method 2.4.1, using mini 
synthesis. Method 2.4.1.4. Several attempts were made to purify all peptides by HPLC 
(Method 2.4.2.1) (4.6 mm x 25 cm CIS column), but the final samples were still 
reasonably impure, as assessed by capillary electrophoresis, where several peaks were 
observed, although the main peak was the intended peptide. This was most probably due 
to an inefficient synthesis which produced various peptides very similar in composition 
which were quite difficult to separate. The best purification method was using HPLC 
with an isocratic gradient of 49% acetonitrile.
The first experiment aimed at verifying whether the peptide IVGLGVQSLKRRRCF 
activated the protease and was cleaved by it at the same time. Activity assays were 
performed using 10 pi of protease (0.08 mg/ml), 10 pi of peptide solution (0.75 mM) 
and 30 pi of assay buffer (cf. Method 2.9.1), and samples were taken and analysed using 
capillary electrophoresis (Method 2.7.1.1). A possibility that was tested at the same time 
was to verify whether the other peptides, IVALGV QSLKRRRCF and 
WGLGVQSLKRRRCF, were also cleaved, due to being directed to the active site, as 
described in the scheme of Figure 3.37, which would then give some credence to the 
model.
In some preliminary experiments, after 5 hours the peptide IVGLGVQSLKRRRCF 
had been cleaved to IVGL and GVQSLKRRRCF with only -30%  of the original peptide 
remaining, whereas neither IV ALGVQ SLKRRRCF nor VVGLGVQ SLKRRRCF 
presented any signs of being digested.
Other experiments tried to assess the ability of the peptides in inhibiting the 
protease. Activity assays were performed as per Method 2.9.1, using the different 
peptides (0.75 mM) as activators, and samples were taken and analysed using capillary 
electrophoresis (Method 2.7.1.1). Also, two possibilities were tested: to check whether
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the previous activation of the protease with each peptide would inhibit it as compared to 
a simultaneous incubation of the protease with the peptides and the substrate 
(LSGAGFSW).
However, the results can be interpreted in various ways. When the protease is 
initially incubated with each of the peptides for 45 min prior to the addition of the 
substrate LSGAGFSW, the protease indeed is activated to a different extent with the 
different peptides, as the following figure shows;
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Figure 3.38 - Activation of the protease with; IVGLGVQSLKRRRCF (♦), IVALGVQSLKRRRCF (■),
and W GLGVQSLKRRRCF (A). The solid lines show the corresponding percentage of digestion of 
LSGAGFSW when the protease is activated with each of the above peptides, whereas the dashed line 
shows the concomitant digestion of the peptide IVGLGVQSLKRRRCF (x) to IVGL and 
GVQSLKRRRCF. Time zero corresponds to the addition of substrate (LSGAGFSW). after 45 min 
incubation of the protease with the above peptides.
Although the peptides IVALGVQSLKRRRCF and WGLGVQSLKRRRCF do 
seem not to activate the protease as efficiently as IVGLGVQSLKRRRCF, this can be 
interpreted in much the same way as for the inefficiency of the peptide 
Ac-GVQSLKRRRCF in activating the protease. Whereas the peptide 
IVGLGVQSLKRRRCF is itself cleaved, thus producing the peptide GVQSLKRRRCF 
which activates effectively the protease, the other two peptides are not able to activate 
the protease as efficiently due to not having the free amino group to the left of the 
glycine, thus presenting a lower rate of cleavage. This phenomenon could also be 
explained in terms of protease inhibition, and the following results also allow for this 
possibility:
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Figure 3.39 - Activation of the protease with: IVGLGVQSLKRRRCF (♦). IVALGVQSLKRRRCF (■).
and WGLGVQSLKRRRCF (A ), The solid lines show the corresponding percentage of digestion of 
LSGAGFSW when the protease is activated with each of the above peptides, whereas the dashed line 
shows the concomitant digestion of the peptide IVGLGVQSLKRRRCF (x) to IVGL and 
GVQSLKRRRCF. Time zero corresponds to the addition of protease.
In the above experiment, the protease was the last to be added, and if the peptides 
IVALGVQSLKRRRCF or WGLGVQSLKRRRCF were inhibiting in the previous 
experiment, even if at the beginning of this experiment all of them seem to activate to the 
same extent, then follows a decrease in the rate of digestion which could also be 
explained in terms of inhibition of the active site of the protease. However, the presence 
of the extra residues to the left of the GV motif could be removing the properties of a 
free amino group.
Therefore, the above experiments were inconclusive. The next step would be to try 
different concentrations of the above peptides, to verify whether the inhibition would 
increase, a consequence of a greater competition for the active site, or whether it would 
decrease, in which only the activating properties of the peptides could be accountable 
for.
Unfortunately, these experiments were not repeated due to the reduced amount of 
peptides available, thus not allowing a statistical treatment of the data to provide some 
quantitative answers regarding the possible rate of activation of the protease by the 
above peptides.
3.5. Importance of C-terminal region of Activating Peptide
The aforementioned experiments tried to elucidate the relevance of the N-terminal 
region of the activating peptide in the activation mechanism of the protease, both in 
terms of size o f the peptide chain and the specificity of the first two residues in the
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efficiency of activation. However, the C-terminal region is known to be involved in the 
activation (Webster et al., 1993), with the participation of cysteine-10. The nature of the 
interaction o f this cysteine with the protease, as well as the importance of its position 
within the activating peptide, were the basis of the following experiments.
3.5.1. Cys Shift in Activating Peptide
Some of the questions that remained to be answered regarded the importance of the 
position of the cysteine in the activating peptide and its environment, namely the striking 
feature of three consecutive arginines adjacent to the cysteine (cf. Figure 1.9), as well as 
the distance between the N-terminal of the peptide and the cysteine. The positively 
charged environment created by the arginines was thought to have a role in the ionisation 
of the cysteine, thus influencing its oxidation kinetics (cf. 3.2.3). Therefore, by shifting 
the cysteine along the arginines, a change in the susceptibility of the resulting peptide to 
ionisation and further oxidation would be expected. However, a change in position 
altering the activation ability could also signify that the distance between the N-terminal 
and the cysteine was of importance, again suggesting that the peptide acts as a whole, as 
discussed in 3.3.3.
3.5.2. Determination of Initial Rates of Peptides with Cys Shift
Two peptides were synthesised, GVQSLKRRCRF and GVQSLKRCRRF, as 
described in Method 2.4.1, using the semi-automated synthesis, Method 2.4.1.2. Both 
peptides were purified by HPLC (Method 2.4.2.1) and as a reference typical percentages 
of acetonitrile for elution of the peptides (4.6 mm x 25 cm CIS column), as well as 
migration times on capillary electrophoresis (CE) are shown in Table 3.18. The peptide 
molecular weights were confirmed by mass spectrometry (Method 2.6) and their 
sequence was confirmed by Method 2,5.
Table 3.18 - Topical values of purification parameters for the peptides GVQSLKRRCRF and 
GVQSLKRCRRF. Migration times for CE are given for a 24 cm x 25 ^m capillary.
Peptide Percentage of acetonitrile Migration time
for peptide elution on CE (min)
GVQSLKRRCRF 45-50 3.7
GVQSLKRCRRF 45-50 4.5
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The kinetic assays again consisted in following the digestion curve of LSGAGFSW 
with time (as described in Method 2.12.1 and discussed in 3.8.3) when the protease was 
activated with each of the Cys-shifted peptides, and comparing it to the activation with 
the original activating peptide.
As stated before, the determination of the initial rates of digestion demanded the use 
of a curve fitting strategy (Method 2.12) due to the limitation of the method used to 
determine the time points of digestion (capillary electrophoresis, Method 2.7.1.1), which 
did not allow to quantify accurately reduced amounts of digestion (cf. 3.8,3). Again, 
several initial rate determinations were made for each peptide activation in order to 
obtain statistically significant values for the final values.
i.5 .22 . The Peptide GVQSLKRRCRF
Kinetic assays were done with this peptide essentially as described in Method 2.9.1. 
In a typical assay, three substrate digestions were followed with time, where the protease 
(0.06 mg/ml) was activated in duplicate by the peptide GVQSLKRRCRF, and activated 
by GVQSLKRRRCF in a control assay, Time points were plotted against its 
correspondent percentage of substrate digestion and a curve was fitted using Method 
2.12. The results are presented in the following table (duplicate assays are displayed 
where two identical rates of digestion are found for the control peptide);
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Table 3.19- Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for actu ation of the protease with the peptide GVQSLKRRCRF (IRac) together with the 
initial rates of the control peptide GVQSLKRRRCF (IRn). The first column indicates the concentration 
of peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative initial
rate.
Conc.
(mM)
IRii
(%/min)
IRac
(%/min)
rac IRsc/lRii
0.15 0.06786 0.98798 0.00268 0.99254 0.039
0.15 0.03833 0.99461 0.00315 0.96311 0.082
0.15 0.06507 0.99079 0.00580 0.98137 0.089
0.15 0.06507 0.99079 0.00702 0.97609 0.108
0.15 0.06584 0.98610 0.00724 0.96816 0.110
0.15 0.07528 0.99108 0.00851 0.99771 0.113
0.15 0.03833 0.99461 0.00506 0.99494 0.132
0.15 0.08153 0.98274 0.01105 0.95756 0.136
0.15 0.02614 0.97699 0.00358 0.89796 0.137
0.15 0.06279 0.99034 0.00914 0.96057 0.146
0.15 0.01905 0.99260 0.00281 0.95543 0.147
0.15 0.05471 0.99724 0.00803 0.99303 0.147
0.15 0.05471 0.99724 0.00823 0.95445 0.150
0.15 0.02816 0.84051 0.00437 0.95238 0.155
0.15 0.06279 0.99034 0.01068 0.99446 0.170
0.15 0.02299 0.98671 0.00419 0.96405 0.182
0.15 0.05991 0.99241 0.01089 0.98726 0.182
0.15 0.05991 0.99241 0.01132 0.98575 0.189
0.15 0.05825 0.99410 0.01137 0.95305 0.195
0.15 0.08390 0.98732 0.01648 0.96922 0.196
0.15 0.08390 0.98732 0.01753 0.99549 0.209
0.15 0.01972 0.88564 0.00426 0.82346 0.216
0.15 0,01151 0.98919 0.00275 0.99206 0.239
0.15 0.09990 0.96726 0.02617 0.97369 0.262
As with previous activation assays, protease activity was found to be quite 
changeable, and a good fitting of the experimental data to the theoretical curve is still 
observed, expressed in correlation coefficient values almost always greater than 0.95. 
The calculated values obtained for the relative initial rate of digestion are however within 
a restricted range, enabling a statistical treatment of the data. Once more, the use of an 
histogram depicting the distribution of the relative initial rate enables the illustration of
the average value to be calculated:
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Figure 3.40 - Histogram depicting the distribution of the relative initial rate IRsc/IRn •
In this histogram, the highest frequency of values is within the interval 0.13-0.15, 
indicating a first approximation to the value of the average to be calculated. Assuming a 
normal distribution, this allowed a final determination of an average value of 0.16 ± 0.06 
for the relative initial rate of protease cleavage when activated with the peptide 
GVQSLKRRCRF as compared to the peptide GVQSLKRRRCF. This result does seem 
to indicate two possibilities: either the vicinity of an aromatic residue such as 
phenylalanine is important for the activation step of the protease by the activating 
peptide, or the distance between the cysteine and the N-terminal of the peptide is o f the 
decisive importance in the activation mechanism, or possibly both these phenomena are 
acting together in preventing an effective protease activation.
3.S.2.2. The Peptide GVQSLKRCRRF
As already mentioned before, also for this peptide kinetic assays were done 
essentially as described in Method 2.9.1. In a typical assay, three substrate digestions 
were followed with time, where the protease (0.06 mg/ml) was activated in duplicate by 
the peptide GVQSLKRCRRF, and activated by GVQSLKRRRCF in a control assay. 
Time points were plotted against its correspondent percentage of substrate digestion and 
a curve was fitted using Method 2.12. The results are presented in the following table 
(duplicate assays are displayed where two identical rates of digestion are found for the 
control peptide):
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Table 3,20 - Experimentally determ ined\alues for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide GVQSLKRCRRF (IR c^) together with the 
initial rates of the control peptide GVQSLKRRRCF (IRn). The first column indicates the concentration 
of peptide used in the assay, the following four columns the initial rates obtained with the respective 
peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together with the 
correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative initial
rate.
Conc.
(mM)
DRii
(%/min)
r 'li IRic
(%/min)
rVc IR4c/IRii
0.15 0.09990 0.96726 0.00146 0.98080 0.015
0.15 0.06584 0.98610 0.00185 0.26219 0.028
0.15 0.08153 0.98274 0.00323 0.99201 0.040
0.15 0.01905 0.99260 0.00083 0.90910 0.043
0.15 0.01151 0.98919 0.00051 0.60000 0.045
0.15 0.07528 0.99108 0.00373 0.95661 0.050
0.15 0.01972 0.88564 0.00105 0.83826 0.053
0.15 0.06786 0.98798 0.00380 1.00000 0.056
0.15 0.02299 0.98671 0.00150 0.98129 0.065
0.15 0.05825 0.99410 0.00435 0.98409 0.075
0.15 0.02614 0.97699 0.00217 0.82876 0.083
0.15 0.02816 0.84051 0.00253 0.91030 0.090
0.074 0.01041 0.97634 0.00226 0.71161 0.217*
0.074 0.01041 0.97634 0.00245 0.93312 0.235*
0.074 0.01041 0.97634 0.00288 0.94243 0.277*
0.074 0.00956 0.94157 0.00307 0.95170 0.321*
0.074 0.01639 0.97262 0.00651 0.91120 0.397*
0.074 0.00956 0.94157 0.00401 0.96224 0.420*
0.074 0.01639 0.97262 0.00793 0.96235 0.484*
0.074 0.00991 0.85992 0.00522 0.98128 0.527*
0.074 0.00991 0.85992 0.00522 0.98797 0.527*
0.074 0.01639 0.97262 0.00870 0.96816 0.531*
*“ Discarded values in the average calculation.
The same observations previously made regarding protease activity variability and 
good fitting of the experimental data to the theoretical curve, expressed in correlation 
coefficient values always greater than 0.95, also apply to these results. The relative initial 
rate of digestion values obtained after the calculations are exhibiting once more a very 
moderate variation, regardless of the concentration o f peptide used for activation, 
allowing for a statistical treatment of the data. Several points found to lie reasonably 
distant from the putative average were discarded, for reasons similar to those stated for 
the peptide QSLKRRRCF. As previously, an histogram depicting the distribution of the 
relative initial rate illustrates the average value to be calculated:
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Figure 3.41 - Histogram depicting the distribution of the relative initial rate HLc/IRn. The void bars 
correspond to values discarded in the average calculation.
It can be seen that the highest frequency of values lies within the interval 0.04-0.07, 
with quite a balanced distribution. This histogram resembles the ones in Figure 3 .32 and 
Figure 3.33 in that it presents a maximum towards the lowest values of the relative initial 
rate, with some scattered values at higher rates corresponding to determinations near the 
limits of detection, as discussed previously in 3.3.2.2 and 3.3.2.3. Therefore, assuming a 
normal distribution and discarding the higher values, this allowed a final determination of 
an average value of 0.054 ± 0.022 for the relative initial rate of protease cleavage when 
activated with the peptide GVQSLKRCRRF as compared to the peptide 
GVQSLKRRRCF. The conclusions drawn previously for the activation with the peptide 
GVQSLKRCRRF can also be applied to this situation. Furthermore, in this case the 
situation is more extreme, as almost no activation occurs, reinforcing the importance of 
both the distance between the cysteine and the N-terminal of the peptide, as well as the 
relevance of the environment surrounding the cysteine.
3.5.3. The Peptide GVQSLARRRCF
In another attempt to try and explain the high conservation of positively charged 
residues to the left of cysteine-10 in the activating peptide (cf. Figure 1.9), also this 
peptide was synthesised to try and elucidate any possible role of lysine-6. I
The peptide GVQSLARRRCF was synthesised as described in Method 2.4.1, using 1
semi-automated synthesis. Method 2.4.1.2. It was then purified by HPLC (Method |
2.4.2.1) and as a reference typical percentages of acetonitrile for elution of the peptide j
(4.6 mm x 25 cm C l8 column), as well as its migration time on capillary electrophoresis j
(CE) are shown in Table 3.21.
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Table 3.21- T>pical \  alues of purification parameters for the peptide GVQSLARRRCF. Migration times
for CE are given for a 24 cm x 25 gm capillary.
Peptide Percentage of acetonitrile Migration time
for peptide elution on CE (min)
GVQSLARRRCF 45-50 4.0
As described before, kinetic assays consisted on following the digestion curve of 
LSGAGFSW with time (as described in Method 2.12.1 and discussed in 3.8.3) when the 
protease was activated with the above peptide, and comparing it to the activation with 
the original activating peptide.
Also as already mentioned before, for this peptide too kinetic assays were done 
essentially as described in Method 2.9.1. In a typical assay, three substrate digestions 
were followed with time, where the protease (0.06 mg/ml) was activated in duplicate by 
the peptide GVQSLARRRCF, and activated by GVQSLKRRRCF in a control assay. 
Time points were plotted against its correspondent percentage of substrate digestion and 
a curve was fitted using Method 2.12. The results are presented in the following table 
(duplicate assays are displayed where two identical rates of digestion are found for the 
control peptide):
Table 3.22 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for activation of the protease with the peptide GVQSLARRRCF (IRgA) together with the 
initial rates of activation with the control peptide GVQSLKRRRCF (IRn). The first colunm indicates 
the concentration of peptides used in the assay, the following four columns the initial rates obtained with 
the respective peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together 
with the correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative
initial rate.
Conc.
(mM)
IR u
(%/min)
r 'u IRôa
(%/min)
r^ 6A IKfiA/IRii
0.15 0.00864 0.98511 0.00214 0.96981 0.248*
0.015 0.00823 0.94074 0.00298 0.87185 0.362
0.15 0.02545 0.99555 0.01161 0.99330 0.456
0.15 0.00864 0.98511 0.00412 0.99027 0.477
0.15 0.02086 0.99531 0.01126 0.97575 0.540
0.015 0.00117 0.58264 0.00068 0.26115 0.579
0.015 0.00419 0.98830 0.00255 0.95146 0.608
0.15 0.01343 0.99022 0.00817 0.98724 0.608
0.15 0.00555 0.99635 0.00373 0.99314 0.673
'-  Discarded value in the average calculation.
In this set of data, the correlation coefficient is almost always greater than 0.95, an 
indication of how well the theoretical curve describes the experimental points. In order to
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get a value for an average relative initial rate of digestion values were plotted on an 
histogram, Only one point was found to lie reasonably distant from the others (a  = 0.3, 
(Dixon and Massey, 1957)), which led to its discarding:
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Figure 3.42 - Histogram depicting the distribution of the relative initial rate IR6a/IRii . The void bar 
corresponds to tlie value discarded in the average calculation.
From the above histogram, it is reasonably clear where the average is going to lie, 
although the predictable centre of the distribution does not present the highest frequency 
of values. Therefore, assuming a normal distribution and discarding the lowest value, 
whiclris clearly outside the distribution and can be attributed to experimental error, this 
allowed a final determination of an average value of 0.54 ± 0.10 for the relative initial 
rate of protease cleavage when activated with the peptide GVQSLARRRCF as 
compared to the peptide GVQSLKRRRCF. This reduction of nearly 50% seems to 
indicate that also the lysine residue seems to be important for the ability of the activating 
peptide in binding to the protease, possibly due to the removal of a positive charge from 
the molecule which will affect the pKa of the N-terminal amino group (cf. 3.2.3.8).
3.5.4. The Effect of the C-terminal Aromatic Residue
Another striking feature of the activating peptide is that an aromatic residue such as 
phenylalanine or tyrosine is always found at the C-terminus (cf. Figure 1.9). This 
prompted an investigation into the role of this residue in the activating peptide. By 
substituting the phenylalanine with an alanine, preliminary results (Kemp, unpublished 
results) exhibited very little or no activation by the resulting peptide GVQSLKRRRCA, 
when incubated with the protease. Tins suggested a role for the aromatic residue in the 
binding of the peptide to the protease, as this residue is close to the cysteine which seems 
to be responsible for the covalent binding.
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More detailed studies were conducted (Hawkins, 1997), in which the ability of the 
peptide GVQSLKRRRCA in activating the protease was compared to that of 
GVQSLKRRRCF both in reduced (monomeric) and oxidised (dimeric) forms. Kinetic 
assays were done essentially as described in Method 2.9.1, and data were treated using 
Method 2.12.1. Results showed that the protease (0.005 mg/ml) activated with the 
reduced form of GVQSLKRRRCA (1 mM) presented a relative initial rate of 0.25 ± 0.03 
as compared to that activated with reduced GVQSLKRRRCF, whereas the oxidised 
form (1 mM) presented a value of 0.34 ± 0.08, not significantly different from the above 
value (p = 0.05). However, these results do stress the importance of the aromatic residue 
in the activation mechanism. An initial hypothesis that this residue might affect the 
acidity of the cysteine, rendering it less prone to reaction with the protease cysteine, was 
eventually discarded as its pÆn was determined (cf. 3.2.3.5) and shown not to be 
significantly different to that of GVQSLKRRRCF.
Further studies (Hawkins, 1997; Reid, 1997) also showed that even with increasing 
concentrations these ratios do not seem to vary significantly, although at very high 
concentrations of each peptide there appeared to be a decrease in the activation abilities 
of the peptides, more in the case of GVQSLKRRRCF than with GVQSLKRRRCA 
(Reid, 1997), a phenomenon that could not be explained, and contradicts previous results 
(Jones a/., 1996).
3.6. Inhibition Studies
Of the peptides whose activation ability was studied, the most striking results were 
those of the N-terminal truncated peptides, in which the removal of GV from the peptide 
seemed to remove most of the ability of the peptide in activating the adenovirus protease. 
Also several modifications in that region, such as the acétylation of the N-terminal amino 
group or the alteration from a valine to either an alanine or a threonine, and their 
consequent reduction in the ability of the resulting peptides in activating the protease 
stressed the importance of this region in the activation process. Two possibilities were 
put forward: (a) the N-terminal region (GV) is necessary for the binding of the peptide to 
the protease and subsequent activation, or (b) although not necessary for binding, the 
N-terminal region is responsible for a conformational change which leads to an active 
form of the protease. Certainly, the interaction of the activating peptide with the protease
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was shown to cause a conformational change, measured in a change of tryptophan 
fluorescence (Jones et aL, 1996).
In order to check for the first possibility, mass spectrometry of the protease in the 
presence of several activating peptides was performed, where an increase of the 
molecular weight of the protease would indicate the existence of a protease-peptide 
complex. Another way of verifying this hypothesis was to perform studies of inhibition of 
activation, whereby adding a peptide to the protease that is unable to activate it would 
conceivably bind to it and prevent the native peptide from binding and further activate 
the protease.
3.6.1. Mass Spectrometry of Protease*Peptide Complexes
In order to assert whether the peptides bound to the protease, several approaches 
have been tried. By radiolabelling the peptide, incubating it with the protease and then 
performing non-reducing SDS-PAGE, the band corresponding to the protease presented 
some radioactivity (Kemp, unpublished results). In a similar fashion, by incubating the 
activating peptide with the protease followed by low acrylamide percentage non­
reducing SDS-PAGE, the band corresponding to the putative protease*peptide complex 
ran at a higher molecular weight than the corresponding band to protease alone (Iqbal, 
unpublished results). All these results seemed to suggest that indeed the activating 
peptide bound to the protease.
Using mass spectrometry provided a method of confirming whether the peptide 
bound to the protease or not, and if it did, whether this binding was covalent or not.
The peptides GVQSLKRRRSF, GVQSL, GVQSLKRRRCF, VQSLKRRRCF, 
QSLKRRRCF and SLKRRRCF were incubated at a protease to peptide ratio of 1:100 
and subjected to mass analysis by time-of-flight mass spectrometry using the matrix- 
assisted laser desorption technique (Method 2.6), and the results are shown in Figure 
3.43.
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Figure 3.43 - Mass spectra of protease peptide complexes: protease alone (a), and after the addition of 
GVQSLKRRRSF (b). GVQSL (c), GVQSLKRRRCF (d), VQSLKRRRCF (e), QSLKRRRCF (f), and 
SLKRRRCF (g). Taken from (Cabrita et at., 1997).
These results show that whereas the protease does not seem to bind to either 
GVQSL or GVQSLKRRRSF, it does seem to form a 1:1 complex with 
GVQSLKRRRCF, VQSLKRRRCF, QSLKRRRCF and SLKRRRCF, which is 
responsible for the increase of the molecular weight of the protease. The observation that 
the protease-peptide complexes were only observed when the peptide added contained a 
cysteine residue provides evidence that these complexes are due to the formation of 
disulphide-bonded heterodimers. This is further corroborated by the observation (Cabrita 
et a i,  1997) that no complex is observed when the peptide GVQSLKRRRCF is 
incubated with a protease mutant where cysteine-104 was replaced by alanine.
Furthermore, it was interesting to observe that in the spectra depicting the complex 
formed with the peptides QSLKRRRCF and SLKRRRCF there seems to be evidence of 
some uncomplexed protease, even when the peptide is present in a 100-fold molar excess 
(cf. Figure 3.43), which suggests that these peptides bind less efficiently.
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3.6.2. Inhibition by N-terminal Truncated Peptides
Having established that the shorter peptides do bind to the protease (of. 3.6.1), albeit 
to a lesser extent, and do not seem to activate it efficiently (cf. 3.3.2.2 and 3.3.2.3), a 
question was raised as to whether those peptides would remain bound to the protease, 
thus preventing the native activating peptide from binding to it, thereby having an effect 
as inhibitors of activation.
To test the above hypothesis, inhibition assays were performed as described in 
Method 2.9.3. Briefly, these consisted of incubating the protease with the putative 
inhibiting peptide for 15 min, followed by incubation with the native activating peptide 
GVQSLKRRRCF for another 15 min. The protease was then tested for digestion by 
adding the substrate LSGAGFSW.
Also for the inhibition assays initial rates of digestion were determined. These too 
were done as described previously (Method 2.12). Several initial rate determinations 
were made for each peptide inhibition in order to obtain statistically significant values for 
the final values.
~3.6.11. The Peptide QSLKRRRCF
Assays of inhibition kinetics were done essentially as described in Method 2.9.3. In a 
typical assay, three substrate digestions were followed with time, where the protease 
(0.06 mg/ml) was inhibited in duplicate by the peptide QSLKRRRCF, and followed by 
activation with GVQSLKRRRCF. The control assay consisted of adding 
GVQSLKRRRCF to the protease and adding water when the activating peptide is being 
added to the test assays. Time points were plotted against its correspondent percentage 
of substrate digestion and a curve was fitted using Method 2.12. The results are 
presented in the following table (duplicate assays are displayed where two identical rates 
of digestion are found for the control peptide):
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Table 3.23 - Experimentally detennined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for inhibition of the protease with the peptide QSLKRRRCF (IR9) together with the initial 
rates of activation with the control peptide GVQSLKRRRCF (IRu). The first column indicates the 
concentration of peptides used in the assay, the following four columns the initial rates obtained with tlie 
respective peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together with 
the correlation coefficient obtained using Method 2.12.1. and the last column indicates the relative
initial rate.
Conc.
(mM)
IRu
(%/min)
r n IR9
(%/min)
iRp/JLRii
0 125 0.07389 0.98995 0.04510 0.99226 0.610
0.125 0.08005 0 96698 0.05168 0.98613 0.646
0.125 0.06464 0.97119 0.04712 0.97846 0.729
0.125 0.06464 0.97119 0.04939 0.97237 0.764
0.125 0.07389 0.98995 0.06057 0.99239 0.820
0125 0.08005 0.96698 0.07052 0.97853 0.881
0.125 0.04650 0.99958 0.04291 0.98522 0L923
Firstly it should be noticed that, as the values for the initial rates did not vary to a 
great extent, not so many values were needed to be determined. Also, the correlation 
coefficient is always greater than 0.95, indicating a close agreement between the 
experimental points and the theoretical curve. Also, the final relative initial rates of 
digestion only vary within a reasonably restricted interval, allowing for a straightforward 
statistical treatment of the data. As in the previous determinations, an histogram 
depicting the distribution of the relative initial rate allows a better illustration of the 
average value to be calculated:
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Figure 3.44 - Histogram depicting the distribution of the relative initial rate IRg/IRu with QSLKRRRCF
used as an inhibitor.
Yet, fi-om the above histogram it is not evident which is the final average, and 
therefore all the values were used in the calculation of the average. This led to a final 
determination of an average value of 0.77 ± 0.12 for the relative initial rate of protease 
cleavage when inhibited with the peptide QSLKRRRCF and followed by activation with
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GVQSLKRRRCF, as compared to the protease activated initially with the latter peptide. 
These results seem to indicate that the peptide QSLKRRRCF does bind to the protease, 
as there is a lower activity of the protease when incubated with it, in agreement with the 
mass spectrometry results (cf. 3.6.1). However, the fact that there is a recovery in 
activity with the addition of the peptide GVQSLKRRRCF indicates that the latter 
peptide is somehow able to displace the inhibiting peptide and bind itself to the protease, 
thus rendering it active. This greater affinity of the native activating peptide for the 
protease reiterates the conclusion previously drawn that the presence of the residues 
glycine and valine in the N-terminal of GVQSLKRRRCF are determinant in the 
activation process of the protease, probably by helping the peptide in binding to it more 
efficiently.
3.6.2.2. The Peptide SLKRRRCF
The assays of inhibition kinetics for this peptide were also done essentially as 
described in Method 2.9.3. In a typical assay, three substrate digestions were followed 
with time, where the protease (0.06 mg/ml) was inhibited in duplicate by the peptide 
SLKRRRCF, and followed by activation with GVQSLKRRRCF. As previously, the 
control assay consisted of adding GVQSLKRRRCF to the protease and adding water 
when the activating peptide is being added to the test assays. Time points were plotted 
against its correspondent percentage of substrate digestion and a curve was fitted using 
Method 2.12. The results are presented in the following table (duplicate assays are 
displayed where two identical rates of digestion are found for the control peptide):
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Table 3.24 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for inhibition of the protease with the peptide SLKRRRCF (ERs) together with the initial 
rates of activation with the control peptide GVQSLKRRRCF (IRu). The first column indicates the 
concentration of peptides used in the assay, the following four columns the initial rates obtained with the 
respective peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together with 
the correlation coefficient obtained using Method 2.12.1. and the last column indicates the relative
initial rate.
Conc.
(mM)
IRu
(%/min)
r i i JRs
(%/min)
r's IRs/lRu
0.125 0.06663 0.98885 0.05045 0.99258 0.757
0.125 0.07016 0.96730 0.05959 0.95881 0.849
0.125 0.06457 0.98259 0.05918 0.95765 0.917
0.125 0.07016 0.96730 0.06497 0.96505 0.926
- - - - 1.079*
0.125 0.06457 0.98259 0.07010 0.98819 1.086
0.125 0.04163 0.98458 0.04544 0.97130 1.092
0.125 0.06663 0.98885 0.07578 0.98542 1.137
- - - - - 1.138*
0.125 0.04163 0.98458 0.05150 0.96682 1.237
- - - - - 1.251*
Values determined by Dr. H. Reddy.
Again for this peptide it can be seen that, as the values for the initial rates did not 
vary broadly, fewer values were determined than in previous assays. Again the 
correlation coefficient is always greater than 0.95, indicating a close agreement between 
the experimental points and the theoretical curve. However, in this case the final relative 
initial rates of digestion are somewhat scattered, which is possibly a result of low 
digestion rates and its consequent greater error in their determination. The following 
histogram depicting the distribution of the relative initial rate illustrates the average value 
to be calculated:
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Figure 3.45 - Histogram depicting the distribution of the relative initial rate IRg/IRu with SLKRRRCF
used as an inhibitor.
As with the previous determination, in the above histogram it is not evident which is 
the final average, and all the values were used in the calculation of the average. This 
resulted in a final average value of 1.04 ±0.16 for the relative initial rate of protease 
cleavage when inhibited with the peptide SLKRRRCF and followed by activation with 
GVQSLKRRRCF, as compared to the protease activated initially with the latter peptide. 
These results do not allow for the conclusion that also the peptide SLKRRRCF binds to 
the protease, as expected from the mass spectrometry results (cf. 3.6.1), as there is no 
reduction in the activity of the protease, although they do not contradict it either. 
Assuming that the peptide does bind, the fact that there is a recovery in activity as the 
peptide GVQSLKRRRCF is added could suggest that the latter peptide is somehow able 
to displace also this inhibiting peptide and bind itself to the protease, thus rendering it 
active. This greater affinity of the native activating peptide for the protease would also 
reinforce the conclusion previously drawn about the importance of the residues glycine 
and valine at the N-terminal of the peptide in the activation process of the protease.
3.6.2,3. Other Peptides
Some more peptides other than the above mentioned were studied in their ability to 
inhibit the protease. These determinations were done by Dr. H. Reddy exactly as 
described previously (cf. 3.6.2) with peptides previously synthesised (with the exception 
of GV, purchased fiom Sigma), and the results are summarised in the following table;
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Table 3.25 - Iiiliibition of the adenovirus protease by other peptides. Results are expressed as percent 
activity (initial rate) relative to that achieved with GVQSLKRRRCF alone and are expressed as the 
mean ± S.E. of at least 3 determinations (adapted from (Cabrita et al., 1997)).
Peptide Activity (%)
GVQSLKRRRCF 100
LKRRRCF 100 ± 6
KRRRCF 108 ± 6
GVQSL 109 + 6
GV 96 ± 4
The results from the above table together with the values obtained in 3.6.2,1 and 
3.6.2.2 show that only the peptide QSLKRRRCF is able to inhibit to some extent the 
protease, which corresponds to the longest peptide that did not activate the protease (cf.
3.3.2). Again, this stresses the importance of the N-terminal region of the activating 
peptide in the activation of the protease. Also, the fact that the neither the peptide GV 
nor GVQSL were able to activate the protease confirms that any peptide has to contain a 
cysteine with which to bind covalently to the protease in order to activate it efficiently. 
This result does suggest that the activating peptide interacts with the protease via two 
distinct regions: covalently through cysteine-10, and electrostatically in the N-terminal 
region of the peptide.
3.6.14. Binding Competition between GVQSLKRRRCF and QSLKRRRCF
Having established that the peptide QSLKRRRCF does bind to the protease (cf.
3.6.1), and is not easily displaced by the native peptide GVQSLKRRRCF (cf. 3.6.2.1), 
the consequent question was to know whether the final binding of each of the peptides 
was competitive and independent of the order in which each peptide was added, or 
whether the peptide GVQSLKRRRCF had a greater affinity in binding to the protease. 
In order to address this question, a modified inhibition assay was performed, in which the 
native peptide GVQSLKRRRCF was added prior to the addition of the peptide 
QSLKRRRCF, to check whether the final activation would be the result of a competition 
between both peptides, or whether the peptide GVQSLKRRRCF remained bound to the 
protease.
The assays of inhibition kinetics were again done essentially as described in Method
2.9.3. In a typical assay, three substrate digestions were followed with time, where the 
protease (0.06 mg/ml) was activated in duplicate by the peptide GVQSLKRRRCF, and 
followed by inhibition with QSLKRRRCF. The control assay consisted of adding
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GVQSLKRRRCF to the protease and adding water when the activating peptide is being 
added to the test assays. Time points were plotted against its correspondent percentage 
of substrate digestion and a curve was fitted using Method 2.12. The results are 
presented in the following table (duplicate assays are displayed where two identical rates 
of digestion are found for the control peptide):
Table 3.26 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for inhibition of the protease with the peptide QSLKRCRRF (IR@) after GVQSLKRRRCF 
was added together with the initial rates of activation with the control peptide GVQSLKRRRCF (IRn). 
The first column indicates the concentration of peptides used in the assay, the following four columns 
the initial rates obtained with the respective peptides in percentage of substrate digested per minute 
(initial conc. : 4.9 mM) together with the correlation coefficient obtained using Method 2 .12.1, and the
last column indicates the relative initial rate.
Conc.
(mM)
IRn
(%/min)
r n ERç
(%/min)
JJR9 /IR 11
0.125 0.05050 0.96876 0.03499 0.95923 0.693*
0.125 0.05923 0.98095 0.04108 0.99882 0.694*
0.125 0.04736 0.99817 0.04038 0.97741 0.853
0.125 0.05082 0.98796 0.05048 0.99123 0.993
0.125 0.05923 0.98095 0.05918 0.99041 0.999
0.125 0.05050 0 96876 0.05355 0.99276 1.060
0.125 0.04736 0.99817 0.05060 0.99017 1.068
0.125 0.05082 0.98796 0.05918 0.99385 1.164
0.125 0.04250 0.97105 0.05172 0.99410 1.217
0.125 0.05338 0.98962 0.06602 0 99626 1.237
0.125 0.04250 0.97105 0.05868 0.99618 1.381
0.125 0.03485 0 99994 0.04877 0.95037 1.399
0 125 0.05338 0.98962 0.07556 0.99455 1.415
0.125 0.03485 0 99994 0.06192 0.97909 1.777*
*- Discarded values in the average calculation.
This table shows a reasonable constancy of the values determined for both the initial 
rates, together with a correlation coefficient always greater than 0.95, indicating an 
excellent agreement between the experimental points and the theoretical curve. Also, as 
the final relative initial rates of digestion are constricted to a reasonably narrow interval, 
this allows for a straightforward statistical treatment of the data. As in the previous 
determinations, an histogram depicting the distribution of the relative initial rate enables 
an easier illustration of the average value to be calculated:
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Figure 3.46 - Histogram depicting the distribution of the relative initial rate IR9/ÏR11 witli QSLKRRRCF 
used as an inliibitor after the addition of GVQSLKRRRCF. The void bars correspond to the values
discarded in the average calculation.
From the above histogram the final average seems to lie within the interval 1,1-1.2, 
although this does not correspond to the highest frequency interval. Some of the extreme 
values in the histogram were considered to lie outside a normal distribution (a  = 0.3, 
(Dixon and Massey, 1957)), and were therefore discarded in the calculation of the 
average. This led to a final determination of an average value of 1.16 ±0.19 for the 
relative initial rate of protease cleavage when activated with the peptide 
GVQSLKRRRCF and followed by inhibition with QSLKRRRCF, as compared to the 
protease activated initially with the native peptide. These results seem to indicate that 
although the peptide QSLKRRRCF binds to the protease when it is added first, the fact 
that there is no significant change in activity when the peptide GVQSLKRRRCF is added 
first indicates that the latter peptide has a greater affinity to the protease, thus not being 
displaced by the other peptide. This greater affinity of the native activating peptide for 
the protease once more reinforces the conclusion previously drawn that the presence of 
the residues glycine and valine in the N-terminal of GVQSLKRRRCF are determinant in 
the binding process of the peptide to the protease.
3,6,3. Inhibition by Cys-Shifted Peptides
It was previously shown (cf. 3.5.1) that the Cys-shifted peptides are poor activators 
of the protease. However, these peptides (GVQSLKRRCRF and GVQSLKRCRRF) do 
conform to the previous requisites deemed necessary for an efficient activation of the 
protease, which are the presence of a GV in the N-terminal region and a cysteine in its 
sequence. As suggested above (cf. 3.5.2.1), it is also possible that the distance between 
the N-terminal and the cysteine is of importance in an efficient activation of the protease.
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Unfortunately, mass spectrometry of possible protease-peptide complexes with the 
above peptides, in order to ascertain whether there is binding of the above peptides to 
the protease or not, was not possible. This would have permitted to assert about the 
influence of the cysteine environment on its ability to bind the peptide to the protease.
However, inhibition studies were made to try and provide an alternate way of 
asserting whether these peptides bound to the protease or not. It was expected that, in 
the case of binding and greater affinity for the protease than the native peptide, some 
inhibition would be observed.
3.6.3.L The Peptide GVQSLKRRCRF
Inhibition assays were done essentially as described in Method 2.9.3. In a typical 
assay, three substrate digestions were followed with time, where the protease 
(0.06 mg/ml) was inhibited by the peptide GVQSLKRRCRF, followed by activation with 
GVQSLKRRRCF. The control assay consisted of adding GVQSLKRRRCF to the 
protease and adding water when the activating peptide is being added to the test assays. 
Time points were plotted against its correspondent percentage of substrate digestion and 
a curve was fitted using Method 2.12. The results are presented in the following table;
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Table 3.27 - Expenmentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for inliibition of the protease with the peptide GVQSLKRRCRF (IRsc) together with the 
initial rates of actuation with the control peptide GVC^SLKRRRCF (IRn). The first colunm indicates 
the concentration of peptides used in the assay, the following four columns the initial rates obtained with 
the respective peptides in percentage of substrate digested per minute (initial conc. : 4.9 mM) together 
with the correlation coefficient obtained using Method 2.12.1, and the last column indicates the relative
initial rate.
Conc.
(mM)
IRn
(%/min)
r u IRsc
(%/min)
r"3c IRac/lRii
0 125 0.01552 0.98049 0.00733 0.99771 0.472
0T25 0.01027 0.90597 0.00607 0.99507 0.591
0 125 0.02248 0.95910 0.01620 0.77583 0.721
0125 0.05680 0.98087 0.04191 0.95553 0.738
0125 0.01167 0.74010 0.00874 0.99179 0.749
0125 0.00778 0.98787 0.00667 0.99605 0.856
0125 0.01926 0.64588 0.01123 0.82118 0.876
0125 0.01301 0.98511 0.01161 0.97003 0.893
0.125 0.01389 0.96789 0.01337 0.94385 0.963
0125 0.01974 0.94394 0.02025 0.99741 1.026
0.125 0.00808 0.93323 0.01042 0.96659 1.290
0.125 0.00949 0.98728 0.01225 0.99076 1.291
0.125 0.00498 0.99215 0 00856 0.78818 1.718
0.125 0.00223 0.80693 0.00526 0.99344 2.358*
Discarded value in the average calculation.
The results in the above table show again a reasonable variability in the initial rates 
determined. Also, the correlation coefficient is not always greater than 0.90, indicating a 
poorer agreement than usual between the experimental points and the theoretical curve. 
Even the final relative initial rates of digestion do vary within a considerably broad 
interval. As in the previous determinations, an histogram depicting the distribution of the 
relative initial rate allows a better illustration of the average value to be calculated:
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Figure 3.47 - Histogram depicting the distribution of the relative initial rate IRac/IRn with 
GVQSLKRRCRF used as an inhibitor. The void bar corresponds to the value discarded in the average
calculation.
From the above histogram the final average seems to lie within the interval 0.8-1.0. 
The extreme value to the right of the histogram was considered to lie outside a normal 
distribution (a  = 0.01, (Dixon and Massey, 1957)), and was discarded in the calculation 
of the average. This resulted in a final average value of 0.94 ± 0.34 for the relative initial 
rate of protease cleavage when inhibited with the peptide GVQSLKRRCRF and 
followed by activation with GVQSLKRRRCF, as compared to the protease activated 
initially with the native peptide. This result means that the Cys-shifted peptide is unable 
to inhibit the protease. From previous results (cf. 3.5.2.1) the peptide does not seem to 
be able to activate it to a reasonable extent either, and this can be due to an inefficient 
binding to the protease or to an incorrect distance between the cysteine and the 
N-terminal GV. Therefore, these results, although corroborating the previous ones, did 
not allow for any further conclusions to be withdrawn.
3.6.3.2. The Peptide GVQSLKRCRRF
Inhibition assays for this peptide were also done essentially as described in Method
2.9.3. In a typical assay, three substrate digestions were followed with time, where the 
protease (0.06 mg/ml) was inhibited by the peptide GVQSLKRCRRF, followed by 
activation with GVQSLKRRRCF. The control assay consisted of adding 
GVQSLKRRRCF to the protease and adding water when the activating peptide is being 
added to the test assays. Time points were plotted against its correspondent percentage 
of substrate digestion and a curve was fitted using Method 2.12. The results are 
presented in the following table:
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Table 3,28 - Experimentally determined values for initial rates (IR) of digestion of the substrate 
LSGAGFSW for inhibition of the protease with the peptide GVQSLKRCRRF (IRic) together with the 
initial rates of activation with the control peptide GVQSLKRRRCF (IRn). The first column indicates 
the concentration of peptides used in the assay, the following four columns the initial rates obtained with 
the respective peptides in percentage of substrate digested per minute (initial conc.: 4.9 mM) together 
with the correlation coefficient obtained using Method 2.12.1. and the last coliunn indicates the relative
initial rate.
Conc.
(mM)
ERii
(%/min)
r i i IR4C
(%/min)
n c IR4c/IR ii
0.125 0.05680 0.98087 0.01364 0.97086 0.240
0.125 0,01552 0.98049 0.00604 0.99677 0.389
0.125 0.01167 0.74010 0.00693 0.91872 0.594
0.125 0.02248 0.95910 0.01556 0.89854 0.692
0.125 0.01301 0.98511 0.01026 0.99706 0.789
0.125 0.01027 0.90597 0.00819 0.99895 0.798
0.125 0.01389 0.96789 0.01134 0.97599 0.817
0.125 0.01282 0.83752 0.01570 0.80186 1.224
0.125 0.00808 0.93323 0.01037 0.91543 1.283
0.125 0.01974 0.94394 0.02543 0.89977 1.288
0.125 0.00949 0.98728 0.02187 0.98349 2.305
0.125 0.00498 0.99215 0.01596 0.98400 3.205*
0.125 0.00778 0.98787 0.04530 0.96017 5.819*
0.125 0.00223 0.80693 0.01566 0.92087 7.020*
Discarded values in the average calculation.
Again it can be noticed that the values for the initial rates did vary considerably, and 
the correlation coefficient was not always greater than 0.90, a reflection of a coarser 
agreement between the experimental points and the theoretical curve. Also the final 
relative initial rates of digestion vary within a reasonably ample interval, making it a 
troublesome task to decide how to treat the data. As in the previous determinations, an 
histogram depicting the distribution of the relative initial rate provided a better 
illustration of the average value to be calculated:
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Figure 3.48 - Histogram depicting the distribution of the relative initial rate IR^c/IRn with 
GVQSLKRCRRF used as an inhibitor. The void bars correspond to values discarded in the average
calculation.
From the above histogram it is clearer that the final average seems to lie within the 
interval 0.5-1.0, quite a broad interval due to the spanning of the data. The values to the 
right of the histogram were considered to lie outside a normal distribution (a  = 0.005, 
(Dixon and Massey, 1957)), and were therefore discarded in the calculation of the 
average, This allowed a final determination of an average value of 0.95 ±0.57 for the 
relative initial rate of protease cleavage when inhibited with the peptide 
GVQSLKRCRRF followed by activation with GVQSLKRRRCF, as compared to the 
protease activated initially with the native peptide. The conclusions to take from this 
result are similar to those for the previous peptide (cf. 3.6.3.1): there is no further 
evidence that the peptide does bind to the protease, or if it does bind, it is readily 
displaced by the native activating peptide.
3.7. The Adenovirus CELO Protease
The CELO (Chicken Embryo Lethal Orphan) is the prototype of avian adenoviruses, 
and it has been shown to be closely related to quail bronchitis virus (Andrewes et al., 
1978). It was first identified as an adventitious contaminant of embryonated eggs during 
attempts to propagate a bovine skin disease agent, and further identified as an infectious 
agent in 1957 (Yates, cited in (Chiocca et al., 1996)). CELO is classified as a fowl 
adenovirus type 1 (FAV-1).
The interest in obtaining this protease relied on it being reasonably dissimilar from 
the human adenovirus type 2 protease and on the sequence of its activating peptide being 
also known (GVATATRRMCY, cf. Figure 1.9), so that the specificity of the latter 
peptide to the protease could be studied, and comparisons could be made regarding the 
interchangeability between activating peptides and proteases. This would possibly allow
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a better insight into which parameters govern the specificity of the interaction between 
the activating peptide and the protease,
3.7.1. Cloning of the Protease Gene into a pE T -llc Vector
In order to clone the protease gene into a pET -llc vector (Novagen), Xba I and 
BamH I restriction sites had to be created (cf, 2.1.1), the former for the 5'-primer and 
the latter for the 3’-primer. Taking into consideration the DNA genome for the CELO 
adenovirus (Ifom GenBank, http://www3.ncbi.nlm.nih.gov/Entrez), the following 
primers were synthesised:
Primer 5’: GGCAACGCTGTCrAGAAAAAAGACGG {Xba I)
Primer 3’: CAGTGAGGArcCTTGTCGGTCTATCGG {BamHI)
The program Amplify (Engels, 1992) was used to test the above primers for 
primability and stability, and resulted in the following values:
Table 3.29 - Values for efficiency of PGR reaction (Engels, 1992) with the designed primers.
Primer Primability Stability
primer-5’ 96% 67%
primer-3 ’ 98% 71%
The program also indicated that with these primers only the protease gene should be 
amplified with PCR, and this was indeed the result of the PCR (Method 2.1.1.2) as 
verified on an agarose gel (Method 2.1.1.1) presenting only one band at the correct size.
The amplified fragment was then extracted from the gel (Method 2.1.1.3) and its 
extremities were then cut with the appropriate restriction enzymes Xba I and BamH I 
(Method 2.1.1.4), and the restricted fragment was then ligated into the pET-1 Ic vector 
(Method 2.1,1.5) also already cut using Method 2.1.1.4.
XL 1-Blue cells (Stratagene) were prepared and transformed with the ligated plasmid 
according to Method 2.1.1.6 and plated in agar plates with ampicillin and tetracycline 
(Method 2.1.1.7) in order to select for transformants which contained the plasmid. A 
mini-prep was done (Method 2.1.1.8) to extract the plasmid, and this was again 
restricted (Method 2.1.1.4) and run on an agarose gel (Method 2.1.1.1) in order to find 
which plasmids had the insert.
The appropriate plasmid was selected and retransformed in XL 1-Blue cells (Method 
2.1.1.6) and a maxi-prep was done (Method 2.1.1.9) in order to prepare a plasmid stock 
with which to transform the host system for expression of the cloned protein
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(BL21(DE3) cells, Novagen). The plasmid was then sequenced (Method 2.1.1.11) and 
the protease was confirmed to have been cloned into the plasmid.
3.7.2. Transformation of the Host System BL21(DE3) with the Vector and 
Expression of the Protease
BL21(DE3) cells (Novagen) were prepared and transformed with the plasmid stock 
according to Method 2.1.1.6 and plated in agar plates with ampicillin (Method 2.1.1.7) in 
order to select for transformants which contained the plasmid. A single cell colony was 
then picked and used to inoculate a 5 ml LB medium, which after growth was used to 
inoculate 2x250 ml of M9 medium, as described in Method 2.1.1.13 for the expression 
of the cloned protease.
3.7.3. Attempts to Obtain Protease Expression
In the meantime, the peptide GV ATATRRMCY, the activating peptide of the avian 
adenovirus CELO, was synthesised by using Method 2.4.1.2 and Method 2.4.1.3, and 
purified using Method 2.4.2.1. Its sequence was then verified using Method 2.5.1.
However, when activity assays were performed using Method 2.9.1 using protease 
directly from the protease extraction, no activity was found after 1 h digestion. A time- 
course of expression was done (Method 2.1.1.14) and this revealed the system not to be 
expressing the protease. Growing the cells in LB rather than M9 did not improve in any 
way the expected expression.
3.7.4. Recioning of the CELO Protease Including a Ribosome Binding Site
An analysis of the vector used (pE T-llc) revealed that when the 5’ restriction site 
for Xba I is used it removes a ribosome binding site which is supposed to enhance the 
translation of the target sequence (Olins and Rangwala, 1989). In order to test whether 
this was the reason why the protease was not being expressed, a primer was designed 
(provided by S. Annan) with which to reamplify the gene from the plasmid, and 
containing the ribosome binding site (rbs); on the other end, a primer designed for 
priming any sequence cloned into pE T -llc  (provided by L. Murray) from the V  end:
Primer 5’: TTCCCCrCTAGAAAAGGAGCGG {Xba / ,  rbs)
Primer 3’: TTATGCTAGTTATTGCTCAGCGGTG
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These primers were then used with the plasmid obtained above on a PCR (Method
2.11.2), and the band obtained at the right size on an agarose gel (Method 2.11.1) was 
extracted (Method 2.1.1.3).
The new fragment obtained was then cut with the appropriate restriction enzymes 
Xba 1 and BamH I (Method 2.1.1.4), and the restricted fragment was then ligated to the 
pET-1 Ic vector (Method 2.1.1.5) also already cut using Method 2.1.1.4, as before.
The new plasmid was then transformed in XL 1-Blue cells (Method 2 1.1.6) and the 
cells plated in agar plates with ampicillin and tetracycline (Method 2.1.1.7) again in order 
to select for transformants which contained the plasmid. A mini-prep was done (Method
2.1 1.8) to extract the plasmid, and this was again restricted (Method 2.1.1.4) and run on 
an agarose gel (Method 2 1 1.1) in order to find which plasmids had the insert.
As with the first plasmid, one that presented the insert was selected and 
retransformed in XL 1-Blue cells (Method 2.1.1 6) and a maxi-prep was done (Method 
2.1.1.9) in order to prepare a plasmid stock with which to transform the host system 
(BL21(DE3) cells, Novagen), and the plasmid was checked for the presence of the insert 
by cutting it with the appropriate restriction enzymes Xba I and BamH I (Method 
2.1.1.4) and running on an agarose gel (Figure 3 .49):
P
1
Figure 3 .49 - Restnction of plasmid pET-1 ic cloned with CELO adenovirus protease, with enzymes 
Xba I and BamH I. The plasmid (P) is shown to contain only one insert (I), w hich should correspond to
the protease gene. Lanes 1 and 2 are duplicates
3.7.5. Transformation of the Host System BL21(DE3) with the Corrected 
Vector and Expression of the Protease
BL21(DE3) cells were again prepared and transformed with the plasmid stock 
according to Method 2.1.16 and plated in agar plates with ampicillin (Method 2.1.1.7) in 
order to select for transformants which contained the plasmid. A single cell colony was
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Figure 3 .50 - Time course of induction of CELO protease in LB. Above is time after induction (h), on 
the left the molecular weight of the markers, and on the right the arrow marks the protein being
expressed.
This protein seems to have a molecular weight of 24-29K, whereas the protease 
should have a molecular weight of 23 .8K. This is not very different from the above, but 
every attempt to try and sequence the protein (Method 2.5.2) only revealed host 
proteins. The reasons for the lack of expression and/or activity were not found.
Possible explanations put forward include (a) the protease is not being expressed or 
is being expressed in a mutant inactive form; (b) the protease is being expressed in an 
insoluble form (a very common situation with over-produced proteins in E. coli 
(Grisshammer and Nagai, 1995)); (c) the protease is being expressed but the assay
1
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then picked and used to inoculate a 5 ml LB medium, which after growth was used to 
inoculate 2x250 ml of M9 medium, as described in Method 2.1.1.13 for the expression 
of the cloned protease.
3.7.6. New Attempts to Obtain Protease Expression
Again, activity assays were performed using Method 2.9 1 using protease directly 
from the protease extraction, and again no activity was found after 1 h digestion. An 
attempt was made at growing the cells in LB rather than M9. A time-course of 
expression was done (Method 2,1.1.14) and this revealed the system to be expressing a 
protein that did not present any proteolytic activity as assessed by digestion of the 
peptide substrate LSGAGFSW:
Time after induction (h)
Std 0 1 2  3
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conditions are not appropriate to enable efficient activation of the protease; or (d) the 
CELO protease is not able to cleave efficiently the substrate LSGAGFSW, possibly due 
to a different substrate specificity, Unfortunately, a thorough systematic approach to this 
problem was not possible,
3.8. Considerations on Some of the Methods Used
Several remarks should be made on some of the procedures used, namely about the 
reproducibility of the method of production and purification of the recombinant protease, 
the accuracy of the assessment of peptide concentration and the validity and limitations 
of the method developed for the determination of initial rates of digestion.
All these points are critically discussed and solutions for the problems encountered 
are proposed together with the assumptions made for their resolution,
3.8.1. Production of Protease
All the protease used in this work was of recombinant origin. It had been previously 
cloned in E. coli BL21(DE3) strains, using the pET-11 system (cf, 2,1.1) (Anderson, 
1990): Several clones were available, which produced protease in different amounts and 
variable degrees of activity (cf, (Pollard, 1997)), Most of the protease used was kindly 
provided by Dr, M, Iqbal (in a concentration of 0,06 mg/ml, with a specific activity of
9,1 nmol of GFSW/min/nmol protease), produced by the conical flasks option described 
in Method 2,1.1,13.
However, as the conical flasks method did not allow for a reproducible source of 
protease, since experimental conditions such as temperature, aeration and agitation could 
not be conveniently controlled, the utilisation of a fermenter was also tried in order to try 
and circumvent these difficulties, as well as providing with a source of greater amounts 
of recombinant protease. This is also described in Method 2,1.1,13, The extraction 
procedure also had to be altered, mainly to accommodate for the larger amount of cells 
to be processed (cf. Method 2,1.2,1),
Tkn attempt to improve the purification process in terms of speed and reproducibility 
after the extraction of the protease was also done, in order to try and provide with a 
more reliable source of protease. The main difference from the former method was to 
elute the protease from the DEtVE column directly to the heparin and CM columns, 
rather than collecting fractions after the first column, pooling them and loading the 
resulting solution onto the last two columns overnight.
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The resulting method consisted of loading the extraction supernatant (-35 ml) onto 
the DEAE column (40 x 1.6 cm) at a flow rate of 2 ml/min in purification buffer (25 mM 
Tris-HCl, pH 8.0), for 20 min. Then the heparin (5x1 cm) and CM (11x1 cm) columns 
were connected in this order to the DEAE column and elution continued at 1 ml/min for 
90 min with the same buffer, in order for the protease to attach to these columns. The 
DEAE column was then disconnected, and the protease eluted at 1 ml/min with 
purification buffer 10% 1 M NaCl, which usually was collected -30  min after the salt 
was applied.
Protease - 30
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Figure 3.51 - Scheme illustrating a typical recorder plot of a single step protease purification. Point A 
corresponds to the connection of the heparin and CM columns, and point B to the discoimection of the 
DEAE column and increase in salt concentration (cf. text for explanation). From point B onwards, the
absorbance scale has changed.
The resulting fractions were reasonably pure for assay purposes, with only one band 
showing on some lanes on SDS-PAGE. This procedure enabled a reduction of 
purification time from 2 days to one afternoon.
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Figure 3.52 - SDS-PAGE of protease fractions purified using tlie single step purification method. The
lane on the left are molecular weight markers, all other lanes are fractions for which a peak was
obsen ed at 280 nm.
After this method was established, a more thorough study was possible on the best 
source of protease to use for purity and activity purposes (Pollard, 1997).
3,8.2. Determination of Peptide Concentration
As a general feature, all the peptides used in this work were synthesised in small 
quantities, typically in amounts of less than 0.5 g. Therefore, the preparation of solutions 
and their subsequent concentration determination was not a straightforward process, due 
to the small amounts involved, which caused the weighing of the solid peptides to be 
quite a difficult task. A solution to this problem consisted of preparing a reference 
solution of known concentration of the peptide GVQSLKRRRCF, and preparing other 
solutions by dissolving a low amount of peptide, with subsequent comparison of 
concentration by one of two methods, reaction with fluorescamine (Method 2.7.2) or 
capillary electrophoresis (Method 2.7.1). The solutions were then diluted accordingly, 
until a uniform concentration was achieved with all the peptide solutions.
Fluorescence as a method for the determination of peptide concentration proved to 
be quite an accurate way of assessing the concentration of peptide solutions. The 
following formula was used to calculate the peptide concentration for a 20 pi sample 
prepared as described in Method 2.7.2.1 :
C = 0.0028 x F / ^  Eqn. 3.8.1
in which F  is the recorder reading (mm), S  is the selected sensitivity of the 
fluorimeter, and C is the concentration of the original sample (mM), prior to the dilution 
in the assay buffer. As previously described, fluorescamine reacts with free primary
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amines in order to produce fluorescent derivatives (cf. 2.7.2). However, the fluorescence 
of the resulting derivative may vary depending on the primary amine that reacted with 
fluorescamine (Bohlen et al., 1973; Stein et a i,  1973). Therefore, the equation above 
can only be used for the peptide GVQSLKRRRCF, from which it was derived, Yet, as 
the other peptides are reasonably similar to this, it was assumed that the final 
fluorescence would not be very dissimilar. For this reason, a second method was also 
used to provide with an additional peptide concentration method.
Capillary electrophoresis provided with a rough method of measuring the 
absorbance at 200 nm of a peptide solution. The resulting electropherogram presented a 
peak whose area could be related to the amount of peptide present. This relationship was 
based upon the assumption that the absorbance at 200 nm is roughly proportional to the 
number of peptide bonds in a peptide (Stoscheck, 1990), provided there is no tryptophan 
in the sequence, as this amino acid also absorbs at 200 nm due to the indole ring. The 
rough relationship found for a peptide solution diluted 1:10 and analysed using Method
2.7.1.1 was the following:
C =  1.6x10*^ X / I / «  Eqn. 3.8.2
in which ^  is the peak area as obtained fi-om the integrator application (cf. 2.7.1.2), 
integrated at a 10 Hz rate, n is the number of peptide bonds in the peptide, and C is the 
concentration (mM) of the original peptide solution, prior to the 1:10 dilution. It should 
be stressed once more that this is a very rough method, usually used as a confirmation of 
concentration, as it is based on a very simplistic model.
3.8.3. Digestion Assays and Determination of Initial Rates
There were three steps involved in the determination of the initial rates of digestion 
of the adenovirus protease: the experimental method used, the collection and analysis of 
time point data, and the data treatment in order to calculate the initial rates. Each of 
these steps comprised certain assumptions as well as some errors that need to be 
assessed regarding the final validity of the values obtained.
3.8.3.1. The Experimental Method
The main feature of these assays was the small volumes involved, due to the 
expensive nature of the products utilised. This led to a greater source of experimental
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error arising from the handling of small quantities, which was minimised by the repetition 
of the assays followed by a statistical treatment of the data obtained.
Another origin of variability was the protease preparations, whose activity was not 
constant, depending on the concentration of each preparation, rendering the 
measurement of absolute rates impractical. Furthermore, the protease is sensitive to 
temperature variations, and the thawing of aliquots yielded variable restoration of 
activity. Therefore, the use of controls and subsequent calculation of relative initial rates 
was the devised solution to circumvent this variability.
The low solubility of the substrate also posed two problems: (a) low measurable 
concentrations of the products of reaction, which made it more difficult to quantify the 
initial substrate digestion, which is discussed further below; and (b) the low substrate 
solubility imposed a working concentration very close to the Km of the protease for this 
substrate (1-10 mM, H. Murray, unpublished results), which should also have 
contributed to the variability of results mentioned above.
3.8,3.2, The Collection and Analysis o f Time Point Data
The collection of point data was made by diluting the sample from the reaction 
mixture in 1:10 diluted capillary electrophoresis buffer, which is an acidic buffer (pH 2.5) 
that inhibits the protease (cf. Method 2.9.1).
As mentioned above, the low substrate concentration in the assay made the 
detection of reaction products at early stages of digestion a troublesome task. To 
illustrate this problem. Figure 3.53 shows a typical electropherogram where digestion of 
substrate reaches about 30% of the initial quantity. In this case, it can be seen that all 
peaks are clearly defined, allowing a straightforward integration for the quantification of 
digestion. It should be noted that the product peaks exhibit different relative areas, which 
is due to the presence of tryptophan in the peptide GFSW, making its corresponding 
peak account for about 75% (average o f -2500 measurements) of the area of products, 
rather than an otherwise expected equitable proportion of both of the product peak 
areas.
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Figure 3.53 - Electropherogram of protease 10 min digestion of the substrate LSGAGFSW. The protease 
was activated with the peptide GVQSLKRRRCF (peak on the left). The relative areas of the peaks and 
respective migration times are; LSGA: 7.26%, 3.18 min: GFSW: 22.49%. 3.48 min: LSGAGFSW:
70,24%. 4.75 min.
If the peaks in Figure 3.53 are clearly defined, the situation is not so clear in Figure 
3.54. This is a typical electropherogram of a low substrate digestion, where the 
attribution of peaks becomes more subjective, due to the small product peaks mingling 
with the background. In this situation, reference peak migration times must be used in 
order to delineate the limits of the putative peaks. Thus, if the undigested substrate peak 
is eluting at a time of 4.75 min (as shown in Figure 3.53) and the corresponding product 
peaks are eluting at 3.18 and 3.48 min (for LSGA and GFSW, respectively, cf. Figure 
3.53), then in the electropherogram of Figure 3.54 and Figure 3.55 the peaks for the 
products are expected to elute at roughly the same corresponding times. This is indeed 
what happens, and although in the electropherogram in Figure 3 .54 the peak for GFSW 
is still reasonably clear, the peak for LSGA would be difficult to discern, and when 
magnified (Figure 3.55) the peak can be identified by searching for a maximum near 
3.18 min, which occurs at 3,25 min. Obviously, these peak attributions can lead to errors 
in the calculation of the relative areas, and the solution to this problem is proposed 
further below.
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Figure 3 .54 - Electropherogram of protease 30 min digestion of the substrate LSGAGFSW. The protease 
was activated with the peptide GVQSLKRRCRF (peaks on the left). Tlie relative areas of the peaks and 
respective migration times are: LSGA: 2.34%. 3.25 min; GFSW: 7.30%. 3.52 min; LSGAGFSW: 
90.35%, 4.87 min. The dashed rectangle is magnified in Figure 3.55.
Another remark has to be made regarding the presence of a peak (or several, as is 
the case in Figure 3.54) corresponding to the activating peptide used. This peak (which 
in Figure 3.54 corresponds to an activating peptide concentration of 0.15 mM in the 
assay) can also be used as a reference peak, as its position usually remains constant, 
although its shape may vary. Some analysis of these peaks was made, regarding the 
oxidation state of the peptide, and the results are discussed in 3.2.2.
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Figure 3.55 - Magnification of the peaks in the dashed rectangle of Figure 3.54. The chosen limits of 
integration are also represented with red lines.
One advantage of this method is that the determination of the amounts of products 
and undigested reagent can be directly measured from the same electropherogram, which
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leads to a smaller error in the determination of these quantities, as a sampling of the 
reaction mixture by this method will always yield all the above quantities in one 
spectrum.
However, one assumption was made that the total area corresponding to the sum of 
the areas of the peaks LSGA, GFSW and LSGAGFSW remained constant. Therefore, 
the percentage of the total area corresponding to the peak LSGAGFSW was taken to be 
equivalent to the percentage of undigested peptide, a value subsequently used in the 
calculations described in Method 2.12 in order to calculate the initial rates from the 
electropherogram data, which is discussed below. This was actually observed not to be 
the case. In fact, the sum of the areas o f all three peaks should decrease with increasing 
percentage of digested products, which can be explained in terms of the loss of a peptide 
bond that contributes to the absorbance at 200 nm. This decrease in the total area leads 
to a difference between the percentage of digestion calculated from the peak area of 
undigested LSGAGFSW and the “real” percentage of digestion.
In order to calculate what is the influence of this difference, the decrease in 
absorbance had to be calculated as a function of the percentage of digestion obtained 
from integration. For this purpose, the decrease in total area was plotted as a function of 
the percentage of the peak area of LSGAGFSW. However, due to experimental error, 
the amounts of substrate used varied between assays, and also the amount of sample 
taken varied within each assay, and therefore the total areas varied between as well as 
within each assay. Consequently, in order to normalise all the data, every total area 
within an assay for different times was plotted against the corresponding percentage of 
substrate (LSGAGFSW peak area). A least-squares regression was then performed to fit 
the decrease in total area with the decrease in percentage of substrate and this was used 
to calculate the extrapolated value of the total area at 100% substrate area (an example is 
shown in Figure 3.56). All the values within the assay were then divided by the above 
extrapolated value to yield a relative total area.
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Figure 3.56 - Illustration of the normalisation process of total area values witliin a digestion assay. A 
linear regression is calculated in order to obtain an extrapolated value for the total area corresponding to
100% substrate (in this example, 170596).
Once all the values of total area were normalised, with all the extrapolated values for 
100% substrate coinciding in the same point, every value from every assay was plotted 
together in order to calculate the overall trend. The result is shown below;
V = 0.0032x4-0.7261
+•
20 40 60
%  digestion
80 100
Figure 3.57 - Calculation of the overall trend of relative total area decrease in a digestion assay.
From the graph in Figure 3.57 it can be seen that there is indeed a decrease of total 
area where there is a greater extent of digestion (lower values for the percentage of 
substrate left), which agrees with the assumption made before. In order to correct the 
percentage values, a correction factor must be calculated with which to multiply the 
areas of the product peaks, so that the total area remains constant, thus allowing for the 
calculation of the “real” percentage of remaining substrate. The inverse of the value
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obtained in Figure 3.57 for 0% substrate (1/0.7261 = 1.377) can then be shown to be the 
correction factor needed for the calculation of the correct value for the percentage of 
substrate, whose correction is calculated by the following equation:
100 X%^Correc,ed%S =
Using Eqn, 3.8.3, the difference between the value for the percentage obtained by 
integration (area of LSGAGFSW peak) and the “real” percentage can be calculated, and 
this can be plotted as a function of the area peak percentage:
10
% digestion
Figure 3.58 - Plot of the difference between percentage of substrate obtained by peak area integration
and correction for constant total area.
From the above graph it can be seen that the greatest difference between the values 
for the percentage of undigested substrate obtained by direct measure of the proportion 
of the LSGAGFSW peak area to the total area and the “real” percentage is of -8% units, 
for 50% digestion of substrate. This means that all the values for the percentage of 
undigested substrate were overestimated to a variable extent, depending on the 
percentage of the substrate peak area in relation to the total area. The implications of this 
result are discussed below.
3.8.3.5. Data Treatmen t
The mathematical treatment done to the experimental data was already described in 
Methods 2.12 and 2.12,1. As described in these methods, the kinetics assumed were of a 
first order reaction, and the reasons for this choice were given therein. It should be noted 
that this assumption was supported by the close fitting of the experimental points, as the 
correlation coefficient will show further below, thus giving it more credence.
The first topic to be addressed in the treatment of data was the selection of the 
points to be considered and those to be discarded in the calculation of the slopes for the
Results and Discussion 766
determination of the initial rates. As mentioned before, low digestions of the substrate 
yielded small product peaks and this could cause its smear with the background, making 
it difficult to delineate the limits of peak areas. The proposed solution around this 
problem was to plot all the digestion data points for a certain assay against their time of 
digestion, fit a digestion curve and discard any points that seem to lie outside the general 
trend. This is illustrated in Figure 3.59. As it can be seen, the point for 5 min digestion 
can be easily discarded. However, the point corresponding to 20 min is not so easily 
discerned.
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Figure 3 .59- Example of low digestion data. The scattering of the data could be attributed to a poor 
definition of the product peaks in the electropherograms, as mentioned above (3.8.3.2). The open point 
was discarded in the calculations. This resulted in a slope of -0.0030 %S/min, with r^ = 0.7321.
Yet, if the 20 min digestion point is also discarded, the fitting is almost exact, as it 
can be seen from Figure 3.60:
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Figure 3.60 - Example of low digestion data. When the point for t = 20 min in Figure 3.59 is also 
discarded the resulting slope has a value of -0.0027 %S/min. with r  = 0.9925.
Therefore, even for low digestions it is possible to obtain reasonably reliable values 
for initial rates of digestion, provided enough points are collected in order to discern a 
trend and to select which are the more reliable points to use in the calculations. Hence 
the collection of at least four time samples in each assay, and usually five.
À second point to be addressed was the necessity for a correction factor for the 
calculation of the “real” percentage of digestion. The following three graphs illustrate the 
influence of the correction in absolute terms, that is, in each individual calculation of 
initial rates of digestion. The first graph in Figure 3.61 shows the change in the 
percentage of undigested substrate (%S) for low amounts of digestion.
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Figure 3.61 - Influence on the correction of data points with the use of Eqn. 3.8.3 for a final digestion of 
-10%. The slopes at t = 0 of the dashed curves calculated as described in Method 2.12.1 are 
-0.00373 %S/inin (r“ = 0.9931) for the original points (Raw Data) and -0.00508 %S/min ( r  = 0.9920) 
after the correction, respectively. The open points at 30 min were discarded in the calculations.
The first point to be noted is that at these low rates the digestion curve is quite 
linear, as it should be expected, The increase in the value of the slope can be calculated 
to be of about 36%, which is quite considerable. In fact, it can be shown that for 
(theoretically) extremely low rates of digestion this increase should tend to 37.7%, a 
value that corresponds to the expected increase arising from the correction factor 
calculated in 3.8.3.2 (equal to 1.377). Curiously, the quality of fitting of the experimental 
points to the analytical curve is better in the raw data than in the corrected form, as it can 
be judged from the values for the correlation coefficient (r^). This can be attributed to a 
fortuitous linear behaviour of the raw data that is deformed by the adjustment made with 
the correction factor.
The second graph, in Figure 3.62, illustrates the variation in the percentage of 
undigested substrate (%S) for intermediate amounts of digestion.
Results and Discussion 769
GO ♦ Raw Data 
. Corrected % :
10 20 
Time (min)
30
Figure 3,62 - Influence on the correction of data points with the use of Eqn. 3.8.3 for a final digestion of 
-50%. The slopes at t = 0 of the dashed curves calculated as described in Method 2.12.1 are 
-0.02086 %S/min (r  ^= 0.9953) for the original points (Raw Data) and -0.02664 %S/nhn (r“ = 0.9992)
after the correction, respectively.
In this situation, the increase in the slope has a value of 28%. As the values of the 
initial rates increase, the difference between the raw data and the corrected values start 
to decrease. This is observed to a further extent in the next graph, in Figure 3.63.
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Figure 3.63 - Influence on the correction of data points with the use of Eqn. 3.8.3 for a final digestion of 
-95% . The slopes at t = 0 of the dashed curves calculated as described in Method 2.12.1 are 
-0.10737 %S/inin ( r  = 0.9634) for the original points (Raw Data) and -0.12026 %S/inin (r^ = 0.9752)
after the correction, respectively.
For reasonably high rates of digestion, as in the example above, the difference is 
even more attenuated, reaching in this case an increase of 12%. It can indeed be proved 
that for higher values of initial rates there is a tendency for the difference to disappear. 
Therefore, the maximum increase between the raw data (from the percentage of the 
substrate peak) and the corrected data occurs at low digestion rates. It is then important 
to know what is the effect of this difference in the calculation of relative initial rates.
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The calculation of relative initial rates consisted of obtaining the initial rate of 
digestion when the protease is activated with the peptide being studied, and dividing it by 
the initial rate of digestion for the protease being activated with the native activating 
peptide (GVQSLKRRRCF), thus yielding a quotient which should express the relative 
capability of activation of the peptide in study.
In order to compare the influence of the correction factor in the above calculations, 
the relative initial rate obtained between the two most extreme cases, of high and low 
digestion can be compared, when using the raw data and the corrected results. 
Therefore, the initial rate using the raw data would be -0.00373/-0.10737 = 0.0347, and 
using the corrected data it would be -0.00508/-0.12026 = 0.0422. Therefore, in the most 
extreme situation, there is a relative increase of 26%. However, when comparing two 
initial rates not too dissimilar, like those obtained for low and intermediate digestion, 
-0.00373/-0.02086 = 0.179 and -0.00508/-0.02664 = 0.191, a relative increase of 6.7%. 
The remaining situation, -0.02086/-0.10737 = 0.194 and -0.02664/-0.12026 = 0.222, 
with a relative increase of 14%, shows that in relative terms the increase is not negligible. 
But in absolute terms the difference in values will be expressed by the statistical 
treatment given to these values, and will be subsequently covered by the standard 
deviation of the sample. In other words, saying that a peptide activates only to an extent 
of 3.5% or 4.2% (using the most extreme situation) does not have any relevance if the 
standard deviation covers this difference. Therefore, as the correction factor was a value 
obtained a posteriori, it was deemed unnecessary to use it in the calculations, although it 
is presented as a more correct approach to the calculations of relative rates.
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4. C onclusions
The adenovirus protease, as most viral proteases (Hellen and Wimmer, 1992), is 
involved in the control of particle assembly and subsequent virus maturation. In order to 
prevent premature cleavage of protein precursors involved in these processes, it has to 
present a control mechanism. This control was at first thought to happen through auto- 
catalytic processing (Chatteijee and Flint, 1987), but this idea was later dismissed 
(Webster and Kemp, 1993), and the control shown to involve the action of the activating 
peptide GVQSLKRRRCF (Webster eta/., 1993) and possibly also viral DNA (Mangel et 
a /,1993).
In the present work, the mechanism by which the activating peptide enables the 
activation of the protease was studied. From a model (cf. Figure 3.3) in which it was 
supposed that the role of the activating peptide was to promote a disulphide bond 
rearrangement within the protease (Webster et a i ,  1993), acting only as a catalyst similar 
to protein disulphide isomerase (Noiva and Lennarz, 1992) or possibly to thioredoxin 
(Holmgren, 1985), it became increasingly evident that the peptide was activating the 
protease by means of covalently binding to it.
However, before discussing the mechanisms by which the protease is rendered 
active, it is deemed necessary to actually try and define what is understood by an active 
protease.
4.1. What is an Active Protease?
When protease activity is discussed, the threshold between active and inactive 
protease always seems to be a choice based on the argument that is trying to be made. 
Whereas recombinant protease expressed in insect cells or E. coli is considered to be 
fully active when it digests -50%  of ovalbumin or less than 50% of canine adenovirus 
pVIl in 18 h in the absence of activating peptide (Keyvani-Amineh et al., 1995b), the 
same protease is considered to be effectively inhibited when processing of human 
adenovirus type 2 pVH is reduced to -10%  digestion in the presence of cystatin, a 
cysteine protease inhibitor (Sircar et ah, 1996).
Also, the recombinant protease is considered to be inactive without activating 
peptide if no digestion of the peptide MSGGAFSW is observed after 12 h, although it 
digests >50% pVII in 3 h (presumably due to the presence of pVt in the cell extract), and
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active in the presence of activating peptide if it digests <50% of the above peptide in 
30 min and also digests >50% pVII in 3 h (Webster et al., 1993).
Clearly, the protease has a different affinity for different substrates and therefore an 
absolute definition for activity should be referred to a common assay system. In the assay 
system used throughout this work (Method 2.9,1), the protease (0.15 mg/ml) was found 
to digest -10%  of the substrate LSGAGFSW in 3 h without activating peptide, whereas 
in the presence o f 0,15 mM of activating peptide it digested -85%  of the substrate in 
10 min, indicating an increase of initial rate of more than 300 fold (average results of 
three assays).
On the other hand, the protease concentration is obviously also o f importance, and 
as it is not mentioned in any of the above results, the comparison of activity between 
different systems becomes virtually impossible. However, if constant protease 
concentration is assumed, as well as a similar substrate affinity (a very rough 
assumption), it can be seen from the graph below that some ‘inactive’ proteases present 
higher digestion rates than others considered to be ‘active’.
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Figure 4.1 - Theoretical plot of substrate digestion curves for different values of initial rates (%S/min), 
based on first order digestion kinetics (cf. Method 2.12).
Indeed, a -50%  digestion of albumin in 18 h would correspond to an initial rate of 
-0.0005 %S/min for an ‘active’ protease, whereas an ‘inactive’ protease that digests 
-10%  of LSGAGFSW in 3 h would have roughly the same initial rate of 
-0.0005 %S/min.
Two main conclusions should be drawn from the above observations: (a) the 
protease does present some proteolytic activity without the presence of activating
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peptide, and this activity can arbitrarily be termed ‘residual’; (b) it is commonly agreed 
that the presence of the activating peptide does increase considerably the proteolytic 
activity of the protease (Diouri et al., 1996; Mangel et al., 1993; Webster et al., 1993), 
Therefore, it was deemed convenient in the discussion below to term the protease in 
the absence of activating peptide as 'inactive', and when in its presence considered as 
'active', and the process by which the activating peptide activates the protease was 
termed 'activation'. Furthermore, the activity of the protease seems to be also either 
enhanced or even achieved through other means, and this will be discussed below (cf. 
4.10).
4.2. Which Cysteines in the Protease are involved in 
Activation/Activity?
When the activating peptide was found to activate the adenovirus protease (Webster 
et al., 1993), in the 11 protease serotypes knovm by then three cysteines were found to 
be fully conserved: cysteine-104, 122 and 126 (numbering as referred to the protease 
from human adenovirus type 2, cf. Figure 1.8). It was then proposed (Webster et al., 
1993) that the activation of the protease would possibly involve a rearrangement of an 
intramolecular disulphide bridge in which the activating peptide would act as a catalyst of 
a thiol-disulphide interchange (cf. model in Figure 3.3).
However, some subsequent findings started to suggest that this model could not 
correspond to the activation mechanism: of the eight cysteines in the adenovirus 
protease, no internal disulphide bonds were found between them (Tihanyi et al., 1993), 
and the avian adenovirus type 1 protease sequence did not present a conserved 
cysteine-126 (Cai and Weber, 1993).
Although an initial attempt to classify the protease based on inhibitor studies 
positioned it among serine proteases (Tremblay et al., 1983), more extensive inhibitor 
studies (Webster et al., 1989b) suggested that it was rather a member of the cysteine 
class, albeit with an unusual mechanism, resembling in its inhibition profile the 3C 
protease of rhinoviruses (Orr etal., 1989),
Furthermore, site-directed mutagenesis studies (Grierson et al., 1994) confirmed the 
protease to be a cysteine protease, as mutants containing altered serines originally 
conserved in all of the known serotypes were active, whereas mutants of either 
cysteine-104 or cysteine-122 presented its activity reduced by over 95%. Other
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independent site-directed mutagenesis studies (Rancourt et a i,  1994) also showed that 
liistidine-54 or cysteine-104 mutants did not present any activity, although mutation of 
cysteine-104 to a serine interestingly turned the protease into a serine-like protease in its 
inhibitory profile. Curiously, these studies revealed that mutation of cysteine-122 into a 
glycine yielded an active mutant, which would seem to indicate cysteine-104 as the 
active-site cysteine (Weber and Tihanyi, 1994). However, this was later confirmed not to 
be the case, as cysteine-122 mutants were actually shown to be cysteine-67 mutants 
(Weber, personal communication).
Expression of protease mutants in insect cells (Jones et a i,  1996) showed however 
that cysteine-104 did not seem to be essential for proteolytic activity, as this mutant was 
able to cleave pTP (a viral protein substrate) to iTP, whereas neither of the mutants of 
histidine-54 or cysteine-122 were able to cleave that substrate. Moreover, when the 
activating peptide was incubated with recombinant protease, this caused a concentration- 
dependent increase in tryptophan fluorescence, concomitant with an increase in 
proteolytic activity, indicating a conformational change of the enzyme when the peptide 
was added. Also, the incubation of the cysteine-104 protease mutant with the activating 
peptide did not cause an increase in tryptophan fluorescence, nor did the incubation of 
wild-type protease with GVQSLKRRRSF or GVQSLKRRRDF, which seemed to 
conform to cysteine-104 being involved in activation and cysteine-122 with catalysis.
Interestingly enough, labelling experiments of the protease (Iqbal, unpublished 
results) with radioactively labelled iodoacetamide only revealed labelling of cysteine-104 
and cysteine-122, in spite of the existence of another 6 cysteines in the protease, which 
suggested that either these two cysteines are unusually reactive or the other six are 
reasonably unreactive, or possibly both. This certainly has been observed before, for 
cysteine groups have been divided into three groups according to their reactivity 
(Hellerman et a i,  cited in (Torchinsky, 1981)): readily reacting, sluggishly reacting, and 
“masked” or “buried”. The causes for this have been ascribed to: activation of thiol 
groups by neighbouring functional groups such as histidine (Hammond et a i, cited in 
(Torchinsky, 1981)), and “masking” of thiols due to them being sterically inaccessible 
(Mirsky, cited in (Torchinsky, 1981)) or forming intramolecular bonds, such as 
thiazolidines or thiazolines (Linderstrom-Lang et a i, cited in (Torchinsky, 1981)), 
thioesters (Mastin et a i,  cited in (Torchinsky, 1981)), or simply involvement in 
hydrophobic interactions (Klotz, cited in (Torchinsky, 1981)).
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4.3. What is the Role of the Cysteine in the Activating Peptide?
The first evidence of the importance of the cysteine within the activating peptide 
came from an experiment (Webster et a l, 1993) where an incubation of the protease 
with the peptide GVQ SLKRRRAF was not able to render the protease active. 
Furthermore, it was also shown that the peptide GVQSLKRRRCF activated the protease 
more efficiently (10 fold increase) in the oxidised (dimeric) form than in the reduced 
(monomeric) form.
Results presented here (cf. 3.2) tried to assess how did the replacement o f the 
cysteine in the activating peptide affect the ability of the activating peptide in rendering 
the protease active. It was initially thought that the cysteine had some particular 
reactivity which would enable the activation of the protease, and thus some substitutions 
of that residue aimed at determining what was that peculiar property. Substitution for a 
serine, quite similar to cysteine in both polarity and structure, although not as reactive 
and not allowing the formation of disulphide bridges (thus acting as an analogue of the 
reduced form of the activating peptide, albeit less reactive), aimed at assessing the 
importance of nucleophilicity; and aspartate, a residue analogous in structure and 
function to a sulphenic acid (RSOH), which has been observed to contribute to redox 
control involving cysteine residues (Abate et a i ,  1990), intended to mimic a possible 
redox control mechanism, although aspartate, unlike sulphenic acid, can only be reduced. 
The peptide GVQSLKRRRAF was used as a negative control.
The results shown in Figure 3.2 show that not only is cysteine the only residue at 
that position that enables an efficient activation of the protease, but also the peptide 
GVQSLKRRRAF, which was supposed to act as the negative control, is more effective 
than any of the others in activating the protease, thus enabling the conclusion that 
cysteine has a particular property that enables the activation, possibly by being able to 
either participate in a thiol-disulphide exchange or by binding itself to some cysteine in 
the protease. This, together with the results presented previously (cf. 4.2), seemed to 
point at an interaction between cysteine-10 of the activating peptide with possibly 
cysteine-104 in the protease.
If cysteine-10 of the activating peptide was responsible for activation, was it 
particularly reactive? To address this question, determination of the pKa values o f the 
peptide was done to assess whether the cysteine was unusually acidic (cf. 3.2.3), and this 
revealed (cf. 3.2.3.8) the latter hypothesis not to be sustainable. The arginines beside the
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cysteine did not alter significantly its acidity either, nor the mutation of the phenylalanine 
to an alanine. Peptides with the cysteine shifted along the arginines also did not activate 
the protease efficiently (cf. 3.5.1), confirming that there had to be another factor 
involved in the activation mechanism, which will be dealt with further below (cf. 4.5).
4.4. Does the Activating Peptide Bind to the Protease?
xAJl the results presented above were not able to elucidate what was the nature of the 
interaction between the activating peptide and the adenovirus protease. In order to 
address this question, several approaches have been tried. As described before (cf. 3.6.1), 
radiolabelling of the peptide followed by incubation with the protease and analysis with 
non-reducing SDS-PAGE revealed some radioactivity on the band corresponding to the 
protease (Kemp, unpublished results). Similarly, incubation of the activating peptide with 
the protease followed by low acrylamide percentage non-reducing SDS-PAGE, showed 
a band corresponding to the putative protease-peptide complex running at an higher 
molecular weight than the corresponding band to protease alone (Iqbal, unpublished 
results). Also, reduced protease was observed to migrate unexpectedly faster than its 
oxidised counterpart (Greber e ta l ,  1996).
However, the definite proof came from mass spectrometry (cf. Figure 3.43, (Cabrita 
et a l ,  1997)), where activating peptide incubated with the protease showed an increase 
on the molecular weight of the protease consistent with a 1:1 protease-peptide complex. 
The fact that the peptide GVQSLKRRRSF when incubated with the protease did not 
cause an increase in the molecular weight of the protease agrees with the assumption that 
the binding of the peptide to the protease is made via a disulphide bond.
Yet, although the peptide KRRRCF has a cysteine, it did not activate the protease 
(Webster et al., 1993), which indicated that something else was missing in this peptide in 
order to produce an effective activation.
4.5. How is the N-terminai Region of the Activating Peptide important?
The fact that KRRRCF was not able to activate the protease prompted an 
investigation into what was the minimum length required for an effective activation of 
the protease by the activating peptide.
The results determined here (cf. 3.3) showed that the removal of the N-terminal 
glycine of the activating peptide causes a reduction in protease activity of about 50%, 
whereas by removing both the glycine and the valine reduced the protease activity to 5%
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of the value achieved with the native activating peptide. Further removal of more 
residues had a similar effect to that of removing glycine and valine. Also, as the mass 
spectra of the N-terminal truncated peptides (cf. Figure 3.43) showed that these peptides 
do bind to the protease, this leads to the conclusion that the N-terminal GV amino acid 
sequence in the activating peptide is essential for efficient activation of the protease.
These results were further confirmed when mutations of the valine in position 2 to 
either threonine or alanine, or an acétylation of the N-terminal, in the activating peptide 
(cf. 3,4) induced a reduction of the protease activity to 50% or less than the activity 
obtained with the native peptide, which shows that these two residues are quite specific 
for activation requirements to be met. This agrees with sequence data for the activating 
peptide (cf. Figure 1.9), in which glycine is conserved in all of the known serotypes and 
valine is only conservatively substituted by leucine.
This is in agreement with the tridimensional structure of the protease-peptide 
complex recently published (Ding et a i ,  1996):
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Figure 4 .2 - Ribbon scheme of the tridimensional structure of the adenovirus type 2 protease complexed
with the activating peptide (Ding et al., 1996)
From the above structure, it can be seen that indeed the activating peptide binds to 
cysteine-104 via its cysteine-10, and the N-terminal of the activating peptide is enfolded 
in a loop region of the protease in the region of residues 135-140, with contacts between 
the N-terminal glycine of the activating peptide and an aspartate at position 142 This 
loop region immediately follows a region where cysteine-122 lies at the far end of a 
helix. It is then quite possible that the mechanism through which the activating peptide 
activates the protease is by “tying together” two minidomains of the protease that in its 
absence are able to move independently. This would have the effect of stabilising the 
catalytic residues in their optimum orientation, which would require interaction from 
both ends of the activating peptide. Therefore, the presence of a GV amino acid 
sequence in the N-terminal at a fixed distance from the cysteine residue seems to be 
critical for an efficient activation of the protease by the activating peptide. This would 
explain why the cysteine-shifted peptides (cf. 3.5.1) were not able to activate the 
protease to a reasonable extent, as the aforementioned distance was shortened
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This model also allows for an explanation as to why the protease presents a 
‘residual’ activity in the absence of activating peptide, for the dynamic nature of the 
protease would enable a small proportion of protease molecules to be in the active 
conformation at any one instant.
These results together with the resolved tridimensional structure of the protease also 
explain why the peptides IVALGVQSLKRRRCF and WGLGVQSLKRRRCF do not 
activate the protease to the same extent as the native activating peptide (cf. 3.4.2.1), as 
the extra sequence at the N-terminal would have a similar effect to that of the 
acétylation.
4.6. Why is there Always an Aromatic Residue at the C-Terminai of the 
Activating Peptide?
An unexpected result was the observation that the peptide GVQSLKRRRCA was 
capable of activating the protease only to 35% or less of the activity achieved by the 
native activating peptide (cf. 3.5.4). Indeed, this peptide seems to present all the 
previously mentioned requisites for an efficient activation of the protease: (a) a cysteine 
in position 10, (b) a GV amino acid sequence at the N-terminal, and (c) eight residues 
between GV and the cysteine. Therefore, the phenylalanine to the right of the cysteine 
must have an effect on the activation, presumably in the binding process, due to it being 
so close to the cysteine. However, the p^a of the cysteine did not seem to be significantly 
altered (cf. 3.2,3.7), which ruled out the possibility of a change in acidity of the cysteine.
It can indeed be noticed (cf. Figure 1.9) that an aromatic residue is always present at 
the C-terminal of the activating peptide, which gives further credence to the assumption 
that this residue must play a particular role in the binding process. Interestingly, it has 
been reported (Bodner et al., 1980; Morgan and McAdon, 1980; Morgan et al., 1978) 
that the proximity of aromatic residues to cysteines enables the formation of sulphur-%- 
bonded chains, which confer extra stability to the folding of proteins, as disulphide bonds 
in proteins usually present a dihedral angle of 90° which takes on partial double character 
(Boyd, cited in (Morgan et al., 1978)), and thus tc-tt bonding could explain the tendency 
of cystine disulphide pairs to interact with aromatic rings. On the other hand, a reaction 
of thiol-disulphide interchange (which presumably will happen between the oxidised 
activating peptide and cysteine-104 of the protease) is reversible (Eldjarn and Pihl, 1957; 
Keire et al., 1992; Kolthoff et al., 1955; Shaked et al., 1980). Therefore, the vicinity of
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an aromatic residue to the cysteine would presumably stabilise the formation of the 
disulphide, thus maintaining it bound to the protease, keeping it active. If this aromatic 
residue is missing, the binding of the peptide to the protease will be less stable and 
therefore more prone to detachment of the activating peptide. This could also be the 
reason why the peptides GVQSLKRRCRF and GVQSLKRCRRF were not able to 
activate the protease (cf. 3.5,1) nor inhibit it (cf. 3.6.3).
An examination of the tridimensional structure of the protease would allow to locate 
where the aromatic ring of the phenylalanine is binding to in the protease molecule, thus 
permitting the confirmation of the above mentioned stabilising effect. Unfortunately, 
although the structure has been solved for more than a year, its co-ordinates still have 
not been made publicly available.
Mass spectrometry of possible protease-peptide complexes between the adenovirus 
protease and the peptide GVQSLKRRRCA (or GVQSLKRRCRF, and 
GVQSLKRCRRF), as well as tryptophan fluorescence change measurements, would also 
benefit the understanding of this mechanism.
4.7. Proposai of a Model of Activation of the Adenovirus Protease
Based on all the results presented above, a model was devised which tries to 
encompass all the observations made about the protease;
SH son ?
InactiveInactive
.AP-SH + AP-SS-AP
SS-AP c
Active
Figure 4.3 - Proposal for a mechanism of activation of the adenovirus protease. AP-SH denotes the 
reduced activating peptide. AP-SS-AP the oxidised activating peptide, the round rectangles the inactive 
protease and the ellipse represents the active protease. See text for explanation.
When the protease is newly synthesised, it is produced in the inactive form A. This 
molecule presents a thiol group (cysteine-104) in the reduced form. This cysteine should
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be reasonably reactive, due to being present at the surface of the molecule. Therefore, 
when purified the protease is quite prone to irreversible oxidation via pathway 1 to an 
inactive (and inactivatable) form B, arguably by forming a sulphenic acid. Possibly, 
cysteine-122 in the active site should also be more prone to oxidation if the catalytic site 
is not in the right conformation. This oxidation can be prevented by adding a reducing 
agent such as p-MeOH or DTT to the buffer. This is a process that should only happen 
in vitro, as in vivo the protease should be protected from oxidation, due to the reducing 
environment in the cytosol (Greber et at., 1996).
However, the conversion of the protease to the active form C requires the binding of 
activating peptide (AP). Tliis can occur more slowly via pathway 2 by reacting with 
reduced activating peptide (as it will require the presence of an oxidant, which is being 
removed if a reducing agent is added), or via pathway 3 by thiol-disulphide interchange 
with the oxidised (dimeric) activating peptide. Either of these two reactions should be 
equilibria demanding a large excess of the activating peptide in order for it to bind to the 
protease. Yet, once the activating peptide binds to the protease, the aromatic residue 
should stabilise the disulphide bond and thus protect reasonably against subsequent 
detachment, as well as the N-terminal. On the other hand, the activating peptide itself 
should exist in an equilibrium between its reduced and oxidised forms (pathway 4).
If a reducing agent is added before the activating peptide, the observed inhibition 
(Webster et at., 1993) could be explained in terms of the activating peptide being 
reduced in pathway 4 and its oxidation leading to activation being prevented. However, a 
reducing agent added after activation should help maintain the active site cysteine in a 
reduced form.
A poorer activation with reduced activating peptide as compared to the oxidised 
form could be due to the fact that a slower rate of activation via slow pathway 2 would 
allow more protease to become inactivatable (inactive B) through pathway 1, whereas 
the oxidised activating peptide would react reasonably quickly via thiol-disulphide 
interchange through pathway 3. The same explanation could account for the lack of 
increase in activation once more activating peptide is added after an initial amount was 
allowed to incubate. A possible verification of this would be to use degassed buffers 
throughout the purification and assay procedures, in which no difference other than the 
time taken to activate should be observed in the activation.
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It was also observed (Iqbal, unpublished observations) that a removal of the excess 
unbound activating peptide did reduce the activity, which can be explained in terms of 
the equilibria 2 and 3 being moved towards the release of activating peptide from the 
protease. It would be interesting to find out whether a subsequent increase of the 
activating peptide concentration would restore activity in oxygen-Ifee conditions.
In terms of the actual binding of the activating peptide to the protease, the data 
presented here do suggest that the binding is reversible (cf. 4.9). Therefore, the 
mechanism by which the peptide can remain reasonably attached to the protease is by a 
combined effort of the N-terminal (shorter peptides do not bind as efficiently as the full 
length activating peptide, cf 4.5), the cysteine, which provides with the covalent bond 
(cf. 4.3) and the aromatic residue close to it which should protect the disulphide bond 
from reduction (cf. 4.6).
The specificity in binding of the activating peptide to the protease and consequent 
conformational change is consistent with the behaviour observed for the protease of the 
adenovirus type 2 temperature-sensitive mutant (tsi, (Weber, 1976)). This mutant was 
shown to present a protease with a mutation from proline to leucine at position 137 
(Weber and Houde, 1987) that prevents proper encapsidation of the protease within the 
newly formed viral particles (Rancourt et al., 1995). It is argued that the mutation from 
proline to leucine causes a small but crucial structural change in the protease that 
prevents its activation with pVI at the non-permissive temperature (39°C), but still 
allowing for activation with the activating peptide GVQSLKRRRCF (Rancourt et al., 
1995), albeit somewhat to a lesser extent than in the case of the wild type (Keyvani- 
Amineh et al., 1995a). As stated above (cf. 4.5), the N-terminal region of the activating 
peptide interacts with a loop region comprising residues 135-140, precisely where the 
proline is located. A mutation from a proline to a leucine should affect the conformation 
of this region, presumably altering the affinity of the activating peptide in binding and 
producing the conformational change that leads to activation, thus conferring a lower 
activity. However, the ability of the activating peptide in rescuing the infectivity of the 
tsI mutant together with the observation that the recombinant tsI is not temperature- 
sensitive in vitro (Rancourt et al., 1995), showing almost the same activity as the wild 
type recombinant protease (Keyvani-Amineh et al., 1995a), are inconsistent with the 
assumption that the conformational change caused by the mutation fi-om proline to 
leucine prevents the activation with pYI (Rancourt et al., 1995). This rescue with
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GVQSLKRRRCF rather seems to indicate that at the non-permissive temperature the 
protease is not interacting with pVI due to the protease not being directed to the 
presence of pVI, thus confirming that the tsi mutant is likely a protein trafficking 
phenotype. The binding of the activating peptide (rescuing) should correct the 
conformation of the tsi protease, thus changing its recognition pattern and enabling it to 
be targeted properly (Vaughan, personal communication).
The reversible transition between the inactive form A of the protease and the active 
form C by reversible binding of the activating peptide should be a reflection of an in vivo 
regulation mechanism of the protease, which might also involve targeting of the protease, 
as the behaviour of the ts I mutant mentioned above seems to suggest. This is supported 
by the observation (Rancourt et a i ,  1995) that the activating peptide inhibits wild type 
virus production when added to adenovirus infected cells, presumably by subverting the 
control mechanism.
4.8. How and Where Does the Activating Peptide Bind to the Protease?
Certainly, there is enough evidence that a covalent bond is formed between 
cysteine-104 of the protease and cysteine-10 of the activating peptide. But where does 
the N-terminal bind to?
The results above also do seem to suggest that proline-137 might be a residue 
involved in the N-terminal interaction between the activating peptide and the protease. 
Certainly, it is a very well conserved residue among different serotypes (cf. Figure 1.8), 
and its mutation to leucine in the tsi mutant did present a lower activity as compared to 
the wild type, and this could be explained in terms of the replacement of a proline, which 
confers a certain rigidity to the loop, by another residue that results in a greater flexibility 
of the protease, which could compromise the correct positioning of the catalytic site 
residues. Furthermore, in the serotypes where this residue is mutated (bovine type 7, 
ovine strain 287, avian type 1 and avian strain 127, cf. Figure 1.8) the corresponding 
peptide is also different. Whereas in ovine strain 287 and avian strain 127 the cysteine in 
the activating peptide is flanked by two tyrosines (cf Figure 1.9), in avian type 1 there is 
a methionine to the left of the cysteine, but cysteine-104 in its corresponding protease 
presents a phenylalanine to its right. Thus, it is plausible that a weaker interaction 
between the N-terminal of the activating peptide and the protease in the serotypes where
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proline-137 is absent might be compensated by a more stable interaction at the disulphide 
bond, provided by aromatic residues flanking on both sides rather than just on one.
This hypothesis would also give more credence to the importance of the existence of 
a binding equilibrium between the protease and the activating peptide, as a peptide that 
would bind too strongly would activate the protease constutively, and a peptide not 
binding tightly enough would not confer enough activity to the protease.
4.9. Is Inhibition of Activation Possibie?
If the protease does require the binding of the activating peptide in order to be fully 
active, a mechanism which prevents the binding of the activating peptide to the protease 
should operate as an inhibitor of activation. This could be achieved by means of finding a 
molecule that would bind to cysteine-104 in the protease, not activating it and not being 
replaced by the native activating peptide, Alternatively, a molecule that would modify 
chemically cysteine-104 to a derivative not allowing disulphide bonding could also serve 
the same purpose, but this would present the disadvantage of possibly reacting with 
other cysteine residues, both in the protease and in other viral and host proteins.
The result that the shorter peptides QSLKRRRCF and SLKRRRCF did not activate 
the protease to a reasonable extent (cf 3.3,2.2 and 3.3.2.3), but still bound to it (cf 
3.6.1) suggested that they could act as inhibitors of activation. However, when inhibition 
assays were performed (cf 3.6.2), only the peptide QSLKRRRCF was able to inhibit 
activation to some extent (reducing the activity to 77% of that achieved with the native 
activating peptide), which indicated that the native activating peptide was able to 
dislodge the shorter peptides, suggesting a reversible binding of the peptides. The reverse 
(substitution of GVQSLKRRRCF by QSLKRRRCF, cf. 3.6.2.4) did not happen, 
indicating a greater affinity of the native peptide for the protease.
A good inhibitor of activation should be able to bind reasonably tightly to 
cysteine-104, and an analogue of the activating peptide should present some 
characteristics to ensure a good binding (cf. 4.7). But the very same characteristics that 
confer good binding properties also activate the protease.
Yet, the mechanism by which the protease is presumably activated (cf. 4.5) involves 
the amino acid sequence GV in the activating peptide to be at a certain distance from the 
cysteine-10, which would stabilise two different regions in the protease at an optimal 
distance for the catalytic apparatus to be efficiently positioned. Therefore, it is possible
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that peptides such as GVQSLLKRRRCF or GVQSKRRRCF. which present all the 
requirements for efficient binding and are reasonably similar to the native activating 
peptide, would indeed bind to the protease, although causing a conformational change 
that would put the catalytic residues either too close together or too far apart, thus 
affecting its catalytic properties.
Another possibility is attempting to block cysteine-104 with a peptide such as YCY. 
This peptide would presumably form a stable and protected disulphide bond with the 
cysteine due to the stabilising effect of aromatic residues on disulphide bonds already 
mentioned above (cf 4.6 and 4.8). Curiously enough, two pVI C-terminal adenovirus 
serotypes already present this sequence (cf. Figure 1.9), which could suggest that this is 
indeed a mechanism already used by some adenovirus serotypes to enhance the binding 
of their activating peptides to their respective proteases.
4.10. What else Activates the Protease?
It has been reported that adenovirus DNA also enhances protease activity (Mangel 
et al., 1993; Mangel et al., 1996), although the requirement seems to be any negatively 
charged polymer (Mangel et al., 1993). However, it also has been argued (Webster et 
al., 1994) that DNA acts only as a stabiliser against reducing agents. The crystal 
structure (Ding et al., 1996) does present four clusters of positive charge ranging in area 
from 45 to 65 Â ,^ and the shortest distance between two of these clusters being -24  Â is 
commensurate with the rise of a single turn of double-stranded DNA. Recombinant 
protease was observed to increase its Km by 2-fold and its Acat by 3-fold when incubated 
with adenovirus DNA in comparison to protease alone, whereas an increase of Km by 2- 
fold and c^at by 355-fold was observed when activating peptide was incubated to the 
protease in comparison to the protease alone (Mangel et al., 1996). Yet, when both 
DNA and activating peptide are incubated together, there is an increase of Km by 2-fold 
and its Kat by 6072-fold as compared to the protease alone (Mangel et al., 1996), 
suggesting that the two molecules act together cooperatively. Curiously, increasing 
concentrations of adenovirus DNA seem to increase activity up to a concentration of 2- 
4 pg/ml, followed by a decrease of activity.
Recently, it was reported (Diouri et al., 1996) that a new stimulation ligand, the 
peptide VEGGS, also stimulates the recombinant protease to a similar extent of that 
achieved with the activating peptide. It was also reported that this ligand increases
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fluorescence emission of tryptophan residues in the protease, suggesting a 
conformational change, and inhibited virus infection, ail in a similar fashion to the 
activating peptide. Once the protease has been activated by one of VEGGS or 
GVQSLKRRRCF, the other peptide does not hirther enhance activity, which suggests 
that the two peptides cause the same conformational change in the protease. However, 
attempts to find if and where does this ligand bind to have proven unsuccessful
4.11. Future Perspectives
Some characteristics of the mechanism by which the activating peptide converts the 
adenovirus protease into its most active form have been elucidated in this work. 
However, this is a never ending subject, and many questions remain unanswered.
Namely, the understanding of the nature of the binding of the N-terminal region of 
the activating peptide to the protease would enable a more rational approach to inhibitor 
design, as well as the understanding of possible targeting mechanisms during virus 
infections.
Also, the results presented above seem to indicate that cysteine-104 in the protease 
exhibits an unusual reactivity, and a better idea of the reasons for this could provide with 
a better insight on the nature of the reversibility of the covalent binding to the activating 
peptide.
The divergence of results concerning the effect of DNA on the activity of the 
protease is also puzzling, and could possibly be related to the assay systems used to 
determine its influence, or could be an indication that DNA can be used as a guidewire 
for the protease to cleave proteins within the viral capsid (Ding et al., 1996).
The ligand VEGGS is also intriguing. The results presented in this work seem to 
indicate that an efficient binding of the activating peptide to the protease requires a joint 
effort of several regions of the peptide in keeping it bound to the protease. This ligand 
does not conform to any of those requirements, and yet it is claimed that it has a similar 
effect to that of the activating peptide (Diouri et al., 1996). The understanding of its 
mechanism of binding and subsequent activation should be able to reveal alternative 
paths for activation, and consequently inhibition.
The understanding of the mechanism by which the adenovirus protease is activated 
should enable a rational design of inhibitors of activation which, together with inhibitors 
directed to the active site (Brown et al., 1996; Cornish et al., 1995; Sircar et al., 1996),
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would allow for the conception of specific inhibitor cocktails which should prove useful 
in anti-viral therapy. Since the protease presents quite a high specificity for both the 
cleavage consensus sequence (Anderson, 1990; Webster et a i ,  1989a) and for the 
activation mechanism, the resulting inhibitors should also be highly selective and not 
interfere with the host proteases, which would present these inhibitors as ideal anti-viral 
agents.
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